

UNCLASSIFIED

|                                                                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                      |
| AD NUMBER                                                                                                                                                                                                            |
| AD871657                                                                                                                                                                                                             |
| NEW LIMITATION CHANGE                                                                                                                                                                                                |
| TO<br>Approved for public release, distribution unlimited                                                                                                                                                            |
| FROM<br>Distribution authorized to U.S. Gov't. agencies and their contractors; Administrative/Operational Use; JUL 1970. Other requests shall be referred to Army Advanced Materiel Concepts Agency, Alexandria, VA. |
| AUTHORITY                                                                                                                                                                                                            |
| USAAMCA ltr, 19 Dec 1973                                                                                                                                                                                             |

THIS PAGE IS UNCLASSIFIED

871657

DDC FILE COPY

Report AMCA-71-004

21  
CB

ANNEX A to AHWG #3

Directed Energies for Military Applications (U)

BIOLOGICAL SENSITIVITIES  
TO  
VARIOUS ENERGY FORMS  
(MATRIX)

Best Available Copy


July 1970

*Ar*

DDC  
RECEIVED  
JUL 17 1970  
B

STATEMENT #3 UNCLASSIFIED

Each transmittal of this document outside the agencies of the  
U.S. Government must have prior approval of \_\_\_\_\_



U.S. ARMY  
ADVANCED MATERIEL CONCEPTS AGENCY

ATTN: Mr. J. H. E. Harkins, P.E. 2131.5  
161

ANNEX A to AHWG #3

[Directed Energies for Military Applications, (U)

BIOLOGICAL SENSITIVITIES

TO

VARIOUS ENERGY FORMS

(MATRIX)

July 1970

US Army Advanced Materiel Concepts Agency  
Washington, D. C. 20315

#### REPRODUCTION

Reproduction of this document to outside agencies of the US Government must have prior approval of the Director, AMCA.

#### DISTRIBUTION

Each transmittal of this document outside of the agencies of the US Government must have prior approval of the Director, AMCA.

#### DISPOSITION

Disposal of this report, when no longer needed, will be by destruction; do not return to the issuing Headquarters.



### ABSTRACT

This report contains biological vulnerabilities to various energy forms such as electromagnetic radiations, ionizing particles, static electric and magnetic fields and acoustical energy forms. The vulnerabilities are given in Watt per  $\text{cm}^2$  or Watt-Seconds per  $\text{cm}^2$  for various body organs and body biological systems (blood circulation, lymphatic system, etc.).

This volume should be of interest to anyone who is concerned about health safety of individuals who would be potentially exposed to the above-mentioned energy forms.

## TABLE OF CONTENTS

|                                                               |     |
|---------------------------------------------------------------|-----|
| Introduction and Approach . . . . .                           | 1   |
| Instructions for Entries into the Matrix. . . . .             | 6   |
| Introduction to Matrices on Ionizing Radiations . . . . .     | 14  |
| Matrices on Particles . . . . .                               | 16  |
| Matrices on X-rays, Gamma Rays. . . . .                       | 27  |
| Appendix A related to Ionizing Radiations . . . . .           | 38  |
| Appendix B related to Ionizing Radiations . . . . .           | 49  |
| Appendix C related to Ionizing Radiations . . . . .           | 61  |
| Appendix D related to Ionizing Radiations . . . . .           | 124 |
| Matrices on UV, Visible and IR Radiations . . . . .           | 126 |
| Appendix A related to UV, Visible and IR Radiations . . . . . | 137 |
| Appendix B related to UV, Visible and IR Radiations . . . . . | 138 |
| Appendix C related to UV, Visible and IR Radiations . . . . . | 139 |
| Appendix D related to UV, Visible and IR Radiations . . . . . | 140 |
| Matrices on LASERS and MASERS . . . . .                       | 141 |
| Appendix A related to LASERS and MASERS . . . . .             | 152 |
| Appendix B related to LASERS and MASERS . . . . .             | 153 |
| Appendix C related to LASERS and MASERS . . . . .             | 154 |
| Appendix D related to LASERS and MASERS . . . . .             | 155 |
| Matrices on Radiofrequency Radiations . . . . .               | 156 |
| Directions for Reading Entries in Matrices. . . . .           | 167 |
| Appendix A related to Radiofrequency Radiations . . . . .     | 168 |
| Appendix B related to Radiofrequency Radiations . . . . .     | 178 |
| Appendix C related to Radiofrequency Radiations . . . . .     | 191 |
| Appendix D related to Radiofrequency Radiations . . . . .     | 193 |
| Matrices on Static Fields . . . . .                           | 198 |
| Appendix A related to Static Fields . . . . .                 | 209 |
| Appendix B related to Static Fields . . . . .                 | 210 |
| Appendix C related to Static Fields . . . . .                 | 211 |
| Appendix D related to Static Fields . . . . .                 | 212 |
| Matrices on Ultrasonics . . . . .                             | 213 |
| Appendix A related to Ultrasonics . . . . .                   | 224 |
| Appendix B related to Ultrasonics . . . . .                   | 225 |
| Appendix C related to Ultrasonics . . . . .                   | 226 |
| Appendix D related to Ultrasonics . . . . .                   | 227 |
| Matrices on Sonics. . . . .                                   | 228 |
| Appendix A related to Sonics. . . . .                         | 239 |
| Appendix B related to Sonics. . . . .                         | 240 |
| Appendix C related to Sonics. . . . .                         | 241 |
| Appendix D related to Sonics. . . . .                         | 242 |
| Matrices on Infrasonics and Barometrics . . . . .             | 243 |
| Appendix A on Infrasonics and Barometrics . . . . .           | 254 |
| Appendix B on Infrasonics and Barometrics . . . . .           | 255 |
| Appendix C on Infrasonics and Barometrics . . . . .           | 256 |
| Appendix D on Infrasonics and Barometrics . . . . .           | 257 |
| Distribution List . . . . .                                   | 258 |

## BIOLOGICAL SENSITIVITIES OF VARIOUS ENERGY FORMS

### INTRODUCTION AND APPROACH:

The Ad Hoc Working Group 3A, consisting of Dr. Z. V. Harvalik, AMCA, COL C. McClure, AR0, Dr. L. Katchmar, HEL, and Mr. J. H. Mathews, AMCA, was convened on 31 July, 1 and 2 August 1968 to discuss biological sensitivities to various energy forms as an aid to assessment of concepts of unconventional weapons. The term "unconventional weapons" was quickly dispensed with as being solution-oriented without establishment of basic problems. The basic problem became one of establishing the scientifically derived biological sensitivities to various energy forms to provide a base for future ad hoc study groups to assess the existing and predicted technological capabilities of generating and delivering such energy forms to produce the biological effects desired. To establish the biological sensitivities to energy forms, a matrix approach was adopted. The energy forms were analyzed and broken out into five distinct areas. These were: (1) electromagnetic energies, (2) particle energies, (3) sonic energies, (4) static fields, and (5) electric currents and plasmoids. Following the establishment of the energy spectrum, discussion centered on the segmentation of biological systems in terms of their potential sensitivities to these energy classes. Seven areas were identified as follows:

1. The sensory mechanism of:
  - a. Eye
  - b. Ear
  - c. Nose
  - d. Skin
  - e. Vestibular
  - f. Kinesthetic (gamma motor system)
2. Other energy receptors were considered:
  - a. Skin as covering
  - b. Body organs
  - c. Central nervous system
  - d. Psychological phenomena

The compilation of these factors are shown in the matrix.

#### MATRIX:

The matrix was constructed in a manner to provide as complete coverage of the biological system as was deemed necessary without undue consideration of whether the data existed or were non-existent. The approach was merely to provide a framework within which most of the available knowledge about biological sensitivities could be incorporated.

The matrix provides for the inclusion of specific numerical energy levels where known and, additionally, provides for the effects of these numerical energy levels in terms of their possible anatomical, physiological, and psychological effects. A remarks section is included for qualification of the data within any given cell.

#### DATA REQUIREMENTS FOR THE MATRIX:

In its idealized form, the data required to complete the matrix would be in the unit of watt/cm<sup>2</sup> or watt-second/cm<sup>2</sup> (joule/cm<sup>2</sup>) to produce a safe exposure level, degradation, incapacitation, and lethality. While watt/cm<sup>2</sup> or joule/cm<sup>2</sup> would be the desirable unit, it is recognized that the data may not exist in the desirable units of energy density; therefore, the specific instructions would be to provide data in their existing units for potential conversion into the desirable units. It should be kept in mind that the potential use of the data is for engineering design purposes and this should be the guiding principle. Wherever a numerical cell entry is made, the original source of the data should be identified in terms of author, publication, volume, page, and year.

#### RECOMMENDATION:

It is recommended that the completed matrix be reproduced and submitted to various organizations for their initial assessment of: (1) the availability of data required by the matrix, (2) the location of the information by individual and/or organization, and (3) a potential time requirement for extraction of data in the form required by the matrix. This initial assessment should be assigned an extremely high priority and answers requested within four weeks of receipt of the matrix.

CB agents are separate areas of investigation and are not included within this particular matrix.

The following individuals were asked to fill-in data as available into the respective matrices:

X-Rays, Gamma-Rays, and Particles

COL James B. Young, VC, Chief, NBC Sciences Division, US Army Medical Research and Development Command, Washington, D. C. 20315

Dr. Marylou Ingram, Department of Radiation Biology and Biophysics, School of Medicine and Dentistry, Rochester University, Rochester, N.Y. 14620

Dr. Aaron Wolfgant, Behavioral Sciences Laboratory, Walter Reed General Hospital, Washington, D. C. 20012

Columbia Research Corporation, Gaithersburg, Maryland 20760

Lasers and Optical Radiations

COL Robert W. Neidlinger, MC, Chief, Laser Section, Surgical Research Branch, US Army Medical Research and Development Command, Washington, D. C. 20315

Microwaves

Mr. William A. Palmisano, Chief, Laser and Microwave Division, US Army Environmental Health Agency, Edgewood Arsenal, Maryland 21010

Dr. Solomon Michaelson (DVM), Department of Radiation Biology School of Medicine and Dentistry, Rochester University, Rochester, N. Y. 14620

MAJ Joseph C. Sharp, Behavioral Radiation Laboratory, Forest Glen Section, Bldg 503, Department of Experimental Psychology, Walter Reed Army Medical Center, Washington, D. C. 20012

Magnetostatic and Electrostatic Fields and Plasmoids, Ions

MAJ Joseph C. Sharp, MSC, Behavioral Radiation Laboratory, Forest Glen Section, Walter Reed Army Medical Center, Washington, D. C. 20012

Ultrasonics

CPT Maurice B. Landers, MC, Surgical Research Branch, US Army Medical Research and Development Command, Washington, D. C. 20315

Dr. Gilbert Baum, Department of Ophthalmology, Albert Einstein College of Medicine, Yeshiva University, 1300 Morris Park Avenue, Bronx, N. Y. 10461

Sonics, Subsonics; and Barometrics

MAJ Daniel T. Sanders, MC, Aviation Medical Officer, US Army Medical Research and Development Command, Washington, D. C. 20315

The returned matrices, containing biological sensitivities to various energy forms, would be used by technical personnel to determine engineering parameters for the various devices utilizing the energy forms appearing in the matrices.

The following individuals and organizations contributed to the information contained in the subject matrices:

Columbia Research Corporation, Gaithersburg, Maryland 20760. Under Contract DAAB09-70-C-0033:

X-rays, Gamma rays  
Particles (Electrons, Protons, Ions, Neutrons) and others

COL James B. Young, VC, Chief, NBC Sciences Division, US Army Medical Research and Development Command, Washington, D. C. 20315 and

COL Robert W. Neidlinger, MC Chief, Laser Section, Surgical Research Branch, US Army Medical Research and Development Command, Washington, D. C. 20314:

Electromagnetic (UV, Visible, IR)  
Electromagnetic (Lasers and Masers)

Dr. Solomon Michaelson (DVM), Department of Radiation Biology, School of Medicine and Dentistry, University of Rochester, Rochester, N. Y. 14620:

Electromagnetic (Microwaves, RF etc)

AHWG #3 Participants:

Magnetostatic and Electrostatic Fields

Dr. Gilbert Baum, Department of Ophthalmology, Albert Einstein College of Medicine, Yeshiva University, 1300 Morris Park Avenue, Bronx, N. Y. 10461:

Ultrasonics

COL James B. Young, VC, Chief, NBC Sciences Division, US Army Medical Research and Development Command, Washington, D. C. 20315 and

COL Robert W. Neidlinger, MC, Chief, Laser Section, Surgical Research Branch, US Army Medical Research and Development Command, Washington, D. C. 20315 and

AHWG #3 Participants:

Sonics  
Infrasonics and Barometrics

BIOLOGICAL SENSITIVITIES

TO

VARIOUS ENERGY FORMS

MATRIX

INCL: Instructions for Entries into the Matrix  
Appendix A, B, C and D

Prepared at US Army, Advanced Materiel Concepts Agency, AMC  
Washington, D. C. 20315

10 September 1968

## INSTRUCTIONS FOR ENTRIES INTO THE MATRIX

The matrix consists of 10 sets, each of which relates to a portion of the energy spectrum. Each set consists of 11 sheets, each of which relates to a sense, body organ or part possibly damageable by a particular energy form.

Each sheet contains 14 columns:

1. ENERGY FORM: Already entered in the matrix, self-explanatory.
2. LEVEL OF INTERACTION: Arbitrarily defined as follows:
  - a. The "Safe Level" may be defined as the maximum level of energy that can be delivered without producing a degradation of function in the system.
  - b. The "Degradation of Function" level is defined as that range of values of delivered energy capable of producing discernible alteration in function of a system without producing total incapacitation of that system.
  - c. "Incapacitation" includes that range of values of delivered energy resulting in loss of function of a system in more than 30% exposed.
  - d. "Lethality" is that value of delivered energy that produces death in more than 30% exposed.

As a first approximation to levels of interaction the following example is given:

| Energy Form Equivalent           | Level of Interaction Equivalent |
|----------------------------------|---------------------------------|
| Blood loss: less than 500 ml     | Safe                            |
| Blood loss: 500-1500 ml          | Degradation                     |
| Blood loss: 1500-3000 ml         | Incapacitation                  |
| Blood loss: greater than 3000 ml | Lethality                       |

Note: These data are not to be construed as absolute.



### 3. to 9. DAMAGE TO (SENSE, BODY ORGAN OR PART)

Columns 3-9 contain the constituent elements of a sense or receptor mechanism. In some cases there will be more than seven, in some cases less. The data required and entered in column nos. 3-9 should be a specific number preferably stated in terms of dose rate,  $\text{Watt/cm}^2$ , or where energy (dose) is of interest or primary concern, in terms of  $\text{Watt-second/cm}^2$  or  $\text{J/cm}^2$ , to produce that effect requested in column 2 for the energy form in column 1. The requested information should be filled in these cells with reference to the appendices pertaining to that data.

### 10., 11., 12. SPECIFIC ADVERSE EFFECTS TO TRANSMISSION

In many cases of interaction of energy with parts of senses or body organs adverse or beneficial effects are observed due to transmission of a signal by the sense or body organ. For example, flickering visible light may cause discomfort to the individual perhaps climaxing in confusion and panic, or pseudo-epileptic seizure, or vomiting.

In addition to the specific number if it is available, columns 10, 11, and 12 should describe in very cogent terms the specific adverse effect of the number entered into the cell. Any appropriate remarks required to qualify the number entered into the specific cells should be inserted in column 14 (Remarks).

### 13. COUNTERMEASURES

Give an indication of whether the effects presented in columns 3 to 12 could be easily protected against, difficult to protect against or impossible to protect against. Protection here should be couched in terms of protection

without adversely affecting the performance capabilities of the individual. For example, it would be easy to protect an individual against any form of radiation by encapsulating him in a lead box. However, the lead box essentially reduces his performance capability to zero and hence is an impossible solution. Included in countermeasures are immunization and therapeutic techniques. Specific information as to the nature of countermeasures should be amplified in Appendix B with appropriate reference. If expansion of easy, difficult or impossible is required, this also should be addressed in Appendix B.

14. REMARKS: Short remarks pertaining to the particular row. If more space is needed, reference in column 14 and enter remarks in Appendix B.

There are four appendices required to support the matrix.

APPENDIX A - BIBLIOGRAPHIC SOURCES. Should contain all relevant literature used to support matrix-entered data.

APPENDIX B - AMPLIFICATION OF REMARKS. Shall contain amplification of the Remarks section of the matrix, if necessary.

APPENDIX C - OTHER POSSIBLE INFORMATION SOURCES. Because the matrix will be filled in by specific people who may not have all sources of information available to them, this appendix should contain all other sources of information which could be explored, if necessary.

APPENDIX D - CATCH-ALL. This appendix is designed to permit the individual respondent to provide his thoughts and/or speculations on the subject area.

Identify Appendix references in cells related to columns 3 to 14 by  
entering in appropriate cells for:

Bibliography (APPENDIX A): A-1,2,.....

Amplification of Remarks (APPENDIX B): B-1,2,.....

Other Possible Information Sources (APPENDIX C): C-1,2,3....

Catch-All (APPENDIX D): D-1,2,3....

## APPENDIX A - Bibliographic Sources

Add pages if necessary.

APPENDIX B - Amplification of Remarks

Add pages if necessary.

APPENDIX C - Other Possible Information Sources

Add pages if necessary.

APPENDIX D - Catch-all

Add pages if necessary.

## INTRODUCTION TO MATRICES ON IONIZING RADIATIONS

This work is the result of a major search of the available world literature on the biological effects of both ionizing electromagnetic and particulate radiation.

Findings are noted for each organ or system on the forms supplied. All doses are expressed in rads (where  $1 \text{ rad} = 10^{-5}$  Joule of deposited energy per gram of matter.) A discussion of units commonly used in radiation biology can be found in Appendix D. When a specific dose for a specified amount of damage to the organ or system was found, it is stated as such in the appropriate box in the matrix along with the reference to the study. When a range of doses was found, meaning that different investigators described the same effect for different doses, the lowest and highest doses that produced the effect are noted along with the particular references. It should come as no surprise that different investigators noted the same effect for different doses when one realizes the great difficulty experienced in reproducing results in biological material even under the best of circumstances. In many of these studies quoted the only common factor was the dose. As would be expected in a field that is relatively new to investigation, there are many organs and systems for which no dose rates have been determined or no specific study can be quoted. These spaces have been either filled with just a reference or left blank. Because electromagnetic ionizing radiation has been the choice until quite recently for the therapy of human disease which lends itself to treatment with ionizing radiation and because the production of particulate ionizing radiation for



therapy, other than those few radioisotopes which are useful in medical therapy, is expensive and cumbersome, the literature is disproportionately concerned with the effects of electromagnetic ionizing radiation, at least as it is concerned with the purpose of this study. The obvious result of this state of affairs is the dearth of references to be found in the matrices dealing with the biological effects of particulate radiation. What literature is available and pertinent to this study is quoted, usually in the form of remarks in Appendix B. The bibliography of sources used for this report comprises Appendix A. Sources that promise possible dose levels but are unavailable either because physically inaccessible or because they are written in a foreign language are in Appendix C.

No attempt has been made to extrapolate data from animal studies to human beings in terms of doses for the reason that such extrapolation is more than likely to be in serious error, e.g., the dose of ionizing radiation to the ovaries of mice which produces a significant increase in congenital abnormalities cannot be extrapolated to the human ovary with any meaningfulness because of a significant difference in the biological development of ova in the two species. When some degree of speculation enters into the dose noted in a box, a footnote to that effect is appended.

Taken in toto, this study points out the large hiatus in our knowledge of the biological effects of ionizing radiation on specific organs and systems in the human being.

| 1                                                         | 2                    | 3                                                                                                                                                                                                              | 4        | 5                      | 6         | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14                                            |
|-----------------------------------------------------------|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|------------------------|-----------|----|----|----|----|----|----|----|-----------------------------------------------|
| PARTICLES (ELECTRONS, PROTONS, IONS, NEUTRONS AND OTHERS) | ENERGY FORM          | REMARKS                                                                                                                                                                                                        |          |                        |           |    |    |    |    |    |    |    |                                               |
|                                                           | LEVEL OF INTERACTION | DAMAGE TO EYE<br>CORNEA<br>PUPIL<br>LENS<br>OPTICAL FLUID<br>CONES<br>RODS<br>EYE MUSCLES<br>ANATOMICAL<br>PHYSIOLOGICAL<br>PSYCHOLOGICAL<br>SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION<br>COGNITIVE EFFECTS |          |                        |           |    |    |    |    |    |    |    |                                               |
|                                                           | SAFE                 | <1,000                                                                                                                                                                                                         | 11,21    | <15<br><200 #          | 07,07,23  | B2 | B2 | B2 | B2 | B2 | B2 |    | \$ for fast neutrons<br># for beta-rays       |
|                                                           | DEGRADATION          | 1,000-29,000                                                                                                                                                                                                   | 11,17,21 | 15-40 #<br>200-2,000 # | *07,07,23 |    |    |    |    |    |    |    | * A1, A9, A11, A16, A17, A19,<br>A20, A22, B3 |
|                                                           | INCAPACITATION       | >25,000                                                                                                                                                                                                        | 11,22,21 | >40 #<br>>2000 #       | 07,12,23  |    |    |    |    |    |    |    |                                               |
|                                                           | LETHALITY            | No dose confined to the orbit will cause whole animal lethality.                                                                                                                                               |          |                        |           |    |    |    |    |    |    |    |                                               |

| 1                                                             | 2                    | 3                                                               | 4        | 5            | 6       | 7 | 8 | 9 | 10                                           | 11          | 12          | 13      | 14               |
|---------------------------------------------------------------|----------------------|-----------------------------------------------------------------|----------|--------------|---------|---|---|---|----------------------------------------------|-------------|-------------|---------|------------------|
| PARTICLES (ELECTRONS, NEUTRONS AND OTHERS), IONS, ENERGY FORM | LEVEL OF INTERACTION | DAMAGE TO EAR                                                   |          |              |         |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | REMARKS |                  |
|                                                               | SAFE                 | DRUM                                                            | OSCILLES | ROUND WINDOW | COCHLEA |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |         | CONTOUR MEASURES |
|                                                               |                      | *                                                               | *        | *            | *       |   |   |   |                                              |             |             |         |                  |
|                                                               |                      |                                                                 |          |              |         |   |   |   |                                              |             |             |         |                  |
|                                                               |                      |                                                                 |          |              |         |   |   |   |                                              |             |             |         |                  |
|                                                               | DEGRADATION          |                                                                 |          |              |         |   |   |   |                                              |             |             |         |                  |
|                                                               | INCAPACITATION       |                                                                 |          |              |         |   |   |   |                                              |             |             |         |                  |
|                                                               | LETHALITY            | No dose localized in the ear will cause whole animal lethality. |          |              |         |   |   |   |                                              |             |             |         |                  |
|                                                               |                      |                                                                 |          |              |         |   |   |   |                                              |             |             |         |                  |

| 1                                                         | 2                    | 3                                                                      | 4              | 5                                             | 6 | 7 | 8               | 9        | 10          | 11          | 12 | 13 | 14                                                                                                  |
|-----------------------------------------------------------|----------------------|------------------------------------------------------------------------|----------------|-----------------------------------------------|---|---|-----------------|----------|-------------|-------------|----|----|-----------------------------------------------------------------------------------------------------|
| PARTICLES (ELECTRONS, PROTONS, IONS, NEUTRONS AND OTHERS) | ENERGY FORM          | DAMAGE TO NOSE                                                         |                | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION: |   |   | COUNTERMEASURES |          |             | REMARKS     |    |    |                                                                                                     |
|                                                           | LEVEL OF INTERACTION | OLFACTORY EPITHELIUM                                                   | OLFACTORY BULB | OLFACTORY TRACT                               |   |   |                 | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC |    |    |                                                                                                     |
|                                                           | SAFE                 | *                                                                      | *              | *                                             |   |   |                 |          |             |             |    |    | *No literature on dosage levels of particulate radiation causing damage to the nose has been found. |
|                                                           | DEGRADATION          |                                                                        |                |                                               |   |   |                 |          |             |             |    |    |                                                                                                     |
|                                                           | INCAPACITATION       |                                                                        |                |                                               |   |   |                 |          |             |             |    |    |                                                                                                     |
|                                                           |                      | No dose confined to the nasopharynx will cause whole animal lethality. |                |                                               |   |   |                 |          |             |             |    |    |                                                                                                     |
|                                                           | LETHALITY            |                                                                        |                |                                               |   |   |                 |          |             |             |    |    |                                                                                                     |

| 1                                                         | 2                    | 3                       | 4                 | 5               | 6 | 7 | 8 | 9                                            | 10          | 11          | 12      | 13 | 14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------------------------------------------------------|----------------------|-------------------------|-------------------|-----------------|---|---|---|----------------------------------------------|-------------|-------------|---------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM                                               | LEVEL OF INTERACTION | DAMAGE TO SKIN (SENSOR) |                   |                 |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | REMARKS |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                           |                      | PRESSURE SENSE          | TEMPERATURE SENSE | CHEMICAL (PAIN) |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |         |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PARTICLES (ELECTRONS, PROTONS, IONS, NEUTRONS AND OTHERS) | SAFE                 | *                       | *                 | *               |   |   |   |                                              |             |             |         |    | *The anatomical makeup of the skin has nerve endings located either in the dermis or in the epidermis. Certainly degradation or incapacitation of either the dermis or epidermis would degrade or incapacitate the sensor faculties of the skin. There are indications <sup>90</sup> , however, that lower doses than those required to cause even epidermal damage have led to sensory changes in touch, pain, and/or thermal sensitivity. Unfortunately, no doses are reported. |
|                                                           | DEGRADATION          |                         |                   |                 |   |   |   |                                              |             |             |         |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                           | INCAPACITATION       |                         |                   |                 |   |   |   |                                              |             |             |         |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                           | LETHALITY            |                         |                   |                 |   |   |   |                                              |             |             |         |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

[illegible]



| 1                                                         | 2                    | 3         | 4     | 5       | 6       | 7               | 8      | 9      | 10                                           | 11          | 12          | 13              | 14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------------------------------------------------------|----------------------|-----------|-------|---------|---------|-----------------|--------|--------|----------------------------------------------|-------------|-------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM                                               | LEVEL OF INTERACTION | DAMAGE TO |       |         |         |                 |        |        | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                           |                      | BLOOD     | LYMPH | MUSCLES | SKELTON | CARDIO-VASCULAR | MARROW | SPLEEN | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PARTICLES (ELECTRONS, PROTONS, IONS, NEUTRONS AND OTHERS) | SAFE                 | ALL       | *     | *       | *       | *               | *      | *      |                                              |             |             |                 | *Excepting long term effects of deposited radionuclides, such as $Sr^{90}$ in bone, no literature on damaging dosage levels from particulate radiation has been found for the anatomical features on this page. This lack of information is perhaps a result of the limited penetration depth of the commonly used low energy beta-rays and thermal neutrons in human or animal tissue. The more deeply penetrating high energy particulate radiation is not yet readily available. |
|                                                           | DEGRADATION          | 25-100    | ALL   |         |         |                 |        |        |                                              |             |             |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                           | INCAPACITATION       | >100      | ALL   |         |         |                 |        |        |                                              |             |             |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                           | LETHALITY            |           |       |         |         |                 |        |        |                                              |             |             |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |



| 1                                                         | 2                    | 3         | 4         | 5        | 6             | 7      | 9 | 10 | 11                                           | 12          | 13          | 14                                                                                                                                                                                                                                                                    |
|-----------------------------------------------------------|----------------------|-----------|-----------|----------|---------------|--------|---|----|----------------------------------------------|-------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM                                               | LEVEL OF INTERACTION | DAMAGE TO |           |          |               |        |   |    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | REMARKS                                                                                                                                                                                                                                                               |
|                                                           |                      | ADRENALS  | PITUITARY | PANCREAS | THYROID       | GONADS |   |    | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                                                                                                                                                                                                                                                                       |
| PARTICLES (ELECTRONS, PROTONS, IONS, NEUTRONS AND OTHERS) | SAFE                 | 85*       | 86*       | 87*      | 88*           | *      |   |    |                                              |             |             | *Excepting the thyroid, where internally deposited radionuclides and high energy particulate radiation have been used to regulate function, no literature on damaging dosage levels from particulate radiation has been found or, the organs or systems on this page. |
|                                                           | DEGRADATION          |           |           |          | 10,000-20,000 |        |   |    |                                              |             |             | #Irradiation localized to the thyroid or gonads will not cause whole animal lethality.                                                                                                                                                                                |
|                                                           | INCAPACITATION       |           |           |          | 10,000        |        |   |    |                                              |             |             |                                                                                                                                                                                                                                                                       |
|                                                           | LETHALITY            |           |           |          | 10,000        | #      |   |    |                                              |             |             |                                                                                                                                                                                                                                                                       |
| COUNTERMEASURES                                           |                      |           |           |          |               |        |   |    |                                              |             |             |                                                                                                                                                                                                                                                                       |

| 1                                                            | 2                    | 3                     | 4       | 5           | 6                         | 7 | 8 | 9 | 10       | 11          | 12          | 13              | 14                                                                                                                                                                                            |
|--------------------------------------------------------------|----------------------|-----------------------|---------|-------------|---------------------------|---|---|---|----------|-------------|-------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM                                                  | LEVEL OF INTERACTION | GASTRO-<br>INTESTINAL | URINARY | RESPIRATORY | LIVER AND<br>GALL BLADDER |   |   |   | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES | REMARKS                                                                                                                                                                                       |
|                                                              |                      |                       |         |             |                           |   |   |   |          |             |             |                 |                                                                                                                                                                                               |
| PARTICLES (ELECTRONS, PROTONS, IONS,<br>NEUTRONS AND OTHERS) | SAFE                 | *                     | *       | *           | *                         |   |   |   |          |             |             |                 | *No literature giving damaging dosage levels for external or internal particulate radiation to the gastrointestinal, urinary, respiratory, and liver and gall bladder systems has been found. |
|                                                              | DEGRA-<br>DATION     |                       |         |             |                           |   |   |   |          |             |             |                 |                                                                                                                                                                                               |
|                                                              | INCAPA-<br>CITATION  |                       |         |             |                           |   |   |   |          |             |             |                 |                                                                                                                                                                                               |
|                                                              | LETHA-<br>LITY       |                       |         |             |                           |   |   |   |          |             |             |                 |                                                                                                                                                                                               |

| 1                                                          | 2                    | 3                                | 4          | 5          | 6           | 7 | 8 | 9            | 10                                           | 11          | 12          | 13              | 14                                                                                                                                                                                                                                                                                                                                                                                 |
|------------------------------------------------------------|----------------------|----------------------------------|------------|------------|-------------|---|---|--------------|----------------------------------------------|-------------|-------------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM                                                | LEVEL OF INTERACTION | DAMAGE TO CENTRAL NERVOUS SYSTEM |            |            |             |   |   | ALPHA RHYTHM | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                                                                                                                                                                                                                                                                                                            |
|                                                            |                      | CEREBRAL HEMISPHERE              | CEREBELLUM | BRAIN STEM | SPINAL CORD |   |   |              | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                                                                                                                                                                                                                                                                                                    |
| PARTICLES (ELECTRONS, PROTONS, IONS, NEUTRONS, AND OTHERS) | SAFE                 | *                                | *          | *          | *           |   |   |              |                                              |             |             |                 | *No literature reporting damaging dosage levels for external radiation to the central nervous system has been found. Harmful effects of beta-emitting radionuclides on the central nervous system were also not found. Although high energy particulate sources of radiation do exist, and have been used to treat intracranial tumors, no literature giving doses has been found. |
|                                                            | DEGRADATION          |                                  |            |            |             |   |   |              |                                              |             |             |                 |                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                            | INCAPACITATION       |                                  |            |            |             |   |   |              |                                              |             |             |                 |                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                            | LETHALITY            |                                  |            |            |             |   |   |              |                                              |             |             |                 |                                                                                                                                                                                                                                                                                                                                                                                    |

| 1                                                          | 2                    | 3                     | 4         | 5 | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                                                                                           |
|------------------------------------------------------------|----------------------|-----------------------|-----------|---|---|---|---|---|----------------------------------------------|-------------|-------------|-----------------|----------------------------------------------------------------------------------------------|
| ENERGY FORM                                                | LEVEL OF INTERACTION | PSYCHOLOGICAL EFFECTS |           |   |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                      |
|                                                            |                      | ASSOCIATIVE SYMBOLS   | ILLUSIONS |   |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                              |
| PARTICLES (ELECTRONS, PROTONS, IONS, NEUTRONS, AND OTHERS) | SAFE                 | *                     | *         |   |   |   |   |   |                                              |             |             |                 | *No literature on the effects of particulate radiation on psychological processes was found. |
|                                                            | DEGRADATION          |                       |           |   |   |   |   |   |                                              |             |             |                 |                                                                                              |
|                                                            | INCAPACITATION       |                       |           |   |   |   |   |   |                                              |             |             |                 |                                                                                              |
|                                                            | LETHALITY            |                       |           |   |   |   |   |   |                                              |             |             |                 |                                                                                              |

| 1                                    | 2                    | 3                                                                | 4      | 5                          | 6                   | 7                 | 8                | 9                              | 10                                           | 11          | 12          | 13              | 14                                                                                                   |
|--------------------------------------|----------------------|------------------------------------------------------------------|--------|----------------------------|---------------------|-------------------|------------------|--------------------------------|----------------------------------------------|-------------|-------------|-----------------|------------------------------------------------------------------------------------------------------|
| ENERGY FORM                          | LEVEL OF INTERACTION | DAMAGE TO EYE                                                    |        |                            |                     |                   |                  |                                | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                              |
|                                      |                      | CORNEA                                                           | IRIDIL | LENS                       | OPTICAL FLUID       | CONES             | RODS             | EYE MUSCLES                    | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                      |
| ELECTROMAGNETIC (X-RAYS, GAMMA RAYS) | SAFE                 | <1,000<br>A1, A19                                                |        | <200<br>A1, A9, A15        |                     | <2,000<br>A15, *  | <1000<br>A10, B9 | <1200<br>A103, *               |                                              |             |             |                 | Reference 4 is a general reference to the effects of ionizing radiation on ocular structures.        |
|                                      | DEGRADATION          | 1,000 - 3,000<br>A1, A19                                         |        | 200 - 1,000<br>A1, A9, A15 |                     | >2,000<br>A15, *  |                  | 1200 - 5,000<br>A1, A103, *    |                                              |             |             |                 | # A9, A10, A16, A19, A20, A25<br>\$ A1, A6, A19, A25, A49, A60                                       |
|                                      | INCAPACITATION       | >3,000<br>A1, A19                                                |        | >1,000<br>*                | 5,000 - 7,000<br>A1 | >30,000<br>A15, * | >2,000<br>A15, * | 19,000 - 49,000<br>A1, A103, * |                                              |             |             |                 | *Experiments conducted on animals, not man.<br>**Dosage levels are general values for muscle tissue. |
|                                      | LETHALITY            | No dose confined to the orbit will cause whole animal lethality. |        |                            |                     |                   |                  |                                |                                              |             |             |                 |                                                                                                      |

| 1                                    | 2                    | 3                                                               | 4        | 5            | 6           | 7             | 8   | 9 | 10                                           | 11          | 12          | 13              | 14                                                                                  |
|--------------------------------------|----------------------|-----------------------------------------------------------------|----------|--------------|-------------|---------------|-----|---|----------------------------------------------|-------------|-------------|-----------------|-------------------------------------------------------------------------------------|
| ENERGY FORM                          | LEVEL OF INTERACTION | DAMAGE TO EAR                                                   |          |              |             |               |     |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                             |
|                                      |                      | DRUM                                                            | OSCICLES | ROUND WINDOW | COCHLEA     | TEMPORAL BONE |     |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                     |
| ELECTROMAGNETIC (X-RAYS, GAMMA RAYS) | SAFE                 | <4,000                                                          | 44,000   | 862,890      |             |               |     |   |                                              |             |             |                 |                                                                                     |
|                                      | DEGRADATION          | >6,000                                                          | >6,000   | 890          | 1900-72,000 | 890, *        |     |   |                                              |             |             |                 | *Experiments conducted on guinea pigs resulted in hearing loss at high frequencies. |
|                                      | INCAPACITATION       |                                                                 |          |              |             | 4000-6,000    | 864 |   |                                              |             |             |                 |                                                                                     |
|                                      | LETHALITY            | No dose localized in the ear will cause whole animal lethality. |          |              |             |               |     |   |                                              |             |             |                 |                                                                                     |

|                                      |                |                                                                        |                |                 |      |   |   |   |                |          |             |                                              |    |                 |         |
|--------------------------------------|----------------|------------------------------------------------------------------------|----------------|-----------------|------|---|---|---|----------------|----------|-------------|----------------------------------------------|----|-----------------|---------|
| 1                                    | 2              | 3                                                                      | 4              | 5               | 6    | 7 | 8 | 9 | 10             | 11       | 12          | 13                                           | 14 |                 |         |
| ELECTROMAGNETIC (X-RAYS, GAMMA RAYS) | ENERGY FORM    | LEVEL OF INTERACTION                                                   |                |                 |      |   |   |   | DAMAGE TO NOSE |          |             | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |    | COUNTERMEASURES | REMARKS |
|                                      |                | OLFACTORY EPITHELIUM                                                   | OLFACTORY BULB | OLFACTORY TRACT |      |   |   |   |                | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC                                  |    |                 |         |
|                                      | SAFE           | 811                                                                    |                |                 |      |   |   |   |                |          |             |                                              |    |                 |         |
|                                      | DEGRADATION    | 2000                                                                   | 1990, 812      | 4000            | 4103 |   |   |   |                |          |             |                                              |    |                 |         |
|                                      | INCAPACITATION |                                                                        |                |                 |      |   |   |   |                |          |             |                                              |    |                 |         |
|                                      | LETHALITY      | No dose confined to the nasopharynx will cause whole animal lethality. |                |                 |      |   |   |   |                |          |             |                                              |    |                 |         |

| 1                                    | 2                    | 3                       | 4                      | 5               | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|--------------------------------------|----------------------|-------------------------|------------------------|-----------------|---|---|---|---|----------------------------------------------|-------------|-------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM                          | LEVEL OF INTERACTION | DAMAGE TO SKIN (SENSOR) |                        |                 |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                      |                      | PRESSURE SENSE          | TEMPERATURE SENSE      | CHEMICAL (PAIN) |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| ELECTROMAGNETIC (X-RAYS, GAMMA RAYS) | SAFE                 | ↓                       | <1000<br>10, *         | ↑               |   |   |   |   |                                              |             |             |                 | *Since there are no nerve endings in the epidermis and dermis, damage to either will degrade or destroy the sensory faculties of the skin. The dosage levels reported are therefore identical to those found from the literature for the dermis. There are indications <sup>90</sup> , however, that lower doses than those required to cause even epidermal damage have led to sensory changes in touch, pain, and/or thermal sensitivity. |
|                                      | DEGRADATION          | ↓                       | 1000-2500<br>10, 10, * | ↑               |   |   |   |   |                                              |             |             |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                      | INCAPACITATION       | ↓                       | >5000<br>10, *         | ↑               |   |   |   |   |                                              |             |             |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                      | LETHALITY            |                         |                        |                 |   |   |   |   |                                              |             |             |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                             |



| 1                                    | 2                    | 3           | 4            | 5                         | 6       | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                                                                                                                                                                                                                                                                 |
|--------------------------------------|----------------------|-------------|--------------|---------------------------|---------|---|---|---|----------------------------------------------|-------------|-------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM                          | LEVEL OF INTERACTION | EPIDERMIS   | DERMIS       | DAMAGE TO SKIN (COVERING) |         |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                                                                                                                                                                                            |
|                                      |                      |             |              |                           |         |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                                                                                                                                                                                    |
| ELECTROMAGNETIC (X-RAYS, GAMMA RAYS) | SAFE                 | <35         | MI, A28, A79 | <1,000                    | MI      |   |   |   |                                              |             |             |                 |                                                                                                                                                                                                                                                                    |
|                                      | DEGRADATION          | 2,000-3,000 | *            | 1,000-2,500               | MI, A74 |   |   |   |                                              |             |             |                 | * A1, A3, A14, A28, A74                                                                                                                                                                                                                                            |
|                                      | INCAPACITATION       | >3,000      | MI, A74      | 25,000                    | A79     |   |   |   |                                              |             |             |                 | # Dosage sufficient to destroy the epidermal layer over a large percentage of the body would kill in a manner analogous to a burn (approximately 75% epidermal destruction will kill for burns, probably less for radiation because of slowed epidermal regrowth.) |
|                                      | LETALITY             | #           |              |                           |         |   |   |   |                                              |             |             |                 |                                                                                                                                                                                                                                                                    |

| 1                                    | 2                    | 3                                | 4                       | 5 | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                                                                                        |
|--------------------------------------|----------------------|----------------------------------|-------------------------|---|---|---|---|---|----------------------------------------------|-------------|-------------|-----------------|-------------------------------------------------------------------------------------------|
| ENERGY FORM                          | LEVEL OF INTERACTION | DAMAGE TO KINESTHETIC            |                         |   |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                   |
|                                      |                      | POSTURAL SENSIBILITY (LABYRINTH) | GAMMA MOTOR SYSTEM      |   |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                           |
| ELECTROMAGNETIC (X-RAYS, GAMMA RAYS) | SAFE                 | <2,000 R <sub>1</sub> *          | <6,000 R <sub>2</sub> # |   |   |   |   |   |                                              |             |             |                 |                                                                                           |
|                                      | DEGRADATION          | >2,000 R <sub>1</sub> *          | >6,000 R <sub>2</sub> # |   |   |   |   |   |                                              |             |             |                 | *In 50% of rats exposed to x-rays.                                                        |
|                                      | INCAPACITATION       | 5,000-22,000 R <sub>1</sub> *    |                         |   |   |   |   |   |                                              |             |             |                 | *In the burro, which has a much lower central nervous system syndrome threshold than man. |
|                                      | LETHALITY            |                                  |                         |   |   |   |   |   |                                              |             |             |                 |                                                                                           |

| 1                                    | 2                    | 3              | 4           | 5           | 6           | 7           | 8               | 9           | 10          | 11                                           | 12 | 13 | 14      |
|--------------------------------------|----------------------|----------------|-------------|-------------|-------------|-------------|-----------------|-------------|-------------|----------------------------------------------|----|----|---------|
| ENERGY FORM                          | LEVEL OF INTERACTION | SAFE           | BLOOD       | LYMPH       | MUSCLES     | SKELETON    | CARDIO-VASCULAR | MARROW      | SPLEEN      | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |    |    | REMARKS |
|                                      |                      | DEGRADATION    | 100-150     | 2,000-3,000 | 1,200-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
|                                      |                      | INCAPACITATION | 2,000-3,000 | 1,200-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
|                                      |                      | LETHALITY      | 100-150     | 2,000-3,000 | 1,200-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
| ELECTROMAGNETIC (X-RAYS, GAMMA RAYS) | SAFE                 | 100-150        | 2,000-3,000 | 1,200-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 | COUNTERMEASURES                              |    |    |         |
|                                      | DEGRADATION          | 2,000-3,000    | 1,200-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
|                                      | INCAPACITATION       | 2,000-3,000    | 1,200-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
|                                      | LETHALITY            | 100-150        | 2,000-3,000 | 1,200-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
| ENERGY FORM                          | LEVEL OF INTERACTION | SAFE           | BLOOD       | LYMPH       | MUSCLES     | SKELETON    | CARDIO-VASCULAR | MARROW      | SPLEEN      | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |    |    |         |
|                                      |                      | DEGRADATION    | 100-150     | 2,000-3,000 | 1,200-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
|                                      |                      | INCAPACITATION | 2,000-3,000 | 1,200-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
|                                      |                      | LETHALITY      | 100-150     | 2,000-3,000 | 1,200-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
| ELECTROMAGNETIC (X-RAYS, GAMMA RAYS) | SAFE                 | 100-150        | 2,000-3,000 | 1,200-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 | COUNTERMEASURES                              |    |    |         |
|                                      | DEGRADATION          | 2,000-3,000    | 1,200-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
|                                      | INCAPACITATION       | 2,000-3,000    | 1,200-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
|                                      | LETHALITY            | 100-150        | 2,000-3,000 | 1,200-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
| ENERGY FORM                          | LEVEL OF INTERACTION | SAFE           | BLOOD       | LYMPH       | MUSCLES     | SKELETON    | CARDIO-VASCULAR | MARROW      | SPLEEN      | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |    |    |         |
|                                      |                      | DEGRADATION    | 100-150     | 2,000-3,000 | 1,200-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
|                                      |                      | INCAPACITATION | 2,000-3,000 | 1,200-5,000 | 2,000-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |
|                                      |                      | LETHALITY      | 100-150     | 2,000-3,000 | 1,200-5,000 | 2,000-5,000 | 2,000-5,000     | 1,000-2,500 | 1,000-2,500 |                                              |    |    |         |

|                                      |                      |               |              |                 |                       |        |   |   |                                              |             |             |                 |                                                                             |
|--------------------------------------|----------------------|---------------|--------------|-----------------|-----------------------|--------|---|---|----------------------------------------------|-------------|-------------|-----------------|-----------------------------------------------------------------------------|
| 1                                    | 2                    | 3             | 4            | 5               | 6                     | 7      | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                                                                          |
| ELECTROMAGNETIC (X-RAYS, GAMMA RAYS) | ENERGY FORM          | DAMAGE TO     |              |                 |                       |        |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                     |
|                                      | LEVEL OF INTERACTION | ADRENALS      | PITUITARY    | PANCREAS        | THYROID               | GONADS |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                             |
|                                      | SAFE                 | 14,000<br>A74 | 10,000<br>A1 |                 |                       |        |   |   |                                              |             |             |                 |                                                                             |
|                                      | DEGRA-DATION         | 24,000<br>A74 | 20,000<br>A1 | 2,000<br>A74, # | 290,000-50,000<br>A74 | B17    |   |   |                                              |             |             |                 |                                                                             |
|                                      | INCAPA-CITATION      |               |              | 8,000<br>A74, # | 290,000<br>A74        | B17    |   |   |                                              |             |             |                 |                                                                             |
|                                      | LETHA-LITY           |               |              |                 |                       | *      |   |   |                                              |             |             |                 | *No dose localized to ovaries or testes could cause whole animal lethality. |
|                                      |                      |               |              |                 |                       |        |   |   |                                              |             |             |                 | #Experiments conducted on rats.                                             |

| 1           | 2                    | 3                                | 4            | 5          | 6            | 7                | 8                | 9            | 10                                           | 11          | 12               | 13              | 14                                                                                                      |
|-------------|----------------------|----------------------------------|--------------|------------|--------------|------------------|------------------|--------------|----------------------------------------------|-------------|------------------|-----------------|---------------------------------------------------------------------------------------------------------|
| ENERGY FORM | LEVEL OF INTERACTION | DAMAGE TO CENTRAL NERVOUS SYSTEM |              |            |              |                  |                  |              | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |                  | COUNTERMEASURES | REMARKS                                                                                                 |
|             |                      | CEREBRAL HEMISPHERE              | CEREBELLUM   | BRAIN STEM | SPINAL CORD  |                  |                  | ALPHA RHYTHM | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC      |                 |                                                                                                         |
|             |                      | 5,000-200,000                    | 3,000-5,000  | >5,000     | >3,000       | N1, N2, N32, B22 | N1, N30, B23     | <1,000       | <1,000                                       | <1,100      | N1, N44, N5, B24 |                 |                                                                                                         |
|             |                      | >1,500                           | 500-2,000    | >1,500     | N1, N51, N65 | N1, N5, N65*     | N1, N44, N5, B24 |              |                                              |             |                  |                 |                                                                                                         |
|             |                      | INCAPA-CITATION                  | DEGRA-DATION | SAFE       |              |                  |                  |              |                                              |             |                  |                 |                                                                                                         |
|             | LETHA-LITY           | 5,000-200,000                    | 3,000-5,000  | >5,000     | >3,000       | N1, N2, N32, B22 | N1, N30, B23     | <1,000       | <1,000                                       | <1,100      | N1, N44, N5, B24 |                 | **In most severe cases, quad-raplegia is the eventual result. Death follows, but from secondary causes. |
|             | INCAPA-CITATION      | 5,000-200,000                    | >3,000       | >5,000     | >3,000       | N1, N2, N32      | N1, N30          | >1,500       | N1, N51, N65                                 | >2,000      | N1, N44, N5, B24 |                 | *Animal experiments on monkeys.                                                                         |
|             | DEGRA-DATION         | >1,500                           | 500-2,000    | >1,500     | N1, N51, N65 | N1, N5, N65*     | N1, N44, N5, B24 |              |                                              |             |                  |                 |                                                                                                         |
|             | SAFE                 | 1,200                            | 4500         | <1,000     | <1,100       |                  |                  | B25          |                                              |             |                  |                 |                                                                                                         |

|                                      |                      |                        |           |   |   |   |   |   |                                                    |             |             |                 |                                                               |
|--------------------------------------|----------------------|------------------------|-----------|---|---|---|---|---|----------------------------------------------------|-------------|-------------|-----------------|---------------------------------------------------------------|
| 1                                    | 2                    | 3                      | 4         | 5 | 6 | 7 | 8 | 9 | 10                                                 | 11          | 12          | 13              | 14                                                            |
| ENERGY FORM                          | LEVEL OF INTERACTION | ASSOCIATIVE<br>SYMBOLS | ILLUSIONS |   |   |   |   |   | SPECIFIC ADVERSE<br>EFFECTS DUE TO<br>TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                       |
|                                      |                      |                        |           |   |   |   |   |   | ANATOMIC                                           | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                               |
| ELECTROMAGNETIC (X-RAYS, GAMMA RAYS) | SAFE                 | 826                    | *         |   |   |   |   |   |                                                    |             |             |                 | *No literature on radiation<br>produced illusions. was found. |
|                                      | DEGRA-<br>DATION     |                        |           |   |   |   |   |   |                                                    |             |             |                 |                                                               |
|                                      | INCAPA-<br>CITATION  |                        |           |   |   |   |   |   |                                                    |             |             |                 |                                                               |
|                                      | LETHA-<br>LITY       |                        |           |   |   |   |   |   |                                                    |             |             |                 |                                                               |

| 1                                            | 2                    | DAMAGE FROM WHOLE BODY RADIATION |                         |                        |             |             |     |  | 10                                           | 11       | 12          | 13          | 14              |                                                                                 |  |
|----------------------------------------------|----------------------|----------------------------------|-------------------------|------------------------|-------------|-------------|-----|--|----------------------------------------------|----------|-------------|-------------|-----------------|---------------------------------------------------------------------------------|--|
| IONIZING RADIATION                           | LEVEL OF INTERACTION | Hematopoietic System             | Gastrointestinal System | Central Nervous System |             |             |     |  | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES | REMARKS                                                                         |  |
|                                              |                      | 200-600                          | >1,000                  | H2, H1                 | >5,000      | A2, H1, H29 |     |  |                                              |          |             |             |                 |                                                                                 |  |
|                                              |                      | 100-200                          | >3,000                  | H2                     | >1,000      | A29         |     |  |                                              |          |             |             |                 |                                                                                 |  |
|                                              |                      | 100-200                          | 100-2,000               | H2, H1, H70            | <1,000      | H29         |     |  |                                              |          |             |             |                 |                                                                                 |  |
|                                              |                      | SAFE                             |                         |                        |             |             |     |  |                                              |          |             |             |                 |                                                                                 |  |
|                                              | INCAPA-CITATION      | 200-1,000                        | H11                     | >3,000                 | H2          | A2, H1, H29 |     |  |                                              |          |             |             |                 |                                                                                 |  |
|                                              | DEGRA-DATION         | 100-200                          | H11, A99                | 100-2,000              | H2, H1, H70 | >1,000      | A29 |  |                                              |          |             |             |                 | Whole body dose % fatalities<br>in rads<br>200 few<br>400-450 50<br>700-800 100 |  |
|                                              | LETRA-LITY           |                                  |                         |                        |             |             |     |  |                                              |          |             |             |                 | LD <sub>50</sub> for man = 360 rads <sup>75</sup>                               |  |
| SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                      |                                  |                         |                        |             |             |     |  |                                              |          |             |             |                 |                                                                                 |  |
| COUNTERMEASURES                              |                      |                                  |                         |                        |             |             |     |  |                                              |          |             |             |                 |                                                                                 |  |
| REMARKS                                      |                      |                                  |                         |                        |             |             |     |  |                                              |          |             |             |                 |                                                                                 |  |

APPENDIX A  
BIBLIOGRAPHIC SOURCES



1. Moss, W.T., W.N. Brand  
Therapeutic Radiology: Rational, Technique, Results, 3rd Ed.  
C.V. Mosley Co., St. Louis, 1969.
2. Upton, A.C.  
Radiation Injury: Effects, Principles and Perspectives  
Univ. of Chicago Press, Chicago, 1969.
3. Archambeau, J.O.  
"The Effect of Increasing Exposures of the  $^{10}\text{B}(n,\alpha)^7\text{Li}$  Reaction on the Skin of Man"  
Radiology 94:179-187, Jan. 1970.
4. Haye, C., H. Jammet, M.A. Dollfus  
L'Oeil et Les Radiations Ionisantes  
Masson et Cie, Paris, 1965.
5. Liebow, A.A., S. Warren, E. DeCoursey  
"Pathology of Atomic Bomb Casualties"  
Am. J. Path., 25:853-1028, Sep. 1949.
6. Abelson, P.H., P.G. Kruger  
"Cyclotron-Induced Radiation Cataracts"  
Science, 110:655-7, 1949.
7. Cohen, L.B., T.F. Graham, W.E. Fry  
"Beta Radiation as an Adjunct to Glaucoma Surgery in the Negro"  
Amer. J. Ophthal., 47:54-61, 1959.
8. Peck, W.S., J.T. McGreer, N.R. Kretschmar, W.E. Brown  
"Castration of the Female by Irradiation"  
Radiology, 34:176-186, 1940.
9. Han, W.T., Jr.  
"Radiation Cataract"  
Arch. Ophthal., 50:618-643, 1953.
10. Cogan, D.G., K.K. Dreisler  
"Minimal Amount of X-Ray Exposure Causing Lens Opacities in the Human Eye"  
Arch. Ophthal., 50:30-34, 1953.
11. Glasstone, S., Ed.  
The Effects of Nuclear Weapons  
U.S.A.E.C., 1962.

12. Riley, E.F., T.C. Evans, R.B. Rhody, P.J. Leinfeldu, R.D. Richards  
"The Relative Biological Effectiveness of Fast-Neutron and X-Radiation-Survival and Cataract Studies of Swiss Mice"  
Radiology, 67:673-685, 1956.
13. Meki, E.B.  
"Effects of Nuclear Weapons on the Vision of Survivors - A Review of the Literature"  
Amer. J. Optom., 39:683-687, 1963.
14. Lacassagne, A., G. Gricouroff (Translated by C.C. Lushbaugh and G.R. Reise)  
Action of Radiation on Tissues - An Introduction to Radiotherapy  
Grime and Stratton, Inc., New York, 1958.
15. Cebis, P.A., W.K. Noell, B. Eickel  
"Ocular Effects Produced by High-Intensity X-Radiation"  
Arch. Ophthal., 53:651-663, 1955.
16. Upton, A.C., K.W. Christenberry, G.S. Melville, J. Furth, G.S. Hurst  
"The Relative Biological Effectiveness of Neutrons, X-Rays, and X-Rays for the Production of Lens Opacities: Observations on Mice, Rats, Guinea Pigs, and Rabbits"  
Radiology, 67:686-696, 1956.
17. Merriam, G.R., Jr.  
"Radiotherapy in Ophthalmology"  
N.Y. St. J. of Med., 56:3683-3685, 1956.
18. Jones, R.F.  
"Glaucoma Following Radiotherapy"  
Brit. J. Ophthal., 42:636-638, 1958.
19. Cogan, D.G.  
"Ocular Effects of Radiation"  
New England J. Med., 259:517-9, 1958.
20. Brown, D.Y.L.  
"Atomic Energy and the Eye"  
Illinois Med. J., 113:159-60, 1958.
21. Buys, N.S., T.C. Kerns  
"Irradiation Damage to the Chiasm"  
Amer. J. Ophthal., 44:483-6, 1959.

22. McDonald, J.E., F.M. Wilson  
"Ocular Therapy with Beta Particles"  
Trans. Amer. Acad. Ophthal. Otolaryng., 63:486-85, 1959.
23. Semalang, K.L. Oey  
"How Much X-Radiation Can the Human Retina Tolerate"  
J. Indones. Med. Ass., 811:18-19, 1958.
24. Ziskla, R.E.,  
Biological Effects of External Beta Radiation  
McGraw Hill, New York, 1951.
25. Merriam, G.R., M.D., E.F. Focht  
"A Clinical Study of Radiation Cataracts and the Relationship to Dose"  
Amer. J. of Roentgen., 77:759-785, 1957.
26. Merriam, G.R., Jr.,  
"The Effects of Beta Radiation in the Eye"  
Radiology, 66:240-45, 1956.
27. Parker, R.G., L.L. Burnett, P. Wootten, D.J. McIntyre  
"Radiation Cataract in Clinical Therapeutic Radiology"  
Radiology, 82:794-798, 1964.
28. Clark, G.L.  
The Encyclopedia of X-Rays and Gamma-Rays  
Reinhold Publishing Corp., New York, 1963.
29. Claus, W.D.  
"Radiation Biology as a Science" in Proceedings of the Conference on  
Radiation Biology  
USAEC Conf-650847, pp. 9-15, N68-19367, Aug. 2-5, 1965.
30. Bailey, O.T., D.E. Smith  
The Central Nervous System - Some Experimental Models of Neurological  
Diseases  
International Academy of Pathology Monograph #9, The Williams and Wilkins  
Company, Baltimore, 1968.
31. Okunewick, J.P., K.M. Hartley  
"Effect of Preirradiation and Post-Irradiation Erythropoietic Stimulation on  
Survival Following Exposure to Hematopoietically Lethal X-Ray Doses"  
AFRRI, SR68-13, May 1968.

32. Upton, A.C.  
"Radiation Effects in Mammalian Tissues" in Proceedings of the Conference  
on Radiation Biology"  
USAEC, Conf-650847, pp. 25-36, Aug. 2-5, 1965.
33. Bacq, Z.M., P. Alexander  
Fundamentals of Radiobiology, 2nd Ed.  
English Language Book Society and Pergamon Press, New York, 1966.
34. M.F. Sullivan, Ed.  
Gastrointestinal Radiation Injury  
Monographs on Nuclear Medicine and Biology #1, Excerpta Medica  
Foundation, 1968, New York.
35. Bond, V.P., T.M. Fliedner, J.O. Archambeau  
Mammalian Radiation Lethality - A Disturbance in Cellular Kinetics  
Academic Press, New York, 1965.
36. Peck, F.C., E.R. McGovern  
"Radiation Necrosis in Acromegaly"  
J. Neurosurg, 25:536-542, 1966.
37. Van Cleave, C.D.  
"Irradiation and the Nervous System"  
Rowman and Littlefield, Inc., New York, 1963.
38. Ferrers, R.G.A., J.M. Obarrio  
"Myelopathy Following Teletherapy with Radioactive Cobalt"  
J. Neurological Sciences, 2:446-450, 1965.
39. Smithers, P.W., J.R. Clarkson, J.A. Strong  
"The Roentgen Treatment of Cancer of the Esophagus"  
Amer. J. Roentgen, 49:606-634, 1943.
40. Greenfield, M.H., F.H. Stack  
"Post-Irradiation Neuropathy"  
Amer. J. Roentgen., 60:617-622, 1948.
41. Dal Santo, G.  
"The 'Blood-Brain Barrier', Its Pathology and Its Importance in Anesthesia"  
Clinical Anesthesia, 3:17-57, 1967.
42. Feder, B.H., R.S. Boswell, J.W. Schaefflein, C.A. Sondheus, J. Stuklbaig  
"Further Observations on Reaction Time and Flicker Fusion in 'Normal'  
Humans Under Daily Irradiation."  
Radiology, 90:335-8, 1968.

43. Coy, P., S. Baker, C.L. Dolmen  
"Progressive Myelopathy Due to Radiation"  
Canad. Med. Ass. J., 100:1129-33, Jun. 28, 1969
44. Atkins, H.L., P. Tretter  
"Time-Dose Considerations in Radiation Myelopathy"  
Acta Radiol. (Ther.), 5:79-94, 1966.
45. Crock, G.  
"Clinical Syndromes of Anterior Segment Ischaemia"  
Trans. Ophthal. Soc. UK, 87:513-33, 1967
46. Pallis, C.A., S. Louis, R.L. Morgan  
"Radiation Myelopathy"  
Brain, 84:460-479, 1961.
47. Boldrey, E., G. Sheline  
"Delayed Transitory Clinical Manifestations After Radiation Treatment of Intracranial Tumors"  
Acta Radiol. (Ther.), 5:5-10, 1966.
48. Lampe, I., R.S. MacIntyre  
"Experiences in the Radiation Therapy of Medulloblastoma of the Cerebellum"  
Amer. J. of Roentgen, 71:659, 1954.
49. "Radiation Cataract - New Evidence on Radiation Dosage to the Lens"  
Brit. J. Radiol., 39:612-617, 1966.
50. Hiller, R.J., T. Fiyino, M.D. Nefzger  
"Lens Findings in Atomic Bomb Survivors"  
Arch. Ophthal., 78:697-704, 1967.
51. Boden, G.  
"Radiation Myelitis of the Brain-Stem"  
J. Faculty of Radiologists, 2:79-94, 1950.
52. Stein, J.J., C.A. Cancu  
"The Carcinogenic Hazards of Ionizing Radiation in Diagnostic and Therapeutic Radiology"  
J. for Clinicians, 17:278-287, 1967.
53. Perris-Taylor, M., D. Brinkley, T. Reynolds  
"Choroido-Retinal Damage as a Complication of Radiotherapy"  
Acta Radiol. (Ther.), 3:431-440, 1965.

54. Parker, R.G., L.L. Burnett, P. Wootton, D.J. McIntyre  
"Radiation Cataract in Clinical Therapeutic Radiology"  
Radiology, 82:794-799, 1964.
55. Thomas, C.I., J.P. Storaasli, H.L. Friedell  
"Lenticular Changes Associated with Beta Radiation of Eye and Their Significance"  
Radiology, 79:588-597, 1962.
56. Arnold, A., P. Bailey, R.A. Harvey, L.L. Haas, J.S. Laughlin  
"Changes in the Central Nervous System Following Irradiation with 23 Mev X-Rays from the Betatron"  
Radiology, 62:37-46, 1954.
57. Cronkite, E.P.  
"Radiation-Induced Aplastic Anemia"  
Sem. Hematology, 4:273-277, 1967
58. Boden, G.  
"Radiation Myelitis of the Cervical Spinal Cord"  
Brit. J. Radiol., 21:464-469, 1948
59. Crompton, M.R., D.D. Layton  
"Delayed Radionecrosis of the Brain Following Therapeutic X-Radiation of the Pituitary"  
Brain, 84:85-101, 1961.
60. Krause, A.C., J.O. Bond  
"Neutron Cataracts"  
Amer. J. Ophthal., 34:25-35, 1951.
61. Borsanyi, S.J., C.L. Blanchard  
"Ionizing Radiation and the Ear"  
JAMA 181:958-961, 1962.
62. Gyorkey, J., F.J. Pollock  
"Radiation Necrosis of the Ossicles"  
Arch. Otolaryng., 71:793-797, 1960.
63. "Abnormalities in Children Exposed to X-Radiation During Various Stages of Gestation. Tentative Timetable of Radiation Injury to the Human Fetus, Pt. 1"  
J. Nuclear Med. 9:471-477, 1968.
64. Lindgren, M.  
"On Tolerance of Brain Tissue and Sensitivity of Brain Tumours to Irradiation"  
Acta Radiol., Suppl. 170, 1958.

65. Arnold, A., P. Bailey, R.A. Harvey  
"Intolerance of the Primate Brainstem and Hypothalamus to Conventional and High Energy Radiations"  
Neurology, 4:575-585, 1954.
66. Hartmann, M.E., M. Fontaine  
"Atrophie De La Glande Lacrymale Avec Irritation Oculaire Après Radiothérapie Delaface"  
Soc.d'Opht. de Paris, 2:191-192, 1947.
67. Grashchenkov, N.I.  
"Morphologic and Pathophysiologic Signs of the Response of the Nervous System to Ionizing Radiation", in Response of the Nervous System to Ionizing Radiation  
T.J. Haley and R.S. Snider, Ed. Academic Press, New York, 1962, 297-314.
68. Kristensson, K., B. Molin, P. Sourander  
"Delayed Radiation Lesions of the Human Spinal Cord"  
Acta Neuropathologica, 9:34-44, 1967.
69. Monro, P., W.G.P. Mair  
"Radiation Effects on the Human Central Nervous System 14 Weeks After X-Radiation"  
Acta Neuropathologica, 11:267-274, 1968.
70. Van Denbrenk, H.A.  
"Results of Prophylactic Postoperative Irradiation in 1,300 Cases of Pterygium"  
Amer. J. Roentgen, 103:723-33, Aug. 1968.
71. Bloch, M., H.J.G. Bloom, J. Penman, L. Walsh  
"Observations on Patients with Cerebral Astrocytoma (Glioblastoma Multiforme) Treated by Irradiation Under Whole-Body Hypothermia"  
Brit. J. Cancer, 20:722-8, Dec. 1966.
72. Vaeth, J.  
"Radiation-Induced Myelitis"  
Prog. In Rad. Therapy, 3:16-26, 1965.
73. Sabanas, A.O., D.C. Dahlin, D.S. Childs, et. al.  
"Post-Radiation Sarcoma of Bone"  
Cancer, 9:528-542, 1956.
74. Behrens, C.F., E. King, J.W.J. Carpender  
Atomic Medicine  
The Williams and Wilkins Company, Baltimore, 1969.

75. "Report of the United Nations Scientific Committee on the Effects of Atomic Radiation, General Assembly Official Records (17th Session )" Suppl. #16 (A/5216).
76. Danowski, T.S., G. Sabeh, R.A. Alley, et. al.  
"Pituitary Ablation Insulin Dosage, and Course of Diabetic Retinopathy" Metabolism, 17:953-965, 1968.
77. Chono, C.Y.L., J.A. Linfoot, J.H. Lawrence  
"High Energy Heavy Charged Particles in Medicine" Radiology, Clin. N. Amer., 7:319-43, Aug. 1969.
78. Chang, C.H., J.L. Pool  
"The Radiotherapy of Pituitary Chromophobe Adenomas" Radiology, 89:1005-16, 1967.
79. Abe, Y., T. Sugai, T. Saito  
"Radiation Angiokeratoma Following Grenz Radiation" Arch. Derm., 100:294-6, 1969.
80. Chee, P.H.Y.  
"Radiation Retinopathy" Amer. J. Ophthal., 66:860-5, 1968.
81. Beck, C.  
"Surface Irradiation of the Eustachian Tube" Arch. Otolaryng., 90:28-31, 1969.
82. Oosterhuis, J.A., D.H. Loewer-Sieger, J. Van Gool  
"Treatment of Diabetic Retinopathy by X-Radiation of the Pituitary" Acta Ophthal., 41:621-639, 1963.
83. Blozis, G.C., J.E. Robinson  
"Oral Tissue Changes Caused by Radiation Therapy and Their Management" Dent. Clin. N. Amer., 643-56, Nov. 1968.
84. Patt, H.M., H. Quastler  
"Radiation Effects on Cell Renewal and Related Systems" Physiol. Reviews, 43:357-396, 1963.
85. McLean, F.C., A.M. Budy  
Radiation, Isotopes and Bone Academic Press, New York, 1964.
86. Mostofi, F.K.  
"Radiation Effects on the Kidney" in The Kidney F.K. Hostofi and D.E. Smith, Eds., Williams and Wilkins Company, Baltimore 1966, 338-386.



87. Hahn, S., D.A. Corgill  
"Conservative Treatment of Radionecrosis of the Mandible"  
Oral Surgery, 24:707-11, Nov. 1967.
88. Gehrig, J.D.  
"Should Teeth be Removed Prior to Radiation Therapy?"  
Dental Clin. N. Amer., 13:929-38, Oct. 1959.
89. Livanov, M.N., I.N. Kondrat'eva  
"Sensitivity of the Nervous System to Low-Level Radiation"  
Academy of Medical Science USSR, Moscow, 1960, AEC-tr-4090.
90. Kimeldorf, D.J., E.L. Hunt  
"Ionizing Radiation: Neural Function and Behavior"  
Academic Press, New York, 1965.
91. Schiroki, L.L.  
Radiobiology and Radiation Hazards  
ATD Report 69-13-22-1, 19 December 1968, Library of Congress.
92. Grollman, J.H., S.M. Bierman, R.E. Ottoman, J.E. Morgan, J. Horns  
"Total Skin Electron-Beam Therapy of Lymphoma Cutis and Generalized Psoriasis:  
Clinical Experiences and Adverse Reactions"  
Radiology, 87:908-915, Nov. 1966.
93. Gregory, P.B., R.C. Milton, M.T. Johnson, T. Taura  
"Spleen Shielding in Survivors of the Atomic Bomb"  
Rad. Res., 33:204-215, 1968.
94. Bachman, A.L., K. Malken  
"Pleural Effusions Following Supervoltage Radiation for Breast Carcinoma"  
Radiology, 72:699-709, 1957.
95. Gass, J.D.M.  
"A Fluorescein Angiographic Study of Macular Dysfunction Secondary to Retinal  
Vascular Disease"  
Arch. Ophthal., 80:606-17, 1968.
96. Field, J.B.  
"The Relative Biological Effectiveness of Fast Neutrons for Mammalian Tissues"  
Radiology, 93:915-20, Oct. 1969
97. Shapiro, N.I., N.I. Nughdin, A.M. Kuzin  
"The Action of Estrogens on the Radiation Reaction in Mice" in Collected Works  
on Radiobiology, N. I. Nughdin, Ed.  
AEC-tr-3740, pp. 13-47, May 1960.

98.     .     son, C.H.  
      "Effects of Irradiation of Brain Tumors on Ventricular Fluid Pressure"  
      Acta Radiol. (Ther.), 6:22-32, Feb. 1967.
99.     Casarett, A.P.  
      Radiation Biology  
      Prentice-Hall, Inc. Englewood Cliff, N.J., 1968.
100.    Frommhold, W., G. Bublitz, G. Gries  
      "The Use of DMSO for the Treatment of Post Irradiation Subcutaneous Plaques"  
      Ann N.Y. Acad. Sciences, 141:603-12, 15 Mar. 1967.
101.    Tubiana, M.  
      "Effects Hematologiques d'Une Irradiation Totale ou Partielle de L'Organism Humain"  
      in Effects of Ionizing Radiations on the Haematopoietic Tissue  
      Panel Proceedings Series, International Atomic Energy Agency, Vienna, 1967.
102.    Raskind, R.  
      "Central Nervous System Damage After Radiation Therapy"  
      Intern. Surg., 48:430-41, 1967.
103.    Grigor'ev, Yu G.  
      "Data on the Reactions of the Human Central Nervous System to Ionizing Radiations"  
      AEC-tr-4264. 1958.
104.    Pierce, C. M., W. E. Bost, H. L. Ward, Hugh E. Voress  
      "The Effects of Radiation and Radioisotopes on the Life Processes: An  
      Annotated Bibliography"  
      USAEC TID-3098, September 1963.
105.    Ingram, Marylou  
      "Biological Effects of Ionizing Radiation: An Annotated Bibliography"  
      USAEC TID-3097, December 1966.

APPENDIX B  
AMPLIFICATION OF REMARKS

Damage From Particulate Radiation to the Eye (A1)

1. Approximately 1000 rads will produce a superficial keratitis (inflammation of the cornea) which, appearing after a latent period of several weeks, will generally subside without serious sequelae. Moderate doses (on the order of 5000 rads or less) produce punctate keratitis. Doses as high as 20,000-30,000 rads will produce ulceration followed by keratinization and telangiectasis.<sup>1</sup> Corneal scarring will appear in a certain number of cases after a latent period inversely proportional to the dose.<sup>26</sup>
2. Because beta-rays and thermal neutrons are absorbed within a thickness of several millimeters of living tissue, the chief ocular structures damaged by such external particulate radiation will be the lens and cornea. Deeper lying structures will not be significantly effected by low energy external particulate radiation. A possible source of damaging dosage levels for the retinal elements, muscles, and vitreous humor would be studies of Beta-emitting radionuclides introduced to the posterior region of the eye or high energy electron, proton, deuteron radiation, capable of deep penetration into human tissue. No such studies have been found in the literature.
3. Radiation causes opacification of the lens or "radiation cataract". Neutrons, especially fast neutrons, have a very high RBE. Consequently, a low dose (approximately 15 rads) can lead to opacities in the lens.

Damage From Particulate Radiation to the Skin as a Covering (A-5)

4. Most of the energy from incident beta-rays or neutrons is absorbed by the epidermis. The dosage levels for epidermal degradation and incapacitation are therefore well known, while dosage levels of particulate radiation sufficient to cause dermal destruction seem to be unknown.

Damage from Particulate Radiation to Adrenals, Pituitary, and Pancreas (A-8)

5. Irradiation may alter adrenal function but this alteration appears to be the result of stress of illness rather than a primary effect of radiation.
6. Pituitary gland irradiation with high energy electrons increases the ACTH content of the blood within one hour of the time of irradiation. The increase lasts for at least 24 hours. Experiments with rats has lead to the conclusion by at least one author that the gonadotropia, somatotropia and thyrotropic activities of the pituitary are either unaffected or slightly stimulated by irradiation if the adrenals are intact.<sup>33</sup>
7. The pancreas of the irradiated rat loses its ability to form citrate.<sup>33</sup>

Damage from Electromagnetic Radiation to the Eye (B-1)8. Possible sequelae of X-ray irradiation of orbit:<sup>53</sup>

punctate staining of cornea  
atrophy of iris  
glaucoma  
cataract  
choiroido-retinal changes

9. The dark adapted human retina is sensitive to low levels of X and gamma radiation. Brief exposures to approximately 1 Mev of X-rays produce perception of an unsaturated bluish light and allows the discrimination of a shadow of a radio-opaque object. Beta and gamma-rays cause the perception of a greenish formless glow.<sup>90</sup>

Damage from Electromagnetic Radiation to the Ear (B-2)

10. Immediate sequelae of a therapeutic dose of X or gamma-radiation are a transient radiation otitis media and vasculitis of the vessels of the inner ear resulting in hearing loss, tinnitus, temporary recruitment, a painful feeling of fullness, and possible obstruction of the eustachian tube caused by swelling of mucosa. Possible late changes include impairment of blood supply to cochlea and auditory ossicles, necrosis of the incus, and acute radionecrosis of temporal bone.<sup>61</sup>



Damage from Electromagnetic Radiation to the Nose (B-3)

11. The nasal cavities show little sensitivity to radiation. In the period immediately following irradiation, there may be alteration or temporary suppression of the sense of smell and hypersecretion of mucus. As a late reaction, many patients complain of dryness of the mucosa with a tendency toward formation of crusts, which is probably due to a transitory atrophy of the mucus secreting glands at the level of the nostril vestibule, the transitional epithelium shows severe radiation reactions which resemble in their development that of other mucocutaneous orifices. (No doses given)<sup>14</sup>
12. 20% of patients receiving localized irradiation to the oral-nasal-pharyngeal regions report experiencing unusual tastes and smells.<sup>90</sup>

Damage from Electromagnetic Radiation to Blood, Skeleton, Cardiovascular System, and Spleen (B-7)

13. Cardiovascular: <sup>1,28</sup>
  - heart <6,000 rads in 6 weeks - safe
  - >6,000 rads in 6 weeks - degrading
  - vessels <1500 rads - safe (1200 rads lead to reversible changes)
  - >1500 - 2000 rads - degrading
14. Skeleton: <sup>87,99</sup>

Osteoradionecrosis (of the mandible) is caused primarily by loss of circulation to the bone, periosteum, and mucosal tissues and may proceed to osteomyelitis with greater destruction anterior and posterior to the irradiated area. Radiation of formed bone may result in a derangement of the synchronization of resorption and new bone deposition, producing either excessive absorption or overgrowth of bone.
15. Blood: Countermeasures for irradiation effects
  1. Pre-irradiation erythropoietic stimulation (by placing experimental animal in a high altitude chamber) enhanced post-irradiation recovery in Swiss mice.<sup>31</sup>
  2. Vitamin C administered to patients undergoing therapeutic radiation eliminates or moderates leukopenia.<sup>39</sup>
16. Spleen:
 

Shielding of the spleen during whole-body irradiation has in some species resulted in markedly improved survival rates.<sup>33</sup> An attempt to assess the effects of splenic shielding on survivors of the Japanese atomic bomb explosions,<sup>93</sup> did not prove that a healthy spleen helps in recovery from radiation in humans. The findings of the study were, however, not inconsistent with that hypothesis.

Damage from Electromagnetic Radiation to the Gonads (B-8)

17.

Gonads: man

< 50-200 rads - safe<sup>1,75</sup>236-365 rads - transient sterility (degradation)<sup>1,75</sup>>400-600 rads - incapacitating<sup>75</sup>

woman

< 100-200 rads - safe<sup>1,5</sup>200-500 rads - degrading<sup>1,2,5</sup>>500-2000 rads - incapacitating<sup>1,5,8</sup>

Damage from Electromagnetic Radiation to Gastrointestinal and Urinary Systems and Liver and Gall Bladder (B-9)

18. Gastrointestinal<sup>1</sup>:

- esophagus - < 5,000 rads-safe  
5-6,000 rads-degrading  
> 6,000 rads-incapacitating
- stomach - < 250-350-safe  
350-1,000-degrading  
> 1,000-incapacitating
- small intestine - < 500-safe  
500-1,000-degrading
- large intestine - < 7,000-safe  
> 7,000-degrading

19. Urinary: <sup>2,99</sup>

- kidney - < 400 rads-safe  
500-2,000 rads-degrading  
> 3,500-4000-incapacitating  
& lethal
- bladder - < 3,000-safe  
3,000-9,000-degrading  
> 9,000 rads-incapacitating

20. Nausea resulting from irradiation can be controlled by doses of Vitamin B<sub>1</sub>.<sup>39</sup>

21. The liver appears to be a radiosensitive organ from studies on mice, rats, and pigeons. The hepatic vascular system must remain intact for some radiation effects to become radiation apparent. A compendium of effects on the liver observed in various species includes

1. increased oxygen consumption
2. no change in liver protein synthesis
3. decreased activity of choline oxidase
4. decreased acetylating capacity
5. increased permeability to phosphate ions.<sup>33</sup>

Damage from Electromagnetic Radiation to the Central Nervous System (B-10)

22. The period until death ensues is inversely proportional to the size of the dose, above a lethal dosage.
23. Cortex and immediate sub-cortical medullary regions are less radiosensitive than deep-seated white matter.<sup>36</sup>
24. Irradiating a shorter length of spinal cord allows a higher dose to be used safely.<sup>58</sup>
25. Effects of irradiation of the head of animals and humans on the EEG are summarized in reference 90. However, no human dosage levels for significant changes in the alpha rhythm have been established.

Psychological Effects from Electromagnetic Radiation (B-11)

26. Chapter 7 and 8 of reference 90 discuss the effects on psychological processes and behavior of animals exposed to varying levels of ionizing radiation. Extrapolation to the human species is hazardous at the present level of understanding of the phenomena.

**APPENDIX C**  
**OTHER POSSIBLE INFORMATION SOURCES**

**EYE**

1. Liegl, O.  
"On the Consequences of a Radiation Overdose in the Neck. A Contribution to the Syndrome of Bilateral Carotid Occlusion"  
Z. Kreislaufforsch, 56:221-34, Mar. 1967.
2. Gorbonosova, N. B.  
"Working Conditions and Health Problems Among Vessel Radiooperators Exposed to the Electromagnetic Field of High Frequency"  
Bull. Inst. Mar. Med. Gdansk, 17:263-6, 1966.
3. Abe, Y.  
"Studies on Beta-Ray Radiation Cataracts in the Human Eye. II. Progression of Beta-Ray Cataracts and Biomicroscope Changes in the Lens with the Low Treatment Dosages"  
Acta Soc. Ophthalm. Jap, 72:1759-73, Sep. 1968.
4. Badmaev, K. N., M. P. Balamutova, B. P. Vakhnovetski  
"On the Problem of Radiosurgical Treatment of Patients with Cranio-pharyngiomas"  
Vop. Neurokhir, 33:13-6, Mar.-Apr. 1969.
5. Azevedo, D. J., J. B. Freire  
"Surgical Effects of Ionizing Radiations Causing Cataracts"  
Rev. Brasil. Oftal, 28:51-4, Mar. 1969.
6. Bider, E., F. Rintelen  
"On Imaginary and Actual Environmental Lesions of the Organ of Vision"  
Landarzt, 42:1333-9, 31 Oct. 1966.
7. Boles-Carenini, B., E. Balestra, C. Landenzi  
"Chronobiodosimetric Evaluation of the Radiosensitivity of the Crystalline Lens and Retina and of the Doses Used in Radiotherapy of Eye Diseases"  
Minerva Radiol, 11:541-5, Oct. 1966.
8. Brovkina, A. F., T. D. Kostjukova  
"Prevention of Complications in the Canaliculus Lacrimalis in Radiotherapy of Cancer of the Skin of the Internal Angle of the Eye"  
Med. Radiol. (Moskva), 11:28-33, Aug. 1966.
9. Canossi, C., M. Belmonte, L. Bergonzi  
"On the Ophthalmologic Use of Beta Therapy"  
Ann. Ottol, 92:194-213, Mar. 1966.
10. Claus, H. G., L. Diethelm, B. Cullmann  
"Eye Changes Following High-Dose Telecobalt Irradiation of Malignant Paranasal Sinus Tumors"  
Strahlentherapie (Sonderb), 68:187-91, 1969.



EYE (cont.)

11. Claus, H.G., I. Diethelm, B. Cullmann  
"Effect of High-Dosage Radiation on the Human Eye"  
Strahlentherapie, 136:395-410, Oct. 1968.
12. Cullmann, B., H.G. Claus  
"Findings on the Eye Following High-Dose Megavolt Therapy of Malignant Paranasal Sinus Neoplasms"  
Ber. Deutsch. Ophth. Ges., 68:244-9, 1968.
13. Endo, Y., M. Nagase, S. Shinriki  
"Prevention of Relapses of Pterygium and Development of Cataracts After the Application of Sr<sup>90</sup>"  
Acta Soc. Ophthal. Jap., 70:429-32, Apr. 1966.
14. Fukuda, M., M. Abe  
"Iatrogenic Disorders in Radiotherapy"  
Rinsho Hosha, 14:533-8, Jul. 1969.
15. Genee, E., G. Weitzel  
"Ciliary Body Irradiation with Fast Electrons in Therapy-Resistant Aphacic Glaucoma"  
Ber. Deutsch. Ophth. Ges., 69:387-91, 1969.
16. Gerstenberg, E., E. Krokowski, K.E. Kleberger  
"Eye Complications Following Irradiation of Carcinoma of the Paranasal Sinuses"  
Strahlentherapie (Sonderb), 68:183-6, 1969.
17. Grutzner, P.  
"Roentgen Cataract"  
Klin. Mbl. Augenheilk., 149:243-5, 1966.
18. Guardascione, V., D.I. Mazzella, M. Bosco, F.S. Galasso  
"Clinico-Statistical Data on the Occupational Pathology of Physicians Exposed to Ionizing Radiations"  
Minerva Med., 59:4091, 29 Sep. 1968.
19. Halama, J.  
"Radiotherapeutic and Radiobiologic Problems of Lens Protection in Children"  
Ber. Deutsch. Ophth. Ges., 69:209-20, 1969.
20. Hirose, I., H. Fujisawa, T. Fujino  
"Amplitudes of Visual Accommodation of Atomic Bomb Survivors in Nagasaki and Hiroshima"  
Folia Ophthal. Jap., 18:346-60, Mar. 1967.

EYE (cont.)

21. Honegger, H.  
"Radiation Cataract After Treatment with Peteosthor (Thorium X)"  
Klin.Mbl.Augenheilk, 155:890-5, Dec. 1969.
22. Zeinaiov, E.I., G.M. Obaturov, I. Chumbarov  
"The Ratio of Absorbed Doses and the Spectral Composition of Beta and Gamma Rays in a Radiochemical Laboratory"  
Gig.Sant, 31:43-6, Feb. 1966.
23. Kleberger, K.E., E. Gerstenberg, E. Krokowski  
"Endangering of the Eye by Modern Radiotherapy of Tumors Near the Eye"  
Klin.Mbl.Augenheilk, 154:401-10, Mar. 1969.
24. Kozyreva, A.L., F.S. Loseva  
"The Status of the Eye in Patients with Erythremia in Relation to Radioactive Phosphorus Therapy"  
Vestn.Oftal, 80:71-2, Mar.-Apr. 1967.
25. Lin, S., G. Polani, L. Taffara  
"On the 'Visibility' of High-Energy Electrons"  
Minerva Fisiconucl, 10:41-7, 1966.
26. Lohse, K., K.E. Kruger  
"Experiences with the Use of Beta Rays in Various Diseases of the Anterior Eye Segment"  
Klin.Mbl.Augenheilk, 148:109-15, 1966.
27. Lommatzsch, P.  
"On the Problem of Radiation Cataract in Beta Irradiation of the Anterior Eye Segment"  
Klin.Mbl.Augenheilk, 150:683-8, 1967.
28. Lutsker, L.S.  
"The Initial Symptoms and Classification of Radiation Cataract"  
Med.Radiol.(Moskva), 12:39-42, Aug. 1967.
29. Machemer, R.  
"Autoradiographic Study on the Regeneration Zones of the Cornea"  
Graefe Arch.Klin.Exp.Ophthal, 170:286-96, 15 Aug. 1966.
30. Munding, F.  
"Results of Primary and Combined Operative-Stereotaxic Irradiation of Pituitary Adenomas"  
Nuclearmedizin Suppl, 2:397+, 1965.
31. Notter, G., B.I. Ruden, B. Zetterquist  
"On the Problem of Radiation-Induced Cataract Formation After Epibulbar in Radiation of the Eye with Sr<sup>90</sup>"  
Strahlentherapie, 136:529-36, Nov. 1968.

EYE (cont.)

32. Offret, G., C. Haye  
"The Ocular Lesions Caused by Atomic Explosions"  
Annee Ther. Clin. Ophthal, 13:47-53, 1962.
33. Sakai, S., S. Ikehata  
"Post Radiation Effects in Maxillary Cancer"  
J. Otolaryng. Jap, 71:1471-6, Oct. 1968.
34. Slavin, L.G., R.G. Mamin  
"The Effect of Radium Therapy on Intraocular Pressure in Hypophyseal Tumors"  
Med. Radiol. (Moskva), 11:7-10, Dec. 1966.
35. Sviridenko, S.G.  
"Pm<sup>147</sup> Beta Therapy of Some Diseases of the Anterior Region of the Eye"  
Med. Radiol. (Moskva), 13:49-54, Feb. 1968.
36. Sweet, W.H.  
"Hemorrhagic Diabetic Retinopathy--Treatment by Hypophyseal Stalk Section or by Bragg-Peak Proton Irradiation"  
Brain Nerve (Tokyo), 19:12-8, Jan. 1967.
37. Tolunaga, T.  
"Result of Follow-Up Study of Atomic Bomb Radiation Cataract in Nagasaki"  
Acta Soc. Ophthal. Jap, 72:1774-81, Sep. 1968.
38. Tron, E., A.A. Volkov  
"The Dynamics of Homonymous Hemianopsia in the Treatment of Cerebral Tumors with Granular Au<sup>198</sup>"  
Med. Radiol. (Moskva), 11:19-26, Oct. 1966.
39. Yamada, E.  
"Radiation Dosimetry with the Sr<sup>90</sup> -Applicator, and its Prophylactic Effect on the Recurrence of Pterygium and Beta-Radiation Cataract"  
Acta Soc. Ophthal. Jap, 73:438-45, Apr. 1969.
- 40 Winkel, K.  
"Radiotherapy of Tumors of the Facial Portion of the Skull"  
Arch. Klin. Exp. Ohr. Nas. Kehlkopfheilk, 187:337-82, 1966.

EAR

1. Pichler, H. J.  
"Otological Problems of Space Flight"  
Msch. Ohrenheilk, 102:168-70, 1968.
2. Bourdial, J.  
"Beta Radiotherapy of Eustachian Tube Swellings. 2500 Applications.  
23 Years' Analysis"  
Sem. Hop. Paris, 45:2871-83, 14 Nov. 1969.
3. Calvet, J., J. Claux, J. Coll  
"Study of Systematic Corticotherapy During Irradiation of Cancers of the  
Otorhinolaryngologic Area Capable of Causing Edema"  
J. Franc. Otorhinolaryng., 17:429-34, May 1968.
4. Flach, M.  
"Intratubal Irradiation in Functional Disorders of the Eustachian Tube"  
Deutsch. Gesundh., 21:897-906, 12 May 1966.
5. Kasperek, L., J. Zamecnik  
"Functional Changes of the Vestibulocochlear Analyzer Caused by Radiation"  
Cesk. Otolaryng., 18:12-8, Feb. 1969.
6. Manojlovic, C., M. Mitrovic  
"Lesions of Hearing Caused by Radioactive Radiations"  
Ann. Otolaryng. (Paris) 84:543-6, Jul.-Aug. 1967.
7. Labayle, J.  
"Case Report of a Radio-Induced Cancer"  
J. Franc. Otorhinolaryng., 16:269-70, Apr. 1967.

NOSE

1. Calvet, J., J. Claux, J. Coll  
"Study of Systematic Corticotherapy During Irradiation of Cancers of the Otorhinolaryngologic Area Capable of Causing Edema"  
J. Franc. Otorhinolaryng., 17:429-34, May 1968.
2. Dufour, P.  
"Treatment of Mucosal Lesions Due to Cobaltotherapy in the O.R.L. Area by Polysilane Gel"  
J. Franc. Otorhinolaryng., 16:613, Nov. 1967.
3. Kleibel, F.  
"External Treatment of Local Irradiation Reactions with a Corticoid-Antibiotic-Vitamin Combination"  
Strahlentherapie, 138:209-12, Aug. 1969.
4. Proux, C., C.G. Toubiana  
"Treatment of Radiomucitis of the Otorhinolaryngologic Areas by a Medication Easily Employable: Lysopaine O.R.L. Tablets"  
Sem. Ther., 43:182-5, Mar. 1967.
5. Glazunov, I.S., V.V. Blagoveshchenskaja, G.N. Martynova  
"Clinico-Physiologic Methods of Studying the Asthenic Syndrome in Persons Coming into Contact with Ionizing Radiation"  
Zh. Nevropat. Psikhiat. Korsakov, 69:667-73, 1969.

SKIN

1. Barth, G.  
"The Knowledge of Radiation Pathology as a Basis for Radiation Protection in Radiology"  
Radiologe, 6:298-303, Aug. 1966.
2. Funshtein, L.V., E.I. Vorob'ev, E.I. Shcherban', et. al.  
"The Importance of the Radiation Load on Organs and Tissue in the Radiotherapy of Certain Malignant Neoplasms and Lymphogranulomatosis"  
Med. Radiol. (Moskva), 12:35-42, Jan. 1967.
3. Heitmann, H. J.  
"Chromosome Mutations of Blood Cells in X-Ray Teleirradiation of the Skin"  
Hautarzt, 17:515-7, Nov. 1966.
4. Lada-Jagas, R., D. Jarczyk  
"Radiation-Induced Changes in Medical Personnel Working with X-Rays"  
Wiad. Lek., 21:771-4, 1 May 1968.
5. Malyshev, A. M., G. I. Kovalenko, R. M. Mordvinova  
"The Effect of Epilatory Doses of X-Ray Irradiation on the Morphological and Protein Composition of the Blood"  
Vestn. Derm. Vener., 43:63-8, Apr. 1959.
6. Piontkovskii, I. A.  
"The Radioembriologic Effect and its Importance in Pathology"  
Pat. Fiziol. Eks. Ter., 11:13-20, Nov.-Dec. 1967.
7. Koslowski, L.  
"Radiation Burden and Burns"  
Strahlenschutz Forsch. Prax., 4:303-14, 1964.
8. Stoppa, I. M.  
"Radiobiologic and Radioprotective Problems in Dental Roentgenology"  
Minerva Stomat., 15:860-7, Dec. 1966.
9. Asai, T., Y. Shono  
" ESR of the Human Black Hair "  
Nippon Acta Radiol., 25:1380-4, Mar. 1966.
10. Astrakhan, V. I., M. M. Nivinskaja, M. S. Starichkov  
" Skin Reactions in the Complex Use of Radiation and Chrysomallin "  
Med. Radiol. (Moskva), 13:16-9, Aug. 1968.
11. Babini, L.  
"Considerations of Clinical Nature on the Behavior of the Skin in Therapy with Fast Electrons of Varying Energy Between 14 and 32 MEV "  
Radiobiol. Radioter. Fis. Med., 21:307-19, Sep.-Oct. 1966.

SKIN (cont.)

12. Balmukhanov, S.B., G.P. Gordienko, L.G. Pozdnukhov  
"Radiation Therapy of Tumors of the Extremities Under Conditions of Local Anoxia"  
Vop. Onkol., 14:29-36, 1968.
13. Barletta, L.P.  
"Radionecrosis, Surgical and Biological Excision"  
Prensa. Med. Argent., 53:1658-61, 29 Jul. 1966.
14. Bek, V., J. Kolar, J. Maresova  
"On Problems in the Clinical Picture and Therapy of Childhood Hemangiomas. 3. Late Somatic Changes Following Hemangioma Radiotherapy in Childhood"  
Strahlentherapie, 135:156-65, Feb. 1968.
15. Berdnikov, V.A.  
"Surgical Treatment of Patient with Radiation Ulcer of a Finger"  
Med. Radiol. (Moskva), 12:88-9, Jan. 1967.
16. Bogdanova, T.V.  
"The Use of Methyluracil in Radiation Epithelitis and Dermatitis in Patients with Laryngeal Neoplasm"  
Vestn. Otorinolaring., 29:80-2, May-Jun. 1967.
17. Bohndorf, W.  
"The Relative Biologic Effect of High Energy Photons and Electrons as Compared to Conventional X-Ray Irradiation from the Clinical Viewpoint"  
Radiologe, 6:103-10, Mar. 1966.
18. Boszkiewicz, T.  
"Complicated Lesions of the Face and Jaws in Acute Radiation Injury"  
Czas. Stomat., 19:657-63, Jun. 1966.
19. Bote, D.V.  
"On a Case of Mandibular Osteoradionecrosis and Late Epithelioma of the Lip Caused by Radium Therapy"  
Arch. Stomat. (Roma), 6:317-33, Oct.-Dec. 1965.
20. Braun-Falco, O.  
"Dynamics of Normal and Pathological Hair Growth"  
Arch. Klin. Exp. Derm., 227:419-52, 1966.
21. Cantarino, M.H., J. Soto Melo  
"Growing Rhythm in the Normal and Psoriatic Epidermis"  
Acta Oncol. (Madrid), 6:225-32, Jul.-Dec. 1967.

SKIN (cont.)

22. Chochia, K. N., R. M. Rabinovich, A. S. Polezhaev  
"Complications in Radiotherapy of Laryngeal Cancer"  
Vop. Onkol, 11:25-31, 1965.
23. Csermely, E., G. De Panfilis  
"The SH-Groups in Irradiated Skin"  
Minerva Derm, 43:505-6, Oct. 1968.
24. Damiani, R.  
"Radiodermatitis and Radionecrosis of the Mammary Region"  
Bull. Sci. Med. (Bologna), 139:16-39, Jan.-Mar. 1967.
25. Egawa, J., Y. Umezaki, S. Matsukawa  
"Electron-Beam Therapy with Linear Accelerator. Physical Considerations for Total Skin Irradiation Therapy"  
Nippon Acta Radiol, 27:1475-9, Feb. 1968.
26. Erdelyi, R.  
"Analysis and Results of Plastic Therapy of 59 Radiation Ulcers"  
Acta Chir. Orthop. Traum. Cech, 35:524-30, Dec. 1968.
27. Eschwege, F., J. Dutreix  
"Cutaneous Reactions Produced by High Energy Electrons"  
Ann Radiol. (Paris), 12:67-74, 1969.
28. Eugster, J.  
"Changes in Cells Caused by Cosmic Radiation"  
Bull. Schweiz. Acad. Med. Wiss., 21:425-6, Mar. 1966.
29. Eugster, J.  
"The Mutagenic Effect of Cosmic Radiation in Human Tissues (Epidermis)"  
Arch. Klaus. Stift. Vererbungsforsch., 38:93-110, 1963.
30. Fischer, A. W.  
"The Clinical Significance of Radiotherapy Sequelae"  
Aesthet. Med. (Berlin), 15:2-3, 20 Jan. 1966.
31. Frommhold, W., G. Bublitz  
"Studies on Subcutaneous Fibroses Following Cobalt Teletherapy and Their Treatment Possibilities with Dimethyl Sulfoxide (DMSO)"  
Strahlentherapie, 133:529-38, Aug. 1967.
32. Fukuda, M., M. Abe  
"Iatrogenic Disorders in Radiotherapy"  
Rinsho Hosha, 14:533-8, Jul. 1969.



SKIN (cont.)

33. Gabka, J.  
"Incidence and Treatment of Major Radiation Induced Ulcerations of the Maxillofacial Area"  
Czas. Stomat., 22:589-95, May-Jun. 1969.
34. Gahlen, W.  
"Histologic Changes in X-Ray Irradiated Tissue"  
Aesthet. Med. (Berlin), 15:193-201, 20 Jun. 1966.
35. Garbagna, P., F.A. Paolini, A. Nicolato  
"Rectosigmoid Lesions Secondary to High-Energy Radiotherapy"  
Minerva Radiol., 14:381-7, Sep. 1969.
36. Glazunov, I.S., V.V. Bragoveshchenskaia  
"Remote Sequelae of Acute Radiation Sickness"  
Zh. Nevropat. Psikhiat. Korsakov, 68:1129-34, 1968.
37. Glazunov, I.S., N. Tereshchenko  
"On the Functional Status of the Nervous Systems of Children at Long Periods After Irradiation (The Application of Gammatherapy to Skin Hemangiomas)"  
Zh. Nevropat. Psikhiat. Korsakov, 68:1438-45, 1968.
38. Georges, J.P.  
"Microcrystalline Rose Oxide of Zinc"  
Sem. Ther., 39:345-6, May 1963.
39. Glasenapp, G.B.  
"Osteomyelitis of the Maxilla Following Radiotherapy for Facial Lupus"  
Hno, 16:46-9, Feb. 1968.
40. Hagedorn, K.  
"X-Ray Treatment of Warts"  
Ugeskr. Laeg., 129:1266-70, 28 Sep. 1967.
41. Iancu, I., G. Dobrescu, D. Danet  
"Surgical Treatment of the Post-Therapeutic Sequels of Skin Cancer"  
Rev. Medicochir. Iasi, 72:891-6, Oct.-Dec. 1968.
42. Ito, E., H. Nakajo, R. Iso  
"Local X-Ray Injury Caused by Fluoroscopy During the Extraction of a Foreign Body"  
Jap. J. Plast. Reconstr. Surg., 9:191-6, Jul. 1966.
43. Jaeger, W.  
"Late Changes of the Skin with the use of a Fine Grid"  
Radiobiol. Radiother. (Berlin), 9:97-105, 1968.

SKIN (cont.)

44. Kamata, R., K. Haruyama, M. Maruyama  
"Skin Reactions in Electron Beam Irradiation. (1st Macroscopic Observations)"  
Nippon Acta Radiol, 28:1688-94, Mar. 1969.
45. Karcher, K.H.  
"A Contribution on the Dosimetry Time Problem in High Energy Electron Therapy"  
Fortschr. Roentgenstr, 105:353-67, Sep. 1966.
46. Kiricuta, I., V. Popesco, E. David  
"Biochemistry, Morphology and Transplantation Problems of Radionecroses"  
Zbl. Skin, 92:1147-52, 1967.
47. Kizhaev, V.I., G.F. Romanenko  
"Surgical Treatment of Late Ulcerative Radiation Injuries of the Skin"  
Med. Radiol. (Moskva), 12:24-8, Oct. 1967.
48. Kleibel, F.  
"External Treatment of Local Irradiation Reactions with a Corticoid-Antibiotic-Vitamin Combination"  
Strahlentherapie, 138:209-12, Aug. 1969.
49. Klostermann, G.F.  
"X-Ray Sequelae in the Skin Following Hemangioma Radiation"  
Strahlentherapie, 130:205-13, Jun. 1966.
50. Klostermann, G.F.  
"On the Dose Dependency of Various X-Ray Induced Late Symptoms of the Skin"  
Z. Haut. Geschlechtskr, 41:132-40, 15 Aug. 1966.
51. Kopp, H., F. Reymann  
"Further Studies of Late Lesions Following Dermatologic Radiotherapy"  
Z. Haut. Geschlechtskr, 42:349-54, 15 May 1967.
52. Kostanecki, W., E. Kwiatkowska, W. Mazurkiewicz  
"Coincidence of Disorders of Hair Growth and Follicular Melanogenesis in Various Pathological Conditions"  
Przegl. Derm, 56:185-91, Mar.-Apr. 1969.
53. Kriner, J.  
"Extensive Ulcerated Nodular Angioma. Radionecrosis"  
Arch. Argent. Derm, 17:287-9, Sep. 1967.

SKIN (cont.)

54. Lenarduzzi, G., C. Valdagni, F. Pozza  
"Evaluation of Late Lesions Following Therapy with Fast Electrons"  
Strahlentherapie, 135:166-75, Feb. 1968.
55. Lozeron, H., A. Maggiora, J. Rossier  
"On the Significance of the Roentgen Dosage Applied in a Unit of  
Time in Dermatologic Radiotherapy"  
Derm. Wschr., 154:537-40, 8 Jun. 1968.
56. Luger, A.  
"Radiation Injury Following Hemangioma Therapy"  
Z. Haut. Geschlechtskr., 40:421 Passim, 15 Jun. 1966.
57. Lukowska, I., W. Krasnik  
"Dermatologic Pictures in Patients with Polycythemia Vera Before  
and After Treatment with Radiophosphorus  $P^{32}$ "  
Pol. Tyg. Lek., 22:417-20, 20 Mar. 1967.
58. Masse, R.  
"Evaluation of Permanent Partial Disability in Radiodermatitis"  
Med. Leg. Domm. Corpor. (Paris), 1:68-71, Jan. 1968.
59. Mennig, H.  
"On the Covering of Radiation-Injured Skin Defects in Face and Neck  
Region"  
Hautarzt, 18:264-8, Jun. 1967.
60. Merli, E.  
"Chronobiodosimetric Considerations on Certain Cases of Cutaneous  
Radionecrosis"  
Radiol. Med. (Torino), 53:261-8, Mar. 1967.
61. Morczek, A.  
"Diagnosis and Therapy of Acute Radiation Injury"  
Z. Aerztl. Fortbild. (Jena), 60:973-8, 1 Sep. 1966.
62. Niklas, K., F. Wachsmann  
"Radiation Injury and Radiation Accidents in X-Ray Units"  
Radiologe, 6:332-8, Aug. 1966.
63. Omel'tanenko, L. M.  
"On the Clinical Picture of Radiation Cancer of the Skin of the Hand"  
Vop. Onkol., 14:3-9, 1968.
64. Orlov, V. M.  
"On the Prevention of Skin Diseases in Workers at a Radiology  
Institute (Functional Changes of the Skin as an Early Indicator of  
Radiation Injury)"  
Klin. Med. (Moskva), 44:22-30, Nov. 1966.

SKIN (cont.)

65. Orlov, V. M.  
"A Case of Acute Radiation Injury of the Hands During Work with an Electronic Accelerator"  
Klin. Med. (Moskva), 45:37-9, Oct. 1967.
66. Pierre, M.  
"Treatment of Occupational Radiodermatitis of the Hands in Physicians"  
Bull. Soc. Franc. Derm. Syph., 74:101, 1967.
67. Pourquier, H.  
"Complications of Radiotherapy of Cancer of the Uterine Cervix at Stage 3"  
J. Radiol. Electr., 49:607-16, Aug.-Sep. 1968.
68. Pratzel, H.  
"Metabolism of the Skin as part of General Metabolism (Dependence from Thermal, Mechanical, Actinic and Inflammatory Effects)"  
Arch. Phys. Ther. (Leipzig), 20:339-48, Sep.-Oct. 1968.
69. Privat, Y., I. Faye, A. Bellossi  
"Appropos of a Difficult Diagnosis After Intensive Radiotherapy of Breast Cancer; Extensive Radiodermatitis or Recurrent Cancer in Erysipeloid Form"  
Bull. Soc. Med. Afr. Noire Lang. Franc., 13:237-8, 1968.
70. Proppe, A., M. Schirren  
"Indication for Radiotherapy as a Function Between Risk of Therapy and Gravity of Disease"  
Aesthet. Med. (Berlin), 16:257-74, 20 Sep. 1967.
71. Roth, W. G.  
"Vitiligo Following X-Irradiation of Multiple Melanoma Metastases"  
Hautarzt, 19:178-80, Apr. 1968.
72. Rotnicki, J., A. Szafrnagel, A. Himmel  
"Adsorption of Short-Living Beta-Radioactive Radon-Decay Products (Radium B and Radium C) by the Skin Surface of Patients During Baths in the Spring "Jerzy" in Ladek-Zdroj"  
Pol. Tyg. Lek., 24:1764-6, 17 Oct. 1969.
73. Santini, R., A. Veneziani  
"The Surgical Repair of X-Ray Lesions"  
Minerva Chir., 22:1003-5, 15 Sep. 1967.
74. Savchenko, E. D., K. A. Molchanova  
"On the Changes in the Neck Skin After Repeated Courses of Radiotherapy for Laryngeal Cancer and Possibilities of Performing Reconstructive Operations"  
Med. Radiol. (Moskva), 13:20-6, Aug. 1968.

SKIN (cont.)

75. Schirren, C.G., I. Dogramadjiew, L. Gruber  
 "Is Erythema Induced During Application of Thorium-S-Varnish Mostly  
 by Alpha- or Beta-Rays"  
 Hautarzt, 18:514-6, Nov. 1967.
76. Schulte-Brinkmann, W.  
 "Radiation Exposure of Patients and Radiologic Personnel During  
 Heart Catheterization and Contrast Media Procedures in the Heart and  
 Great Vessels. 3. Discussion of the Measurements--Literature"  
 Strahlentherapie, 129:460-71, Mar. 1966.
77. Schulte-Brinkmann, W.  
 "X-Ray Exposure of Patients and Radiological Examiners in  
 Bronchographies Under Anesthesia"  
 Fortschr. Roentgenstr., 105:710-6, Nov. 1966.
78. Schulte-Brinkmann, W., E. Von Cysewski  
 "The Somatic and Genetic Irradiation Exposure of the Patient in Areal  
 Kymography of the Heart"  
 Strahlentherapie, 135:675-80, Jun. 1968.
79. Sheviakov, V.V.  
 "Experience in the Surgical Treatment of Radiation Damage to the Skin"  
 Vestn. Khir. Grekov., 100:95-7, Feb. 1968.
80. Shioya, N.  
 "Plastic Surgery Technic for Ulcer Due to Irradiation Following Surgery  
 of Breast Cancer"  
 Shujutsu, 21:439-42, May 1967.
81. Sigal, M.Z., G.I. Volodina  
 "Reaction of Dermo-Epidermal Autotransplants to Massive Irradiation"  
 Radiobiol. Radiother. (Berlin), 9:737-44, 1968.
82. Sigal, M.Z., G.I. Volodina  
 "The Use of Radioactive Phosphorus (Radiometry and Autoradiography)  
 for the Study of the Functional Status of the Irradiated Dermoepidermal  
 Graft"  
 Khirurgiia (Sofia), 20:576-82, 1967.
83. Smirnova, O.V., V.V. Selikhova  
 "The Status of the Autoflora and Bactericidal Capacity of the Skin in  
 Patients Receiving Radiotherapy"  
 Med. Radiol. (Moskva), 13:61-3, Mar. 1968.

SKIN (cont.)

84. Sonnabend, E.  
"Radiation Exposure and Radiation Protection in Radiodiagnosis in Dentistry"  
Zahnaerztl. Mitt., 59:1062-6, 1 Nov. 1969.
85. Steigleder, G.K., J. Trnka  
"Basaliomas with Skin-Adnexal Differentiation in Particular Sweat Glands, and Carcinoma (Epithelioma) Spinocellulare Segregans on Scars of Tuberculosis Cutis Luposa, Treated by Radiotherapy"  
Z. Haut. Geschlechtskr., 43:97-103, 1 Feb. 1968.
86. Szirmai, E.  
"Treatment of Radiation Reactions with Solcoseryl"  
Acta Oncol. (Madrid), 6:242-7, Jul.-Dec. 1967.
87. Szymczykowa, B.  
"Effect of Local Application of Vitamin A on the Course of Postirradiation Reactions in Human Skin"  
Pol. Przegl. Radiol., 32:529-35, Jul.-Aug. 1968.
88. Ueno, K., M. Yoshida, H. Yaoita  
"Soft X-Ray Therapy of Bowen's Disease Occurring on Malignant Radiation Dermatitis"  
Rinsho Hosha, 13:903-13, Nov. 1968.
89. Ugland, O.M.  
"Radiation Injuries and Their Treatment by Plastic Surgery"  
T Norsk. Laegeforen., 88:957-62, 15 May 1968.
90. Valkov, V.S.  
"On Treatment of Bulbous and Ulcerative Roentgen Dermatitis"  
Radiobiol. Radiother. (Berlin), 8:553-6, 1967.
91. Volodina, G.I.  
"The Reaction of a Dermo-Epidermal Autotransplant to X-Irradiation"  
Med. Radiol. (Moskva), 13:75-8, Feb. 1968.
92. Watanabe, M.  
"The Experimental and Clinical Studies on the Effects of Local Cooling Irradiation"  
Nippon Acta Radiol., 29:284-303, Jun. 1969.
93. Zeinalov, E.I., G.M. Obaturov, I. Chumbarov  
"The Ratio of Absorbed Doses and the Spectral Composition of Beta and Gamma Rays in Radiochemical Laboratory"  
Gig.Sanit, 31:43-6, Feb. 1966.

SKIN (cont.)

94. Ziegler, G., H. Luthy, B. Gahwiler  
"The Duration of the Presence of Radioactive Metal Ions on the Skin"  
Dermatologica (Basel), 137:259-62, 1968.
95. Glazunov, I.S., V.V. Blagoveshchenskaia, G.N. Martynova  
"Clinico-Physiologic Methods of Studying the Asthenic Syndrome in Persons  
Coming into Contact with Ionizing Radiation"  
Zh. Nevropat. Psikhiat. Korsakov., 69:667-73, 1969.

LABYRINTH

1. Pichler, H. J.  
"Otological Problems of Space Flight"  
Mschr. Ohrenheilk, 102:168-70, 1968.
2. Labayle, J.  
"Case Report of a Radio-Induced Cancer"  
J. Franc. Otorhinolaryng, 16:269-70, Apr. 1967.



GAMMA MOTOR SYSTEM

1. Barabanova, A. V.

"The Status of the Motor Function in Chronic Exposure to Radiation"  
Med. Radiol. (Moskva), 12:42-7, Aug. 1967.

BLOOD

1. Abrate, M., L. Santoro, G. Balotti, et. al.  
"Hematological Picture and Hepatic and Renal Function After Intracavitary, Interstitial and Intra-Arterial Administration of  $P^{32}$ "  
Minerva Radiol, 12:54-6, Jan.-Feb. 1967.
2. Adam, G., A. Molnar, M. Peter, et. al.  
"The Effect of Ferronascin on the Blood Cell Count of Patients on Radiation Therapy"  
Strahlentherapie, 134:561-73, Dec. 1967.
3. Alex, R., H. Horst-Meyer  
"Influence of Ionising Rays on the Granulocyte Zinc Content in Patients with Gynecologic Carcinoma During Biaxial Telecobalt Therapy and in Persons Professionally Exposed to Irradiation"  
Radiobiol Radiother. (Berlin), 9:689-93, 1968.
4. Andersen, V., S.F. Sorensen, S.A. Killmann  
"Treatment of Chronic Lymphocytic Leukemia with Extracorporeal Radiation of the Blood"  
Nouv. Rev. Franc. Hemat, 8:709-18, Sep.-Oct. 1968.
5. Antoshchina, M.M.  
"The Effect of Gamma Rays on the Genesis of Aneuploidy in Mitosis"  
Radiobiologia, 8:89-91, Jan.-Feb. 1968.
6. Bakman, S.M., L.R. Perel'man  
"Blood Eosinophils, (Literature Review)"  
Probl. Gemat, 14:47-53, Jun. 1969.
7. Bauchinger, M., O. Hug  
"Chromosome Aberrations Following Radium Roentgen Therapy of Gynecologic Tumors"  
Strahlentherapie, 131:109-21, Sep. 1966.
8. Baudach, H., E. Magdon, K.H. Botte, et. al.  
"Studies on the Use of Leukocyte Concentrates for Radiation Biological Research on Mast Cells"  
Strahlentherapie, 134:66-79, Sep. 1967.
9. Bauer, R.  
"Radiation Hematology Past and Present"  
Strahlentherapie, 136:387-94, Oct. 1968.
10. H.D. Bergeder  
"Radiation Effects on Biological Membranes"  
Strahlenschutz Forsch Prax, 9:100-14, 1969.

BLOOD (cont.)

11. Bernardi, L., F. Mainoldi  
 "The Use of Lysozyme in Leukopenias due to Ionizing Radiations"  
 Minerva Radiol., 12:325-36, Sep. 1967.
12. Blanding, G., P. Caruso, F. Conti, et. al.  
 "Panirradiation and Erythrocytic Enzymatic Activity. II. Research in Vitro"  
 Radiobiol. Radiother. Fis. Med., 21:377-80, Nov.-Dec. 1966.
13. Borner, W.  
 "Radiation Exposure in Nuclear Medicine"  
 Radiologe, 6:323-7, Aug. 1966.
14. Bragina, V.A., G.I. Kirsanova  
 "Chamber Bath Therapy with Naphthalene Emulsions in Disorders of the  
 Peripheral Blood Circulation in Patients Chronically Exposed to Ionizing  
 Radiation"  
 Gig. Tr. Prof. Zabol., 12:43-5, Jan. 1968.
15. Bresson, Y., A. Bellossi  
 "Preliminary Study of the Effects of Uniform Magnetic Field on the Blood"  
 Bull. Soc. Med. Afr. Noire. Lang. Franc., 14:612-4, 1969.
16. Buhr, A., H. Horst-Meyer  
 "Behavior of Granulocyte and Lymphocyte Count as well as the Nuclear Segment  
 Index of Neutrophil Granulocytes in the Peripheral Blood of Persons  
 Professionally Exposed to Irradiation in Correlation to the Personal  
 Dosimeter Value"  
 Radiobiol. Radiother. (Berlin), 9:683-7, 1968.
17. Calapaj, G.G.  
 "Environmental Ionizing Radiations - Problems of Dosimetry, Biological  
 Damage and Protection"  
 Ann. Sanit. Pubblica, 27:1093-138 Contd, Sep.-Oct. 1966.
18. Casassa, P.M., A. Cugini, A. Sosso, et. al.  
 "Thrombodynamographic Study on the Behavior of the Blood Coagulation Process  
 in Patients Treated with Cobalt Teletherapy"  
 Minerva Radiol., 13:65-75, Jan.-Feb. 1968.
19. Chone, B., H.B. Fuchs  
 "Studies of the Course of Leukocyte Concentrate During and After Therapeutic  
 Irradiation"  
 Radiobiol. Radiother. (Berlin), 10:489-503, 1969.
20. Chone, B., G. Manidakis  
 "Echinacin Test for the Provocation of Leukocytes in Effective Radiotherapy"  
 Deutsch. Med. Wschr., 94:1406-10, 4 Jul. 1969.

BLOOD (cont.)

21. Chone, B.  
"Clinical Possibilities of Differentiation of Radiation Hematologic Reactions"  
Radiobiol. Radiother. (Berlin), 8:335-51, 1967.
22. Chone, B.  
"Internal Medical Possibilities and Hematological Limits in Radio - and  
Chemotherapy of Tumors"  
Radiologe, 6:111-27, Apr. 1966.
23. Chone B., J. Becker  
"Beginning, Development and Improvement of Hematologic Radiation Protection"  
Strahlentherapie, 131:51-68, Sep. 1966.
24. Chvojka, Z.  
"Changes in the White Blood Picture Following Therapy of Patients with  
Tumors with Telecobalt Therapy and Inhibiting Betatron Irradiation"  
Sborn. Ved. Prac. Lek. Fak. Karlov. Univ., 10, Suppl- 469-74, 1967.
25. Ciocatto, E., M. Abrate, G. Baiotti, et. al.  
"Reactions Induced in the Body by Loco-Regional Administration of  
Radioisotopes"  
Minerva Med., 58:4489-90, 12 Dec. 1967.
26. Crespo Diez, A., F. Arnaiz Bueno, J. Ortiz Berrocal  
"Morphologic Demonstration of the Spleen and Kidneys Using  
Mercuryhydroxypropane-Acetate Marked with Hg<sup>197</sup> (AMHP-Hg<sup>197</sup>)"  
Rev. Esp. Enferm. Apar. Dig., 27:5-23, Jan. 1968.
27. David, A.  
"Course and Prognosis of Occupational Hematologic Radiation Injuries"  
Int. Arch. Gewerbepath., 24:271-86, 1968.
28. De Vecchi, A.  
"Clinical Experimentation with a New Radioprotective Compound  
(Methyl-Methionine-Sulfone Chloride)"  
Radiobiol. Radiother. Fis. Med., 22:355-70, Sep.-Oct. 1967.
29. Eisenach, R., H. Horst-Meyer  
"Studies of the Blood Picture in Man During Administration of  
Radiophosphorus"  
Radiobiol. Radiother. (Berlin), 9:179-82, 1968.
30. Field, E.O., K.D. Dawson, J.W. Dolphin, et. al.  
"Study of Lymphocyte Kinetics by Means of Extracorporeal Radiation of the  
Blood and Analysis of Chromosome Aberrations"  
Nouv. Rev. Franc. Hemat., 8:685-90, Sep.-Oct. 1968.

BLOOD (cont.)

31. Fleischmann, T.  
"Chromosome Anomalies in Hematologic Diseases"  
Orv. Hetil, 109:2866-70, 29 Dec. 1968.
32. Gabelov, A.A., K.V. Goreacheva, N.M. Evdokimov, et. al.  
"Changes in the Peripheral Blood of Patients with Cancer of the Lungs and Uterine Cervix During the Course of Megavolt Therapy"  
Vop. Onkol, 13:49-54, 1967.
33. Gerhardt, P.  
"Influence of Ionizing Radiation on the Carbohydrate Metabolism in Leukocytes"  
Strahlentherapie, 138:602-6, Nov. 1969.
34. Gerhardt, P.  
"Studies on the Influence of Ionizing Radiation on Erythrocytes. I. Review Of the Literature, Original Material and Methods of Examination"  
Strahlentherapie, 137:300-14, Mar. 1969.
35. Gerhardt, P.  
"Studies on the Influence of Ionizing Radiation on Erythrocytes. II. Findings"  
Strahlentherapie, 137:478-92, Apr. 1969.
36. Gerhardt, P.  
"Studies on the Influence of Ionizing Radiation on Erythrocytes. 3. Discussion and Summary"  
Strahlentherapie, 137:564-71, May 1969.
37. Gerhardt, P.  
"New Aspects on Radiation Effects on Erythrocytes"  
Radiol. Austria, 18:239-43, 1968.
38. Gerhardt, P.  
"The Effect of Ionizing Radiation on the Resistance of Hemoglobin"  
Radiobiol. Radiother. (Berlin), 10:407-11, 1969.
39. Gerhardt, P.  
"Increased Formation of Heinz Bodies in the Erythrocytes Following Radiation Exposure"  
Strahlenschutz. Forsch. Prax, 7:307-9, 1967.
40. Gerhardt, P.  
"Heinz Body Formation and Chronic Radiation Exposure - Further Report"  
Fortschr. Roentgenstr., 107:529-33, Oct. 1967.

BLOOD (cont.)

41. Gheorghe, N., I. Plesca  
"Action of Small Doses of Radioactive Radiations on the Body"  
Med.Intern.(Eucur), 21:21-7, Jan. 1969.
42. Glowiak, B., B. Halawa, R. Palczynski, et. al.  
"Effect of Baths and Inhalation of Radon Water of Swieradow on the  
Radioactivity of Human Blood and Urine"  
Pol.Tyg.Lek, 24:1955-7, 22 Dec. 1969.
43. Gillon, J. J.  
"Medical Supervision of Workers Exposed to Ionizing Radiations"  
Arch.Mal.Prof, 28:601-4, Jul.-Aug. 1967.
44. Gol'dberg, E. D.  
"Assessment of Shifts in Blood Indices in Chronic Occupational Irradiation  
of Radiologists"  
Med.Radiol.(Moskva), 11:53-5, Aug. 1966.
45. Hansen, N.E.  
"Leukopenia"  
Tandlaegebladet, 73:267-73, Apr. 1969.
46. Hennig, K., W.G. Franke, P. Woller, et. al.  
"Present Results in Spleen Scintigraphy with Bromomercuri-Hydroxypropane  
(BMHP-Hg<sup>197</sup>)"  
Nuclearmedizin, 4:370-82, 1 Jul. 1965.
47. Horst-Meyer, H.  
"Hematological Changes in Persons Occupationally Exposed to Radiation  
in Dependence on Individual Dosage."  
Strahlentherapie, 137:315-9, Mar. 1969.
48. Horst-Meyer, H., S. Mau, C. Petroff  
"Studies on the Importance of the Nuclear Segment Index of the Neutrophil  
Granulocytes in the Evaluation of Irradiation-Induced Hematologic Changes  
in the Peripheral Blood"  
Strahlentherapie, 134:255-62, Oct. 1967.
49. Horst-Meyer, H.  
"Hematologic Changes in Subjects Occupationally Exposed to Radiation in  
Absence of Personal Dosimetric Values"  
Strahlentherapie, 135:428-36, Apr. 1968.
50. Horst-Meyer, H.  
"Thromboelastographic Studies in Persons Occupationally Exposed to Radiation"  
Strahlentherapie, 129:456-9, Mar. 1966.

BLOOD (cont.)

51. Ivanova, T.F.  
"Changes in the Peripheral Blood in Patients During Gamma-Irradiation and Chemotherapy of Cancer of the Breasts"  
Vop.Onkol, 14:96-7, 1968.
52. Jorke, D., L. Wedekind  
"The Behavior of Various Types of Lymphocyte and Lymphoid Cells Under the Influence of Ionizing Rays"  
Fortschr Roentgenstr, 108:104-15, Jan. 1968.
53. Kholin, V.V.  
"On Changes in Leukocyte Composition in Patients with Cancer of the Uterine Cervix During Combined Radiation Therapy"  
Vop.Onkol, 15:32-6, 1969.
54. Korbler, J.  
"Anemia Following Spinal Irradiation"  
Strahlentherapie, 137:694-9, Jun. 1969.
55. Kozlov, V.M.  
"The Time Interval Between Irradiation and Mitosis in a Culture of Human Leukocytes and the Number of Chromosomal Aberrations"  
Radiobiologiya, 8:79-81, Jan.-Feb. 1968.
56. Kriklava, J., Z. Vich, D. Koskova  
"Nuclear Residua in Peripheral Erythrocytes in Persons Exposed to Long-Term Radiation"  
Vnitri.Lek, 15:223-8, Mar. 1969.
57. Kriklava, J., Z. Vich  
"Blood Picture in Employees of Uranium Mines in the District of Pribram"  
Cas.Lek.Cesk, 107:1367-72, 1968.
58. Lada-Jagas, R., D. Jarczyk  
"Radiation-Induced Changes in Medical Personnel Working with X-Rays"  
Wiad Lek, 21:771-4, 1 May 1968.
59. Largiader, F.  
"Immunosuppression During Clinical and Experimental Organ Transplantation"  
Naturwissenschaften, 55:429-34, Sep. 1968.
60. Lebedeva, N.E., E.I. Gintsburg, K.S. Trincer  
"On the Radiomimetic Effect of Tyrosine Oxidation Products on the Eythrocyte Membrane"  
Radiobiologiya, 7:148-50, Jan.-Feb. 1967.

BLOOD (cont.)

61. Malyshev, A.M., G.I. Kovalenko, R.M. Mordvinova  
 "The Effect of Epilatory Doses of X-Ray Irradiation on the Morphological and Protein Composition of the Blood"  
 Vestn.Derm.Vener, 43:63-8, Apr. 1969.
62. Meindersma, T.E.  
 "Extracorporeal Irradiation of Blood in Leukemia"  
 Folia.Med.Neerl, 10:93-5, 1967.
63. Michailov, V., T. Dragnev, I. Harbov  
 "The Influencing of Leukopenia During Radiotherapy of Breast Carcinoma and Cancer of the Small Pelvic Organs Using Splenic Diathermy"  
 Radiobiol.Radiother.(Berlin), 9:329-33, 1968.
64. Micu, D., D. Niculescu-Zinca, N. Raiciulescu, et. al.  
 "Preliminary Research on Some Blood Cytoenzymochemical Changes Caused By Post-Therapeutic Internal Contamination with Radioactive Isotopes"  
 Stud.Cercet.Med.Intern, 10:327-34, 1969.
65. Miyachi, M.  
 "A Study of Radiation Injury of the Erythrocyte Membrane"  
 Nippon Acta Radiol, 28:1587-601, Mar. 1969.
66. Morandini, G.C., G. Gerna, G. Carosi, et. al.  
 "Inflammatory Cellular Reactions in Patients with Neoplasms Treated with High Energy Radiotherapy"  
 Arch.Sci.Med.(Torino), 124:497-505, Nov. 1967.
67. Morczek, A., W. Schmidt, W. Lessel  
 "Results of Statistical Hematologic Studies on Persons Occupationally Exposed to Radiation at the Low Dosage Range"  
 Radiobiol.Radiother.(Berlin), 9:107-23, 1968.
68. Morczek, A., H.J. Otto  
 "On the Problem of Bone Marrow Function Tests in Radiation Exposure"  
 Radiobiol.Radiother.(Berlin), 8:357-60, 1967.
69. Moser, K., J. Schwarzmeier, A. Lujf  
 "In Vitro Studies on the Effect of Roentgen Radiation on the Erythrocyte Metabolism"  
 Folia.Haemat.(Leipzig), 90:296-302, 1968.
70. Murzenko, D.I.  
 "Early Changes in the Peripheral Blood After the Effects of X-Ray Long-Wave Irradiation"  
 Med.Radiol.(Moskva), 13:87-9, Jun. 1968.



BLOOD (cont.)

71. Musshoff, K.  
"Radiotherapy of Leukoses"  
Internist (Berlin), 9:484-9, Dec. 1968.
72. Nenci, G.G., E. Del Piano, B. Lisi  
"Behavior of Heinz-Body Production, Glucose-6-Phosphate Dehydrogenase and Glutathion Reductase Activity, and Concentration and Stability of Reduced Glutathion in Erythrocytes Irradiated in Vivo and in Vitro"  
Haematologica, 52:551-62, 1967.
73. Neumeister, K.  
"On Leukopenia Occurrence in X-Ray and Cobalt Teletherapy"  
Strahlentherapie, 133:349-53, Jul. 1967.
74. Nosek, J., H. Bartonova  
"Alkaline Hemolysis of Erythrocytes of Miners in Uranium Mines"  
Cas.Lek.Cesk, 108:78-81, Jan. 1969.
75. Novakova, E., J. Nosek  
"Howell-Jolly Bodies in Normoblasts of Persons Exposed to the Hazard of Small Doses of Ionizing Radiation"  
Cas.Lek.Cesk, 108:318-20, 14 Mar. 1969.
76. Nunziante Cesaro, A., A. Granata, D. Germano  
"Aldolase Activity of the Plasma After Roentgen Irradiation of the Blood in Vitro"  
Folia.Med.(Napoli), 51:43-51, Jan. 1968.
77. Pazderova, J., A. David, Z. Roth  
"The Influence of Ionizing Radiation on the Health Status of Exposed Workers"  
Int.Arch.Gewerbepath, 23:127-40, 1967.
78. Pfannenstiel, P.  
"Behavior of the Peripheral Blood Picture and the Plasma Protein Fractions After Therapeutic Radioisotope Incorporation"  
Strahlenschutz.Forsch.Prax, 9:49-66, 1969.
79. Pohl, P.  
"On the Therapy of Irradiation-Induced Leukopenia with Esberitox"  
Med.Klin., 64:1546-7, 1969.
80. Ryneiskair, V.A., T.D. Mirimova  
"Certain Indices of the Blood Coagulation System in Children at Remote Periods Following Roentgen Therapy"  
Pediatria, 45:64-8, Aug. 1966.

BLOOD (cont.)

81. Salmi, H.A.  
 "The Hematological Effects of Chronic Low-Level Exposure to Ionizing Irradiation"  
 Sotilaslaak Aikak, 43:77-85, 1968.
82. Sasaki, T.  
 "Effects of Ionizing Radiation on Human Leukocyte Chromosomes"  
 J. Jap. Obstet. Gynec. Soc., 20:631-40, Jun. 1968.
83. Schiffer, L.M., A.D. Chanana, E.P. Cronkite, et. al.  
 "Extracorporeal Radiation of the Blood in Chronic Lymphocytic Leukemia"  
 Nouv. Rev. Franc. Hemat., 8:691-700, Sep.-Oct. 1968.
84. Schulte-Wissermann, H., H. Hille, H.J. Jesdinsky, et. al.  
 "Effect of Climate at Median Altitudes and the Weather on the Blood Count"  
 Acta Haemat.(Basel), 42:281-95, 1969.
85. Schmidt, R. H. Horst-Meyer  
 "Examination of the Influence of Biaxial Telecobalt Therapy in Gynecological Carcinomas on the Human Leukocyte Count"  
 Radiobiol. Radiother (Berlin), 8:99-102, 1967.
86. Sokolova, N.M., L.Z. Klechikov, E.K. Sabidzhelinskaia  
 "Change in the Phagocytic Activity of Leukocytes in Patients with Cancer of the Cervix Uteri Undergoing Radiotherapy"  
 Vop. Onkol., 12:32-5, 1966.
87. Dietz, W.  
 "On the Possibility of Seizing the Radiation Effect on the Organism from the Peripheral Blood with the Resistance Value of Leukocytes"  
 Strahlenschutz Forsch. Prax., 4:159-81, 1964.
88. Feremans, W.  
 "Comparison of the Effects X-Rays, Gamma-Rays, Cobalt 60 and High-Energy Electrons on Human Blood Cell Chromosomes Irradiated in Vitro"  
 Europ. J. Cancer, 2:279-84, Aug. 1966.
89. Hashi, M., Y. Tanaka  
 "Radioprotective Effect of 3'Nucleotide Under Radiotherapy"  
 Nippon Acta Radiol., 26:432-6, Aug. 1966.
90. Helde, M.  
 "New Methods for the Evaluation of Blood Examinations in the Medical Surveillance"  
 Strahlenschutz Forsch. Prax., 4:147-58, 1964.

BLOOD (cont.)

91. Hollard, D., M. Servoz-Gavin, J. Damault  
"Effects of High Dose Irradiation on Platelet Function in Vitro"  
Hemostase, 6:57-64, Jan.-Mar. 1966.
92. Ishihara, T.  
"Chromosome Aberrations in Irradiated Human Subjects"  
Jap. J. Hum. Genet., 11:43-52, Oct. 1966.
93. Kriger, I.U., A. Tambiev, L.A. Zakirov  
"The Effect of Antibiotics on Radiation and Photodynamic Injury of Erythrocytes"  
Dokl. Akad. Nauk. SSSR, 163:1275-7, 11 Aug. 1965.
94. Lambin, P.  
"The Practical Importance of Hematologic Examinations in the Surveillance of Radiation Exposed Persons"  
Strahlenschutz. Forsch. Prax., 4:95-110, 1964.
95. Morczek, A., K. Abraham  
"On the Mechanism of the Radiation Effect on the  $K^+-Na^+$  Exchange in Erythrocytes"  
Biophysik, 4:113-7, 1967.
96. Romanini, A.  
"Late Hematologic Diseases Caused by Ionizing Radiations"  
Minerva Fisiconucl., 10:52-7, 1966.
97. Spaander, J.  
"On the Utilization of Blood Examinations in the Surveillance of Laborers"  
Strahlenschutz. Forsch. Prax., 4:111-46, 1964.
98. Solodova, R.A., D.A. Bodrova, N.V. Vershinin  
"On the Prevention of Late Clinical Manifestations in People Working with Constant-Action Luminous Substances (SPD)"  
Klin. Med. (Moskva), 44:35-40, Nov. 1966.
99. Spoljar, M., F. Zunter, M. Kubovic, et. al.  
"Changes in the Blood Elements, Serum Proteins as Well as Sternal Bone Marrow During and After X-Irradiation of the Thoracic Wall in Breast Carcinoma"  
Strahlentherapie, 133:238-44, Jun. 1967.
100. Strutsovskaja, S.V.  
"Local Complications of Radiotherapy in Patients with Cancer of the Cervix Uteri"  
Vop. Onkol., 12:26-31, 1966.

BLOOD (cont.)

101. Sugimoto, K.  
 "Studies of Hematopoietic Function Disturbance Due to the Therapy of Intrapelvic Malignant Tumors in Women. (2)"  
 J. Jap. Obstet. Gynec. Soc., 20:577-84, Jun. 1968.
102. Teixeira-Pinto, A.A.  
 "Lysis of Blood Basophil Granulations Subjected to the Action of X-Rays"  
 CR Soc. Biol. (Paris), 162:1870-2, 3 Apr. 1969.
103. Ueno, Y.  
 "On an Estimation of the Ability of Chemical Radioprotectors Against Leukopenia During Radiation Therapy"  
 Nippon Acta Radiol., 28:1337-40, Jan. 1969.
104. Waller, H.D., H.D. Schoen  
 "Sulphydryl Groups in the Erythrocytes of Patients Under Therapy with Ionizing Radiation"  
 Klin. Wschr., 44:186-9, 15 Feb. 1966.
105. Waller, H.D., H.D. Schoen  
 "Heinz Body Formation and GSH Content in Erythrocytes with Glucose-6-Phosphate Dehydrogenase Deficiency and Disruption of Glutathione Synthesis After X-Irradiation in Vitro"  
 Klin. Wschr., 44:189-94, 15 Feb. 1966.
106. Weinreich, J.  
 "Autoimmune Hemolytic Anemia and as a Result of X-Ray and Cytostatic Treatment in Lymphatic Leukemia"  
 Allerg. Asthma. (Leipzig), 12:264-6, Dec. 1967.
107. Zablocka, I., J. Prokopczuk  
 "Studies on Reversal of Hemolysis Using Cr<sup>51</sup>. Preliminary Report"  
 Pol. Arch. Med. Wewnet., 39:243-6, 1967.
108. Zuk, A.  
 "Shiels' Method in the Evaluation of Qualitative Changes in Lymphocytes of Employees Exposed to Ionizing Radiation"  
 Pol. Tyg. Lek., 24:1264-7, Aug. 1969.
109. Suzuki, M., S. Sasakawa, E. Hiroi, et. al.  
 "Hematological Characteristics of Patients with Cervical Carcinoma Treated by Radiotherapy"  
 J. Jap. Obstet. Gynec. Soc., 18:647-52, Jul. 1966.
110. Zhavoronkova, L.A., N.N. Katulkina, T.N. Kovalevskaja, et. al.  
 "The Use of Transfusion of Freshly Preserved Blood and Leukocytes in Patients with Tumors of the Female Genitalia During Radiotherapy"  
 Med. Radiol. (Moskva), 11:40-4, Mar. 1966.

BLOOD (cont.)

111. Zographov, D.G., D.N. Gospodinowa  
"On the Hematology of Occupational Radiation Injuries. I. Follicular and Sinus Lymphocytes"  
Deutsch. Gesundh., 21:826-9, 5 May 1966.
112. Fukuda, M., M. Abe  
"Iatrogenic Disorders in Radiotherapy"  
Rinsho Hosha, 14:533-8, Jul. 1969.

LYMPH

1. Andersen, V., S.E. Sorensen, S.A. Killmann  
"Treatment of Chronic Lymphocytic Leukemia with Extracorporeal Radiation of The Blood"  
Nouv. Rev. Franc. Hemat., 8:709-18, Sep.-Oct. 1968.
2. Aso, Y., Y. Hoshino, I. Murahashi  
"Histochemical Evaluation of the Effect of Radioisotopes on Dehydrogenases in Lymph Nodes"  
Jap. J. Urol., 60:433-8, May 1969.
3. Baclesse, F.  
"Is it Still Possible to Operate on Breast Neoplasms Which Have Been Treated with Cobalt 60 Radiation"  
Strahlentherapie, 131:15-20, Sep. 1966.
4. Badmaeva, V.V., A.P. Morozov  
"Morphological Changes in Regional Lymph Nodes in Patients with Breast Cancer During Intratissular Administration of Au<sup>198</sup>"  
Med. Radiol. (Moskva), 13:26-34, Aug. 1968.
5. Barousch, R.  
"Thorotrast Damage. Review and Report of 3 Cases"  
Wien. Med. Wschr., 119:681-5, 11 Oct. 1969.
6. Barth, G.  
"The Knowledge of Radiation Pathology as a Basis for Radiation Protection in Radiology"  
Radiologe, 6:298-303, Aug. 1966.
7. Bauchinger, M., O. Hug  
"Chromosome Aberrations Following Radium Roentgen Therapy of Gynecologic Tumors"  
Strahlentherapie, 131:109-21, Sep. 1966.
8. Beduhn, D., H. Kuttig.  
"The Moving Beam Irradiation of the Pra-Aortic Lymph Nodes with Co<sup>60</sup> Gamma Rays"  
Strahlentherapie, 132:481-6, Apr. 1967.
9. Binet, J.L., J. Bernard  
"Circulation of Lymphocytes"  
Rev. Franc. Etud. Clin. Biol., 14:235-7, Mar. 1969.
10. Buhr, A., H. Horst-Meyer  
"Behavior of Granulocyte and Lymphocyte Count as Well as the Nuclear Segment Index of Neutrophil Granulocytes in the Peripheral Blood of Persons Professionally Exposed to Irradiation in Correlation to the Personal Dosimeter Value"  
Radiobiol. Radiother. (Berlin), 9:683-7, 1968.

LYMPH (cont.)

11. Field, E.O., K.D. Dawson, J.W. Dolphin, et. al.  
 "Study of Lymphocyte Kinetics by Means of Extracorporeal Radiation of the Blood and Analysis of Chromosome Aberrations"  
 Nouv. Rev. Franc. Hemat, 8:685-90, Sep.-Oct. 1968.
12. Frischbier, H.J., G. Mohle  
 "Possibilities of Telecobalt Therapy of the Lumbar Lymphatic System"  
 Strahlentherapie, 132:487-96, Apr. 1967.
13. Fonshtein, L.V., E.I. Vorob'ev, E.I. Shcherban', et. al.  
 "The Importance of the Radiation Load on Organs and Tissue in the Radiotherapy of Certain Malignant Neoplasms and Lymphogranulomatosis"  
 Med. Radiol. (Moskva), 12:35-42, Jan. 1967.
14. Garrett, J.V., L.G. Lajtha  
 "4 Cases of Chronic Lymphocytic Leukemia Treated with Extracorporeal Radiation of the Blood"  
 Nouv. Rev. Franc. Hemat, 8:701-8, Sep.-Oct. 1968.
15. Golob, E., P. Fischer, E. Kunze-Muhl  
 "Effect of Culture Time on Radiation-Induced Chromosome Aberrations in Human Lymphocytes in the Peripheral Blood"  
 Strahlentherapie, 137:63-7, Jan. 1969.
16. Hartweg, H., H.E. Schmitt, K. Renner  
 "Studies on the Behavior of Binuclear Lymphocytes Following Radiotherapy"  
 Strahlentherapie, 113:245-51, Jun. 1967.
17. Heitmann, H.J.  
 "Chromosome Mutations of Blood Cells in X-Ray Teleirradiation of the Skin"  
 Hautarzt, 17:515-7, Nov. 1966.
18. Heitmann, H.J.  
 "Cytogenetic Studies on Blood Cells in the Roentgenotherapy of Eczema"  
 Hautarzt, 19:31-3, Jan. 1968.
19. Jorke, D., L. Wedekind  
 "The Behavior of Various Types of Lymphocyte and Lymphoid Cells Under the Influence of Ionizing Rays"  
 Fortschr. Roentgenstr, 108:104-15, Jan. 1968.
20. Knoth, W., G. Ehlers  
 "The Effect of X-Rays on the DNA Content of Malignant Melanoma Cells"  
 Arch. Klin. Exp. Derm, 233:77-81, 1968.

LYMPH (cont.)

21. Kop'eva, T. N.  
"Morphologic Changes in the Thymus Gland in Myasthenia Under the Effect of Radiation Therapy"  
Ark. Pat., 30:13-9, 1968.
22. Kriklava, J., Z. Vich  
"Blood Picture in Employees of Uranium Mines in the District of Pribram"  
Cas. Lek. Cesk., 107:1367-72, 1968.
23. Kuttig, H.  
"Radiotherapy of Wilm's Tumor"  
Radiobiol. Radiother. (Berlin), 9:247-52, 1968.
24. Lamarque, J. L., A. Pages, H. Pujol, et. al.  
"Radiologic Anatomy and Semeiologic Value of Lymph Node Images in Lymphography"  
J. Radiol. Electr., 48:253-62, May 1967.
25. Largiader, F.  
"Immunosuppression During Clinical and Experimental Organ Transplantation"  
Naturwissenschaften, 55:429-34, Sep. 1968.
26. Laskowski, J., J. Lysakowska  
"Post-Irradiation Changes in Axillary Nodes in the Course of Preoperative Treatment of Breast Cancer with Roentgen Rays"  
Nowotwory, 18:33-43, Jan.-Mar. 1968.
27. Ludvik, W., F. Wachtler, W. Zaunbauer  
"Changes in Lymphography Due to Surgical Operation and Ionizing Radiation. Regeneration of the Lymphatic System"  
Fortschr. Roentgenstr., 110:307-21, Mar. 1969.
28. Markovits, P., R. Blache, C. Gasquet, et. al.  
"Radiological Appearances of Lymphographies Performed After Irradiation"  
Ann. Radiol. (Paris), 12:835-47, 1969.
29. Malska-Waniewska, I., E. Studencki, T. Naganski  
"Lymphographic Picture of Lymph Nodes Following Roentgen Irradiation"  
Strahlentherapie, 137:9-13, Jan. 1969.
30. Malska-Waniewska, I., E. Studencki, T. Naganski  
"Lymphographic Pictures of Lymph Nodes After Roentgen-Ray Irradiation"  
Nowotwory, 18:161-8, Apr.-Jun. 1968.



LYMPH (cont.)

31. Zographov, D.G., D.N. Gospodinova  
 "On the Hematology of Occupational Radiation Injuries. I. Follicular and Sinus Lymphocytes"  
 Deutsch.Gesundh, 21:826-9, 5 May 1966.
32. Micu-D., D. Niculescu-Zinca, N. Raiciulescu, et. al.  
 "Preliminary Reserach on Some Blood Cytoenzymochemical Changes Caused by Post-Therapeutic Internal Contamination with Radioactive Isotopes"  
 Stud.Cercet.Med.Intern, 10:327-34, 1969.
33. Musshoff, K.  
 "Radiotherapy of Leukoses"  
 Internist (Berlin), 9:484-9, Dec. 1968.
34. Nemec, J., M. Neradilova, V. Zamrazil, et. al.  
 "Hematologic Changes in the Treatment of Thyrotoxicosis and Cancer of the Thyroid Gland with Radioactive Iodine 131-I"  
 Cas.Lek.Cesk, 107:742-8, 14 Jun. 1968.
35. Novakova, E., J. Nosek, D. Koskova  
 "Method of Lymphograms and Lymphograms of Miners in Uranium Mines"  
 Vnitri.Lek, 14:973-80, Sep. 1968.
36. Novakova, E.  
 "Nucleolar Coefficient of Lymphocytes of Uranium Miners"  
 Vnitri.Lek, 14:256-60, Mar. 1968.
37. Pizon, P.  
 "Consequences of Radiologic Explorations Using Thorium"  
 Presse.Med, 77:241-4, 8 Feb. 1969.
38. Renner, K., H. Hartweg, H. Renner  
 "The Degenerating Cell Forms of In Vitro Stimulated Lymphocytes"  
 Blut, 19:151-5, 1969.
39. Schiffer, L.M., A.D. Chanana, E.P. Cronkite, et. al.  
 "Extracorporeal Radiation of the Blood in Chronic Lymphocytic Leukemia"  
 Nouv. Rev. Franc. Hemat, 8:691-700, Sep.-Oct. 1968.
40. Schlienger, M., C. Parmentier, A. Laugier, et. al.  
 "Splenic Radiotherapy in the Treatment of Chronic Lymphocytic Leukemias, its Analogies with Extracorporeal Radiation"  
 Nouv. Rev. Franc. Hemat, 8:719-32, Sep.-Oct. 1968.

LYMPH (cont.)

41. Schroder, K., H.A. Ladner, G. Pemsel  
 "Demonstration of Radiation Induced Percentual Changes in Peripheral Lymphocyte Type by Means of a Cytochemical Method"  
 Strahlenschutz, Forsch. Prax, 7:311-7, 1967.
42. Skalska-Vorerodt, J., I. Hliniakowa, J. Godawski  
 "Radiolymphography with Application of I-131 (I. Technical Problems)"  
 Pol. Przegl. Radiol, 33:709-14, Sep.-Oct. 1969.
43. Strambi, E., S. Tagliati  
 "Clinical and Dosimetric Study of a Case of Accidental Irradiation in the Use of a Cobalt 60 Source"  
 Med. Lavoro, 58:573-87, Oct. 1967.
44. Tanaka, Y., Y. Koroda, T. Hashimoto  
 "The Occurrence and Significance of Anomalous Lymphocytes in Peripheral Blood After Radiation Exposures"  
 Nippon Acta Radiol, 27:429-36, Jul. 1967.
45. Tischer, W.  
 "Diagnosis and Therapeutic Possibilities in Thymus Gland Hyperplasia in Infancy"  
 Kinderaerztl. Prax, 35:333-40, Aug. 1967.
46. Toroptsev, I.V.  
 "Morphological Characteristics of the Biological Action of Magnetic Fields"  
 Arkh. Pat, 30:3-12, 1968.
47. Ueno, Y.  
 "Radiosensitivity of the Lymphocyte"  
 Saishin. Igaku, 24:1382-9, Jul. 1969.
48. Vich, Z., M. Beran  
 "The Nuclear Structure of Lymphocytes in Uranium Miners"  
 Cas. Lek. Cesk, 106:1186-7, 27 Oct. 1967.
49. Vishnevskaja, E.E., E.V. Trushnikova  
 "Appraisal of the Radiation Changes and Metastatic Lesions of the Lymphatic System of the Pelvis with the Aid of Lymphography"  
 Vop. Onkol, 13:32-8, 1967.
50. Zuk, A.  
 "Shiels' Method in the Evaluation of Qualitative Changes in Lymphocytes of Employees Exposed to Ionizing Radiation"  
 Pol. Tyg. Lek, 24:1264-7, Aug. 1969.

LYMPH (cont.)

51. Buschmann, O., R. Hunig  
"Thorotrast Poisoning"  
Med.Klin, 61:14-8, 7 Jan. 1966.
52. Helde, M.  
"New Methods for the Evaluation of Blood Examinations in the Medical Surveillance"  
Strahlenschutz, Forsch.Prax, 4:147-58, 1964.
53. Szasz, G., I. Voros, J. Lakos  
"The Influence of Roentgen-Irradiation on the Course of Adrenaline Lymphocytosis"  
Radiobiol.Radiother.(Berlin), 7:241-7, 1966.
54. Szobor, A., E. Kornyei  
"Myasthenia Gravis and Dysthyreosis"  
Nervenarzt, 37:337-42, Aug. 1966.

MUSCLES

1. Barabanova, A. V.  
"The Status of the Motor Function in Chronic Exposure to Radiation"  
Med. Radiol. (Moskva), 12:42-7, Aug. 1967.
2. Pichler, H. J.  
"Otological Problems of Space Flight"  
Mschr. Ohrenheilk, 102:168-70, 1968.
3. Niklas, K., F. Wachsmann  
"Radiation Injury and Radiation Accidents in X-Ray Units"  
Radiologe, 6:332-8, Aug. 1966.

SKELETON

1. Funshtein, L.V., E.I. Vorob'ev, E.I. Shcherban', et. al.  
"The Importance of the Radiation Load on Organs and Tissue in the Radiotherapy of Certain Malignant Neoplasms and Lymphogranulomatosis"  
Med. Radiol. (Moskva), 12:35-42, Jan. 1967.
2. Pichler, H. J.  
"Otological Problems of Space Flight"  
Möchr. Ohrenheilk, 102:168-70, 1968.
3. Spoljar, M., F. Zunter, M. Kubovic, et. al.  
"Changes in the Blood Elements, Serum Proteins as well as Sternal Bone Marrow During and After X-Irradiation of the Thoracic Wall in Breast Carcinoma"  
Strahlentherapie, 133:238-44, Jun. 1967.
4. Sugimoto, K.  
"Studies of Hematopoietic Function Disturbance due to the Therapy of Intrapelvic Malignant Tumors in Women"  
J. Jap. Obstet. Gynec. Soc, 20:577-84, Jun. 1968.
5. Vishnevskaja, E. E., E. V. Trushnikova  
"Appraisal of the Radiation Changes and Metastatic Lesions of the Lymphatic System of the Pelvis with the Aid of Lymphography"  
Vop. Onkol, 13:32-8, 1967.
6. Koslowski, L.  
"Radiation Burden and Burns"  
Strahlenschutz-Forsch. Prax, 4:303-14, 1964.
7. Barletta, L. P.  
"Radionecrosis. Surgical and Biological Excision"  
Prensa. Med. Argent, 53:1658-61, 29 Jul. 1966.
8. Bote, D. V.  
"On a Case of Mandibular Osteoradionecrosis and Late Epithelioma of the Lip Caused by Radium Therapy"  
Arch. Stomat. (Roma), 6:317-33, Oct.-Dec. 1965.
9. Chatzephotiades, D., I. Eleutheriades, P. Papademetriou  
"Some Observations in Radionecrosis of the Jaw"  
Stomatologia (Athen), 26:123-34, May-Jun. 1969.
10. Friez, P., E. Alexandre, C. Lesage  
"Apropos of a Rare Form of Odonto-Radionecrosis"  
Acta Stomat. Belg, 65:495-500, 1968.

SKELTON (cont.)

11. Fukuda, M., M. Abe  
"Iatrogenic Disorders in Radiotherapy"  
Rinsho Hosha, 14:533-8, Jul. 1969.
12. Gabka, J.  
"Incidence and Treatment of Major Radiation Induced Ulcerations of  
the Maxillofacial Area"  
Czas.Stomat, 22:589-95, May-Jun. 1969.
13. Glasenapp, G.B.  
"Osteomyelitis of the Maxilla Following Radiotherapy for Facial Lupus"  
Hno, 16:46-9, Feb. 1968.
14. Guella, A., M. Zadra  
"Observations on the Treatment of Tumors of the Mouth and New Prospects  
of Radiotherapy. Personal Experience"  
Ann.Laring, 65:620-9, Sep.-Oct. 1966.
15. Hahn, G., D.A. Corgill  
"Conservative Treatment of Radionecrosis of the Mandible"  
Oral Surg, 24:707-11, Nov. 1967.
16. Kunimitsu, T.  
"Microradiographic Observation on Osteoradionecrosis"  
J.Jap.Stomat.Soc, 35:529, Sep. 1968.
17. Lenarduzzi, G., C. Valdagni, F. Pozza  
"Evaluation of Late Lesions Following Therapy with Fast Electrons"  
Strahlentherapie, 135:166-75, Feb. 1968.
18. Merlini, C.  
"Pathogenetic and Clinical Aspects of Radiation Injury by X-Ray in  
Dentistry"  
Rass.Trim.Odont, 48:553-68, Oct.-Dec. 1967.
19. Niklas, K., F.Wachsmann  
"Radiation Injury and Radiation Accidents in X-Ray Units"  
Radiologe, 6:332-8, Aug. 1966.
20. Perzyna, B., K. Stawinski  
"Delayed Lesions in the Teeth and the Mandible of a Child After  
Therapeutical X-Ray Application"  
Deutsch.Stomat, 18:908-12, Dec. 1968.

SKELETON (cont.)

21. Pourquier, H.  
"Complications of Radiotherapy of Cancer of the Uterine Cervix at Stage 3"  
J. Radiol. Electr., 49:607-16, Aug.-Sep. 1968.
22. Schubert, H., H.J. Rapp.  
"Osteoradionecrosis of the Mandible Following Telecobalt and Electron Radiotherapy of Tumors on the Floor of the Mouth and Cheek"  
Radiobiol. Radiother. (Berlin), 9:279-86, 1968.
23. Schule, H.  
"Clinical Manifestations and Prevention of Radiation Injuries to the Teeth, Mouth and Jaws"  
Deutsch. Zahnaerztl. Z., 22:103-26, Feb. 1967.
24. Boszkiewicz, T.  
"Traumas of the Skull and Brain in Acute Postirradiation Disease"  
Otolaryng. Pol., 21:219-22, 1967.

CARDIOVASCULAR

1. Bogoliubov, V.M., E.N. Denisov  
"The Preparation of Standards for Radioactive Protein Compounds"  
Med.Radiol.(Moskva), 11:85-6, Jun. 1966.
2. Bragina, V.A., G.I. Kirsanova  
"Chamber Bath Therapy with Naphthalene Emulsions in Disorders of the  
Peripheral Blood Circulation in Patients Chronically Exposed to Ionizing  
Radiation"  
Gig.Tr.Prof.Zabol, 12:43-5, Jan. 1968.
3. Breit, A.  
"Arteriography Before and After Tumor Irradiation"  
Fortschr.Roentgenstr, 111:329-44, Sep. 1969.
4. Brina, A., G. Lo Cicero  
"Behavior of the Cardiovascular System During Radium Therapy of Genital  
Neoplasms"  
Ann.Ostet.Gynec, 90:825-42, Dec. 1968.
5. Ciocatto, E., M. Abrate, G. Baiotti, et. al.  
"Reactions induced in the Body by Loco-Regional Administration of  
Radioisotopes"  
Minerva Med, 58:4489-90, 12 Dec. 1967.
6. Dziuk, E.  
"Effect of X-Rays and Gamma Radiation on the Heart"  
Pol.Arch.Med.Wewnet, 43:1201-6, Aug. 1969.
7. Fonshtein, L.V., E.I. Vorob'ev, E.I. Shcherban', et. al.  
"The Importance of the Radiation Load on Organs and Tissue in the  
Radiotherapy of Certain Malignant Neoplasms and Lymphogranulomatosis"  
Med.Radiol.(Moskva), 12:35-42, Jan. 1967.
8. Ganse, R.  
"The Changes in the Atypical Vessels of Cervix Carcinoma Under Telecobalt  
Irradiation"  
Geburtsch.Frauenheilk, 27:476-80, May 1967.
9. Gordon, Z.V.  
"Radiofrequency Electromagnetic Fields as a Health Factor"  
Gig.Tr.Prof.Zabol, 10:3-6, Oct. 1966.
10. Gurevich, I.B., N.V. Nikolaeva, B.P. Shvedskii, et. al.  
"Changes in the Cardiovascular System in Patients with Erythemia Treated by  
p 32"  
Med.Radiol.(Moskva), 12:28-32, Oct. 1967.



CARDIOVASCULAR (cont.)

11. Hecht, A.  
"On the Specificity of Enzyme Histochemical and Electron Microscopic Reactions of the Myocardium as a Response to Pathogenic Stimuli"  
Z. Ges. Inn. Med., 24:97-102, 15 Feb. 1969.
12. Kaneda, H., A. Takaoka, M. Maeda, et. al.  
"Problems in Radiotherapy of Lung Cancer. 1. Its Primary Site and Therapeutic Effects"  
Jap. J. Cancer Clin., 14:101-4, Feb. 1968.
13. Klein, E.  
"About the Possible Influence of Atmospherics on Myocardial Infarctions"  
Aerztl. Forsch., 22:240-53, 10 Jul. 1968.
14. Kleinert, H., H. Kuttig, C. Wieland  
"Electrocardiographic Studies During Co<sup>60</sup> Teletherapy of the Heart Region"  
Strahlentherapie, 134:339-49, Nov. 1967.
15. Lepskaia, E.S.  
"Roentgenological Symptomatology of Primary Rheumocarditis in Children and Its Relation to the Activity of the Rheumatic Process (According to A.I. Nesterov)"  
Pediatriia, 46:20-3, Feb. 1967.
16. Liegl, O.  
"On the Consequences of a Radiation Overdose in the Neck. A Contribution to the Syndrome of Bilateral Carotid Occlusion"  
Z. Kreislaufforsch., 56:221-34, Mar. 1967.
17. Menozzi, V., U. Dusi, G.G. Ferri  
"Anatomohistologic Aspects of the Cardiac Damage Due to Ionizing Radiation"  
Riv. Anat. Pat. Oncol., 31:90-7, Jan. 1967.
18. Messerschmidt, O., W. Oehlert  
"Studies on Combination Damages. 10. Histopathological Studies on Mice Following Whole Body Irradiation in Combination with Open Skin Lesions"  
Strahlentherapie, 136:229-36, Aug. 1968.
19. Nagai, S., T. Matsuo  
"Changes in the Heart After Radiotherapy"  
Iryo, 21:1016-21, Sep. 1967.
20. Pichler, H.J.  
"Otological Problems of Space Flight"  
Mschr. Ohrenheilk., 102:168-70, 1968.

CARDIOVASCULAR (cont.)

21. Piontkovskii, I.A.  
"The Radioembriologic Effect and its Importance in Pathology"  
Pat.Fiziol.Eksp.Ter, 11:13-20, Nov.-Dec. 1967.
22. Toroptsev, I.V.  
"Morphological Characteristics of the Biological Action of Magnetic Fields"  
Arkhn.Pat, 30:3-12, 1968.
23. Dusi, U., G.G. Ferri  
"Cardiac Damage Caused by Antineoplastic Radiotherapy"  
Boll.Soc.Ital.Cardiol, 11:844-8, 1966.
24. Ganse, R.  
"Changes in Atypical Blood Vessels of Cancer of the Uterine Cervix Under the Effects of Radium Irradiation"  
Geburtsh.Frauenheilk, 26:391-6, Apr. 1966.
25. Gorbosova, N.B.  
"Working Conditions and Health Problems Among Vessel Radiooperators Exposed to the Electromagnetic Field of High Frequency"  
Bull.Inst.Mar.Med.Gdansk, 17:263-6, 1966.
26. Kleibel, F.  
"Pathogenesis and Treatment of Radiogenic Hypotensive Circulation Disorders"  
Deutsch.Med.J, 17:326-9, 31 May 1966.
27. Kleibel, F.  
"Experimental Studies on the Hypotension Induced by Radiation and its Treatment with Noradrenaline Derivatives"  
Med.Welt, 14:725-8, 2 Apr. 1966.
28. Theisen, H.  
"Mondor Phlebitis as a Result of Roentgen Irradiation"  
Med.Welt, 7:378-9, 18 Feb. 1967.

BONE MARROW

1. Agamova, K.A., M.L. Brin  
"The State of Megakaryocytes of the Bone Marrow in Patients with Breast and Lung Cancer During Radioactive Colloidal Au<sup>198</sup> Therapy"  
Med.Radiol.(Moskva), 11:81-4, Feb. 1966.
2. Andersen, V., S.F. Sorensen, S.A. Killmann  
"Treatment of Chronic Lymphocytic Leukemia with Extracorporeal Radiation of the Blood"  
Nouv.Rev.Franc.Hemat, 8:709-18, Sep.-Oct. 1968.
3. Barth, G.  
"The Knowledge of Radiation Pathology as a Basis for Radiation Protection in Radiology"  
Radiologe, 6:298-303, Aug. 1966.
4. Bauer, R.  
"Clinical Problems in Radiation Hematology"  
Aerztl.Forsch, 23:139-46, 10 Apr. 1969.
5. Bauer, R.  
"Radiation Hematology Past and Present"  
Strahlentherapie, 136:387-94, Oct. 1968.
6. Bernard, J.  
"The Preleukemic Aplasias"  
Nouv.Rev.Franc.Hemat, 9:41-8, Jan.-Feb. 1969.
7. Cardini, G., G. Riggio, M. Pegoraro, et. al.  
"Radioprotection of the Chromosomes of Human Medullary Cells in Vitro. II. Protective Effects of Methionine, Glutamic Acid, Phenylalanine and Tryptophan Against the Indirect Action of Ionizing Radiations"  
Radiobiol.Radioter.Fis.Med, 22:371-5, Nov.-Dec. 1967.
8. Chone, B., H.B. Fuchs  
"Studies of the Course of Leukocyte Concentrate During and After Therapeutic Irradiation"  
Radiobiol.Radiother.(Berlin), 10:489-503, 1969.
9. Chone, B.  
"Internal Medical Possibilities and Hematological Limits in Radio- and Chemotherapy of Tumors"  
Radiologe, 6:111-27, Apr. 1966.
10. David, A.  
"Course and Prognosis of Occupational Hematologic Radiation Injuries"  
Int.Arch.Gewerbepate, 24:271-86, 1968.

BONE MARROW (cont.)

11. Fleischmann, T.  
"Chromosome Anomalies in Hematologic Diseases"  
Orv. Hetil, 109:2866-70, 29 Dec. 1968.
12. Franzen, J.  
"Means of Reducing Somatic Radiation Hazards"  
Fortschr. Roentgenstr, 105:893-9, Dec. 1966.
13. Fuchs, G., J. Hofbauer  
"On Injury to the Bone Marrow in Simultaneous Radio- and Cytostatic- Therapy"  
Radiol. Austria, 18:233-8, 1968.
14. Franzen, J.  
"Means of Reducing Somatic Radiation Hazards"  
Fortschr. Roentgenstr, 105:893-9, Dec. 1966.
15. Gebert, P., K. Lorenz  
"Malignant Hemoblastoses Following Prophylactic and Therapeutic Procedures"  
Deutsch. Gesundh, 23:1318-22, 11 Jul. 1968.
16. Gerna, G., R. Moratti, G. Carosi, et. al.  
"Erythroblastometric Research on the Bone Marrow of Irradiated Subjects"  
Arch. Sci. Med. (Torino), 124:506-22, Nov. 1967.
17. Gheorghe, N., I. Plesca  
"Action of Small Doses of Radioactive Radiations on the Body"  
Med. Intern. (Eucur), 21:21-7, Jan. 1969.
18. Gorizontova, M. N.  
"Some Indices of Mitotic Activity of the Bone Marrow Under the Effect of  
Ionizing Radiation"  
Med. Radiol. (Moskva), 11:55-6, Dec. 1966.
19. Horst-Meyer, H., S. Mau, C. Petroff  
"Studies on the Importance of the Nuclear Segment Index of the Neutrophil  
Granulocytes in the Evaluation of Irradiation-Induced Hematologic Changes  
in the Peripheral Blood"  
Strahlentherapie, 134:255-62, Oct. 1967.
20. Klare, K. H., A. Morczek, H. J. Otto  
"Late Regeneration of the Human Bone Marrow Cells After Intensive  
Irradiation"  
Radiobiol. Radiother. (Berlin), 10:609-12, 1969.

BONE MARROW (cont.)

21. Lipats, A.A.  
 "Current Views on Erythropoiesis in Normal and Pathological Conditions  
 (Literature Review)"  
 Probl.Gemat, 12:38-45, Feb. 1967.
22. Maisin, H., E. Salamon, J. Longueville  
 "Effects of the Association of Cytotoxins and X-Rays on the Bone Marrow of  
 Rats. Clinical Deductions and Initial Results"  
 Rev. Med.Liege, Suppl 1-155+, Oct. 1968.
23. Morczek, A., K.H. Clare, H.J. Otto  
 "The Regeneration of the Bone Marrow After Therapeutic Roentgen Irradiation"  
 Radiobiol.Radiother.(Berlin), 8:351-6, 1967.
24. Morczek, A., H.J. Otto  
 "On the Problem of Bone Marrow Function Tests in Radiation Exposure"  
 Radiobiol.Radiother.(Berlin), 8:357-60, 1967.
25. Novakova, E., J. Nosek  
 "Howell-Jolly Bodies in Normoblasts of Persons Exposed to the Hazard of  
 Small Doses of Ionizing Radiation"  
 Cas.Lek.Cesk, 108:318-20, 14 Mar. 1969.
26. Riggio, G., A. Galimberti, G. Cardini  
 "Indirect Action of Ionizing Radiations. Possibility of Quantitative  
 Analysis by Means of Counting Chromosome Fragments"  
 Endocr.Sci.Cost, 29:141-4, Mar. 1967.
27. Schiffer, L.M., A.D. Chana, E.P. Cronkite, et. al.  
 "Extracorporeal Radiation of the Blood in Chronic Lymphocytic Leukemia"  
 Nouv. Rev.Franc.Hemat, 8:691-700, Sep.-Oct. 1968.
28. Schlienger, M., C. Parmentier, A. Laugter, et. al.  
 "Splenic Radiotherapy in the Treatment of Chronic Lymphocytic Leukemias, Its  
 Analogies with Extracorporeal Radiation"  
 Nouv. Rev. Franc.Hemat, 8:719-32, Sep.-Oct. 1968.
29. Spoljar, M., F. Zunter, M. Kubovic, et. al.  
 "Changes in the Blood Elements, Serum Proteins as Well as Sternal Bone  
 Marrow During and After X-Irradiation of the Thoracic Wall in Breast  
 Carcinoma"  
 Strahlentherapie, 133:238-44, Jun. 1967.
30. Stecherg, B. Kubanek, R. Zahnrt, et. al.  
 "On the Effect of Thorotrast on the Bone Marrow"  
 Blut, 16:328-32, Mar. 1968.

BONE MARROW (cont.)

31. Stenfert Kroese, W. F.  
"Drug Therapy in Hodgkin's Disease"  
Nederl. T. Geneesk, 112:1691-6, 21 Sep. 1968,
32. Svet-Moldavskii, G., Pavlotskii, A. I.  
"Selective Radiation Protection of Bone Marrow and Other Organs by Substances  
Linked with Macromolecular and Corpuscular Carriers"  
Dokl. Akad. Nauk. SSSR, 177:1223-4, 11 Dec. 1967.
33. Franzen, J., R. Wolf, K. H. Brod  
"Radiation Exposure of the Bone Marrow in Mass Chest X-Ray Examinations  
with Special Reference to the Distribution of the Cell Marrow"  
Radiol. Austria, 15:265-79, 1966.
34. Neutsch, W. D., E. Schumann, R. Werner  
"On Measurement of Bone Marrow Function Before and After Radiotherapy in  
Breast and Genital Cancer in Women"  
Strahlentherapie, 129:189-99, Feb. 1966.
35. Stoppa, I. M.  
"Radiobiologic and Radioprotective Problems in Dental Roentgenology"  
Minerva Stomat, 15:860-7, Dec. 1966.
36. Wichrzycka, E. B. Iesko  
"Cytologic Changes of the Bone Marrow Cells in Person ; Occupationally  
Exposed to Ionizing Radiation"  
Pol. Tyg. Lek, 21:921-4, 13 Jun. 1966.
37. Zanetti, M., F. Micheloni, S. Damilano  
"Survey on the Radiation Doses Received by the Population of the Republic of  
San Marino Following the Use of X-Rays for Medical Diagnosis. Estimation of  
Mean Bone Marrow Dose per Inhabitant"  
Ig. Mod, 59:89-97, 1966.

SPLEEN

1. Barousch, R.  
"Thorotrast Damage. Review and Report of 3 Cases"  
Wien, Med. Wschr., 119:681-5, 11 Oct. 1969.
2. Bauer, R.  
"Clinical Problems in Radiation Hematology"  
Aerzt. Forsch., 23:139-46, 10 Apr. 1969.
3. Binet, J.L., J. Bernard  
"Circulation of Lymphocytes"  
Rev. Franc. Etud. Clin. Biol., 14:235-7, Mar. 1969.
4. Berner, W.  
"Radiation Exposure in Nuclear Medicine"  
Radiologe, 6:323-7, Aug. 1966.
5. Danieli, G.  
"Therapy of Hemoblastosis. III. The Chronic Leukoses"  
G. Clin. Med., 47:934-52, Oct. 1966.
6. Garrett, J.V., L.G. Lajtha  
"4 Cases of Chronic Lymphocytic Leukemia Treated with Extracorporeal  
Radiation of the Blood"  
Nouv. Rev. Franc. Hemat., 8:701-8, Sep.-Oct. 1968.
7. Michailov, V., T. Dragnev, I. Harbov  
"The Influencing of Leukopenia During Radiotherapy of Breast Carcinoma and  
Cancer of the Small Pelvic Organs Using Splenic Diathermy"  
Radiobiol. Radiother. (Berlin), 9:329-33, 1968.
8. Musshoff, K.  
"Radiotherapy of Leukoses"  
Internist (Berlin), 9:484-9, Dec. 1968.
9. Parmentier, C., M. Schlienger, M. Hayat, et. al.  
"Splenic Irradiation in Decompensated Chronic Lymphocytic Leukemia"  
J. Radiol. Electr., 49:187-98, Mar.-Apr. 1968.
10. Pawelski, S., L. Konopka, B. Kotelba-Witkowska, et. al.  
"Studies of the Survival-Time of Cr<sup>51</sup> Tagged Platelets in Healthy Subjects  
and in Thrombocytopenia"  
Pol. Tyg. Lek., 22:1649-54, 23 Oct. 1967.
11. Perugini, S., E. Ascari, G. Fontana  
"Current Therapeutic Possibilities in Idiopathic Myelofibrosis. Observations  
on 47 Cases"  
Clin. Ter., 45:21-60, 15 Apr. 1968.

SPLEEN (cont.)

12. Pizon, P.  
"Consequences of Radiologic Explorations Using Thorium"  
Presse.Med, 77:241-4, 8 Feb. 1969,
13. Schiffer, L.M., A.D. Chanana, E.P. Cronkite, et. al.  
"Extracorporeal Radiation of the Blood in Chronic Lymphocytic Leukemia"  
Nouv.Rev.Franc.Hemat, 8:691-700, Sep.-Oct. 1968.
14. Schlienger, M., C. Parmentier, A. Laugier, et. al.  
"Splenic Radiotherapy in the Treatment of Chronic Lymphocytic Leukemias,  
its Analogies with Extracorporeal Radiation"  
Nouv.Rev.Franc.Hemat, 8:719-32, Sep.-Oct. 1968.
15. Schoen, D., R. Bauer  
"Results of Spleen Irradiation in 175 Clinical Cases of Chronic Myeloid  
Leukemia"  
Strahlentherapie, 135:1-10, Jan. 1968.
16. Svet-Moldavskii, G., A.I. Pavlotskii  
"Selective Radiation Protection of Bone Marrow and Other Organs by Substances  
Linked with Macromolecular and Corpuscular Carriers"  
Dokl.Akad.Nauk.SSSR, 177:1223-4, 11 Dec. 1967.
17. Koslowski, L.  
"Radiation Burden and Burns"  
Strahlenschutz.Forsch.Prax, 4:303-14, 1964.
18. Roloff, W.  
"Thorotrast Injuries"  
Z.Aerztl.Fortbild.(Jena), 60:488-95, 15 Apr. 1966.



ADRENALS

1. Borner, W., H. Kleinfelder, M. Nadjmi  
"Partial Radioressection of the Pituitary by Yttrium 90 for the Therapy of  
Cushing's Syndrome"  
Nuclearmedizin Suppl, 2:391+, 1965.

PITUITARY

1. Gros, C., B. Vlahovitch, P. Frerebeau  
"Observations on a Series of 87 Cases of Radioactive Hypophysectomy"  
Neurochirurgie, 12:663-70, Nov. 1966.
2. Handa, H., E. Tani, M. Adyagi  
"Hypophysectomy and its Clinical Aspects"  
Clin.Endocr.(Tokyo), 15:819-33, Oct. 1967.
3. Klotz, H.P.  
"Remark on the Pathogenesis of Edematous Exophthalmos (Appropos of a Case Treated by Intra-Hypophyseal Radioactive Gold)"  
Ann.Endocr.(Paris), 28:484-90, Jul.-Aug. 1967.
4. Modrego, S.P., J.E. Yelasco, J.J. Tafalla  
"Radiohypophysectomy in Breast Neoplasms (Report of the Results of 100 Cases)"  
J.Radiol.Electr., 48:798-800, Nov. 1967.
5. Munding, F.  
"Results of Primary and Combined Operative-Stereotaxic Irradiation of Pituitary Adenomas"  
Nuclearmedizin Suppl., 2:397+, 1965.
6. Scheer, K.E., E. Klar  
"Results of Transsphenoidal Hypophysectomy with Radiogold in Consideration of the Complications, Problems Following Treatment and Hormonal Control"  
Nuclearmedizin Suppl., 2:379+, 1965.
7. Sweet, W.H.  
"Hemorrhagic Diabetic Retinopathy--Treatment by Hypophyseal Stalk Section or by Bragg-Peak Proton Irradiation"  
Brain Nerve (Tokyo), 19:12-8, Jan. 1967.
8. Borner, W., H. Kleinfelder, M. Nadjmi  
"Partial Radioressection of the Pituitary by Yttrium 90 for the Therapy of Cushing's Syndrome"  
Nuclearmedizin Suppl., 2:391+, 1965.
9. Dzizn, N.M., E.E. Bril', I.B. Livshits  
"Some Problems of the Effect of Irradiation of the Diencephalo-Hypophyseal Region in the Pathological State on the Endocrine Glands"  
Probl.Endokr.(Moskva), 15:33-7, May-Jun. 1969.
10. Vasculescu, T., H. D'Andre, H. Ratiu  
"Clinical and Experimental Studies on the Effect of Low Doses Roentgen Ray Doses on the Central Nervous System. Summary of the Activity of the Department During the 1952-1965 Period"  
Radiobiol.Radiother.(Berlin), 7:331-49, 1966.

THYROID

1. Fukuda, M., M. Abe  
"Iatrogenic Disorders in Radiotherapy"  
Rinsho Hosha, 14:533-8, Jul. 1969.
2. Reboul, J., J.M. Caille, M. Bellet  
"Treatment of Basedow Hyperthyroidism by Protracted Doses of Radioactive Iodine"  
Sem.Hop Paris, 45:1884-94, 8 Jun. 1969.
3. Ulitovskii, D.A.  
"Dosimetric Findings on the Characteristics of Irradiation of the Nervous System After Incorporation of NaI<sup>131</sup>"  
Zh. Nevropat.Psikhiat.Korsakov, 67:1162-7, 1968.

GONADS

1. Barth, G.  
"The Knowledge of Radiation Pathology as a Basis for Radiation Protection in Radiology"  
Radiologe, 6:298-303, Aug. 1966.
2. Franzen, J.  
"Means of Reducing Somatic Radiation Hazards"  
Fortschr Roentgenstr, 105:893-9, Dec. 1965.
3. Gheorghe, N., I. Plesca  
"Action of Small Doses of Radioactive Radiations on the Body"  
Med. Intern. (Eucur), 21:21-7, Jan. 1969.
4. Toroptsev, I. V.  
"Morphological Characteristics of the Biological Action of Magnetic Fields"  
Arkh. Pat., 30: 3-12, 1968.
5. Stoppa, I. M.  
"Radiobiologic and Radioprotective Problems in Dental Roentgenology"  
Minerva Stomat, 15:860-7, Dec. 1966.
6. Lenarduzzi, G., C. Valdagni, F. Pozza  
"Evaluation of Late Lesions Following Therapy with Fast Electrons"  
Strahlentherapie, 135:166-75, Feb. 1968.
7. Schubert, K., G. Frankenberg  
"On the Determination of Testosterone and Additional Alpha, Beta-Unsaturated Ketosteroids of the C19 Series in Urine"  
Endokrinologie, 53:322-36, 1968.
8. Schulte-Brinkmann, W.  
"Radiation Exposure of Patients and Radiologic Personnel During Heart Catheterization and Contrast Media Procedures in the Heart and Great Vessels. 3. Discussion of the Measurements--Literature"  
Strahlentherapie, 129:460-71, Mar. 1966.
9. Schulte-Brinkmann, W., E. Von Cysewski  
"The Somatic and Genetic Irradiation Exposure of the Patient in Areal Kymography of the Heart"  
Strahlentherapie, 135:675-80, Jun. 1968.
10. Sonnabend, E.  
"Radiation Exposure and Radiation Protection in Radiodiagnosis in Dentistry"  
Zahnaerztl. Mitt, 59:1062-6, 1 Nov. 1969.

GASTROINTESTINAL

1. Barth, G.  
"The Knowledge of Radiation Pathology as a Basis for Radiation Protection in Radiology"  
Radiologe, 6:298-303, Aug. 1966.
2. Borner, W.  
"Radiation Exposure in Nuclear Medicine"  
Radiologe, 6:323-7, Aug. 1966.
3. Hillemand, B., G. Cerebonnet  
"Appendicitis with a Tumoral Form"  
Sem. Hop. Paris, 45:1211-3, 14 Apr. 1969.
4. Messerschmidt, O., W. Oerlert  
"Studies on Combination Damages. 10. Histopathological Studies on Mice Following Whole Body Irradiation in Combination with Open Skin Lesions"  
Strahlentherapie, 136:229-36, Aug. 1968.
5. Fukuda, M., M. Abe  
"Iatrogenic Disorders in Radiotherapy"  
Rinsho Hosha, 14:533-8, July 1969.
6. Morczek, A.  
"Diagnosis and Therapy of Acute Radiation Injury"  
Z. Aertzt. Fortbild. (Jena), 60:973-8, 1 Sep. 1966.
7. Niklas, K., F. Wachsmann  
"Radiation Injury and Radiation Accidents in X-Ray Units"  
Radiologe, 6:332-8, Aug. 1966.
8. Pourquier, H.  
"Complications of Radiotherapy of Cancer of the Uterine Cervix at Stage 3"  
J. Radiol. Electr., 49:607-16, Aug.-Sep. 1968.

URINARY (INCLUDES KIDNEY)

1. Abrate, M., I. Santoro, G. Baiotti, et. al.  
"Hematological Picture and Hepatic and Renal Function After Intracavitary, Interstitial and Intra-Arterial Administration of  $P^{32}$ "  
Minerva Radiol, 12:54-6, Jan.-Feb. 1967.
2. Borner, W.  
"Radiation Exposure in Nuclear Medicine"  
Radiologe, 6:323-7, Aug. 1966.
3. Campanacci, L., P. Patrese, G.F. Romagnoli, et. al.  
"Nephropathy Secondary to Irradiation"  
Folia.Med.(Napoli), 51:905-33, 12 Dec. 1968.
4. Ciocatto, E., M. Abrate, G. Baiotti, et. al.  
"Reactions Induced in the Body by Loco-Regional Administration of Radioisotopes"  
Minerva Med, 58:4489-90, 12 Dec. 1967.
5. Funshtein, L.V., E.I. Vorob'ev, E.I. Shcherban', et. al.  
"The Importance of the Radiation Load on Organs and Tissue in the Radiotherapy of Certain Malignant Neoplasms and Lymphogranulomatosis"  
Med.Radiol.(Moskva), 12:35-42, Jan. 1967.
6. Glowiak, B., Halawa, R. Palczynski, et. al.  
"Effect of Baths and Inhalation of Radon Water of Swieradow on the Radioactivity of Human Blood and Urine"  
Pol.Tyg.Lek, 24:1955-7, 22 Dec. 1969,
7. Messerschmidt, O., W. Oehlert  
"Studies on Combination Damages. 10. Histopathological Studies on Mice Following Whole Body Irradiation in Combination with Open Skin Lesions"  
Strahlentherapie, 136:229-36, Aug. 1968.
8. Vizkelety, J.  
"On the Radiation Damage of the Urinary Bladder Following Radium Therapy of Portio Cancer"  
Z.Urol, 60:433-5, Jun. 1967,
9. Mori, Y., T. Hara, M. Nagano, et. al.  
"Bleeding Death Presumable Due to Telangiectasis of the Bladder Following Cobalt-60 Therapy"  
Acta Urol.Jap, 12:185-7, Feb. 1966.
10. Fukuda, M., M. Abe  
"Iatrogenic Disorders in Radiotherapy"  
Rinsho Hosha, 14:533-8, Jul. 1969.
11. Schubert, K., G. Frankenberg  
"On the Determination of Testosterone and Additional Alpha, Beta-Unsaturated Ketosteroids of the C19 Series in Urine"  
Endokrinologie, 53:322-36, 1968.

RESPIRATORY

1. Funshtein, L.V., E.I. Vorob'ev, E.I. Shcherman', et. al.  
 "The Importance of the Radiation Load on Organs and Tissue in the  
 Radiotherapy of Certain Malignant Neoplasms and Lymphogranulomatosis"  
 Med. Radiol. (Moskva), 12:35-42, Jan. 1967.
2. Messerschmidt, O., W. Oehlert  
 "Studies on Combination Damages. 10. Histopathological Studies on Mice  
 Following Whole Body Irradiation in Combination with Open Skin Lesions"  
 Strahlentherapie, 136:229-36, Aug. 1968.
3. Solodova, R.A., D.A. Fodrova, N.V. Vershinin  
 "On the Prevention of Late Clinical Manifestations in People Working with  
 Constant-Action Luminous Substances (SPD)"  
 Klin. Med. (Moskva), 44:35-40, Nov. 1966.
4. Toroptsev, I.V.  
 "Morphological Characteristics of the Biological Action of Magnetic Fields"  
 Arkh. Pat., 30:3-12, 1968.
5. Schulte-Brinkmann, W.  
 "X-Ray Exposure of Patients and Radiological Examiners in Bronchographies  
 Under Anesthesia"  
 Fortschr. Roentgenstr., 105:710-6, Nov. 1966.
6. Becker, H.W., C. Becker  
 "Studies on the Possibility of Influencing the Respiration Center by  
 X-Irradiation"  
 Strahlentherapie, 129:51-63, Jan. 1966.

LIVER AND GALL BLADDER

1. Abrate, M., L. Santoro, G. Baiotti, et. al.  
"Hematological Picture and Hepatic and Renal Function After Intracavitary, Interstitial and Intra-Arterial Administration of P<sup>32</sup>"  
Minerva Radiol, 12:54-6, Jan.-Feb. 1967.
2. Antoine, B., C. Debray, C. Nezelof, et. al.  
"Congenital Liver Fibrosis"  
Presse Med, 77:167-9, 25 Jan. 1969.
3. Barousch, R.  
"Thorotrast Damage. Review and Report of 3 Cases"  
Wien.Med.Wschr, 119:681-5, 11 Oct. 1969.
4. Bauer, R.  
"Clinical Problems in Radiation Hematology"  
Aerztl.Forsch, 23:139-46, 10 Apr. 1969.
5. Borner, W.  
"Radiation Exposure in Nuclear Medicine"  
Radiologe, 6:323-7, Aug. 1966.
6. Ciocatto, E., M. Abrate, G. Baiotti, et. al.  
"Reactions Induced in the Body by Loco-Regional Administration of Radioisotopes"  
Minerva Med, 58:4489-90, 12 Dec. 1967.
7. Messerschmidt, O., W. Oehlert  
"Studies on Combination Damages. 10. Histopathological Studies on Mice Following Whole Body Irradiation in Combination with Open Skin Lesions"  
Strahlentherapie, 136:229-36, Aug. 1968.
8. Musshoff, K.  
"Radiotherapy of Leukoses"  
Internist (Berlin), 9:484-9, Dec. 1968.
9. Pawelski, S., L. Konopka, B. Kotelba-Witkowska, et. al.  
"Studies of the Survival-Time of Cr<sup>51</sup> Tagged Platelets in Healthy Subjects and in Thrombocytopenia"  
Pol.Tyg.Lek, 22:1649-54, 23 Oct. 1967.
10. Pizon, P.  
"Consequences of Radiologic Explorations Using Thorium"  
Presse.Med, 77:241-4, 8 Feb. 1969.



LIVER AND GALL BLADDER (cont.)

11. Svet-Moldavskii, G, A.I. Pavlotskii  
"Selective Radiation Protection of Bone Marrow and Other Organs by  
Substances Linked with Macromolecular and Corpuscular Carriers"  
Dokl. Akad. Nauk. SSSR, 177:1223-4, 11 Dec. 1967.
12. Roloff, W.  
"Thorotrast Injuries"  
Z. Aerztl. Fortbild. (Jena), 60:488-95, 15 Apr. 1966.

CNS

1. Amico, G., R. Canger  
"Late Cerebral Radionecrosis with Hypertensive Endocranial Evolution"  
G.Psichiat.Neuropat, 95:533-45, 1967.
2. Gheorghe, N., I. Plesca  
"Action of Small Doses of Radioactive Radiations on the Body"  
Med.Intern.(Eucur), 21:21-7, Jan. 1969.
3. Mandybur, T.I., I. Gore  
"Amyloid in Late Postirradiation Necrosis of Brain"  
Neurology (Minneap), 19:983-92, Oct. 1969.
4. Piontkovskii, I.A.  
"The Radioembriologic Effect and its Importance in Pathology"  
Pat Fiziol.Eksp.Ter, 11:13-20, Nov.-Dec. 1967.
5. Gorbonosova, N.B.  
"Working Conditions and Health Problems Among Vessel Radiooperators  
Exposed to the Electromagnetic Field of High Frequency"  
Bull.Inst.Mar.Med.Gdansk, 17:263-6, 1966.
6. Bachurzewski, J., A. Pawlowski, J. Wasylyszyn  
"Effect of the Nervous System on the Course of Radiation Reactions After  
the Use of Soft Roentgen Rays"  
Przegl.Derm, 56:179-83, Mar.-Apr. 1969.
7. Fukuda, M., M. Abe  
"Iatrogenic Disorders in Radiotherapy"  
Rinsho Hosha, 14:533-8, Jul. 1969.
8. Glazunov, I.S., V.V. Bragoveshchenskaia  
"Remote Sequelae of Acute Radiation Sickness"  
Zh.Nevropat.Psikhiat.Korsakov, 68:1129-34, 1968.
9. Glazunov, I.S., N. Tereshchenko  
"On the Functional Status of the Nervous Systems of Children at Long  
Periods After Irradiation (The Application of Gammatherapy to Skin  
Hemangiomas)"  
Zh.Nevropat.Psikhiat.Korsakov, 68:1438-45, 1968.
10. Kirzon, M.V., M.G. Pshenikova  
"Propagation of Non-Impulse Effects along a Nerve from a Region Exposed  
to X-Irradiation"  
Biofizika, 2:686-697, 1957.

CNS (cont.)

11. Niklas, K., F. Wachsmann  
"Radiation Injury and Radiation Accidents in X-Ray Units"  
Radiologe, 6:332-8, Aug. 1966.
12. Winkel, K.  
"Radiotherapy of Tumors of the Facial Portion of the Skull"  
Arch.Klin.Exp.Ohr.Nas.Kehlkopfheilk, 187:337-62, 1966.
13. Badmaev, K.N., V.I. Samoilov  
"Radiosensitivity of the Hypothalamus During Megavolt Radiation Therapy of Brain Tumors"  
Med.Radiol.(Moskva), 12:13-7, Feb. 1967.
14. Baldus, S.  
"On Late Damage to the Spinal Cord After Radiation of Tumors of the Head and Neck Region"  
Z.Laryng-Rhinol.Otol, 45:123-9, Feb. 1966.
15. Becker, H.W., C. Becker  
"Studies on the Possibility of Influencing the Respiration Center by X-Irradiation"  
Strahlentherapie, 129:51-63, Jan. 1966.
16. Borner, W., H. Kleinfelder, M. Nadjmi  
"Partial Radioressection of the Pituitary by Yttrium 90 for the Therapy of Cushing's Syndrome"  
Nuclearmedizin Suppl, 2:391+, 1965.
17. Labayle, J.  
"Case Report of a Radio-Induced Cancer"  
J.Franc.Otorhinolaryng, 16:269-70, Apr. 1967.
18. Glazunov, I.S., V.V. Blagoveshchenskaia, G.N. Martynova  
"Clinico-Physiologic Methods of Studying the Asthenic Syndrome in Persons Coming into Contact with Ionizing Radiation"  
Zh.Nevropat.Psikhiat.Korsakov, 69:667-73, 1969.
19. Draznin, N.M., E.E. Brill, I.B. Livshits  
"Some Problems of the Effect of Irradiation of the Diencephalo-Hypophyseal Region in the Pathological State on the Endocrine Glands"  
Probl.Endokr.(Moskva), 15:33-7, May-Jun. 1969.
20. Kuhnt, U.  
"Visual Reaction Potentials in Humans and Cats as a Function of Intensity"  
Pflueger Arch.Ges.Physiol, 298:82-104, 1967.

CNS (cont.)

21. Lehmann, W., W. Zett, K. Neumeister  
"Consequences of Irradiation of the Cervical Spinal Cord Following Radiotherapy of Tumors in the Cervical Region. I. Clinical Studies" Radiobiol.Radiother. (Berlin), 9:435-43, 1968.
22. Losev, A.A.  
"On Assessing Fatigability and Attention in Persons Exposed to Small Doses of Ionizing Radiation in the Course of Their Work" Gig. Tr. Prof. Zabol, 11:50-2, Aug. 1967
23. Muller, W.  
"Light Stimulation of Various Wavelengths in Provocation of the Cortical Response" Graefe, Arch. Klin. Exp. Ophthal, 171:287-91, 1967.
24. Stratev, I., K. Rodel  
"Excentric High Voltage Pendulum Therapy of Tumors Located Near the Spine" Strahlentherapie, 132:362-9, Mar. 1967.
25. Talairach, J., C. Schaub, G. Szikla  
"Clinical Dosimetry and Long-Term Therapeutic Results in Cushing's Disease" Ann. Endocr. (Paris), 29:103-13, Jan.-Feb. 1968.
26. Ulitovskii, D.A.  
"Dosimetric Findings on the Characteristics of Irradiation of the Nervous System After Incorporation of NaI-<sup>131</sup>" Zh. Nevropat. Psikhiat. Korsakov, 67:1162-7, 1968.
27. Vasulescu, T., H. D'Andre, H. Ratiu  
"Clinical and Experimental Studies on the Effect of Low Doses Roentgen Ray Doses on the Central Nervous System. Summary of the Activity of the Department During the 1952-1965 Period" Radiobiol.Radiother. (Berlin), 7:331-49, 1966.
28. Zett, W., W. Lehmann, K. Neumeister  
"Consequences of Irradiation of the Cervical Spinal Cord Following Radiotherapy of Tumors in the Cervical Region. II. Electromyographic Studies" Radiobiol.Radiother. (Berlin), 9:445-53, 1968.
29. Bernasconi, V., M. Giovanelli, C. Perria  
"Delayed Cerebral Radionecrosis with Pseudo-Tumoral Evolution" Minerva. Neurochir, 11:48-41, 1967.
30. Boszkiewicz, T.  
"Traumas of the Skull and Brain in Acute Postirradiation Disease" Otolaryng. Pol, 21:219-22, 1967.

CNS (cont.)

31. Geets, W.  
"Influence of Ionizing Radiations on the Development of the Nervous System"  
Acta.Genet.Med.(Roma), 16:275-310, Jul. 1967.
32. Milczarek, H., S. Zalejski, J. Mazurkiewicz  
"Changes in the Nervous System in Individuals Working Within the Range  
of Microwave Radiation"  
Pol.Tyg Lek, 22:1924-7, 11 Dec. 1967.
33. Okhrimenko, N.N., V.T. Bakhur, I. Likhachev  
"On the Clinical Picture of Myelopathy Developing After Radiation Therapy"  
Zh.Nevropat.Psikhiat.Korsakov, 69:674-9, 1969.
34. Quadbeck, G.  
"Physiology and Pathology of the Blood-Brain Barrier"  
Hippokrates, 38:45-53, 31 Jan. 1967.
35. Schmidt, H., K. Muller  
"Late Radiation Injury to the Cervical Spinal Cord Following Radiotherapy  
for Tongue Carcinoma"  
Strahlentherapie, 135:176-80, Feb. 1968.

APPENDIX D

CATCH-ALL

#### D-1 Radiation Units (74, 99)

rad = absorption of 100 ergs of energy/gm of irradiated material, regardless of the type of ionizing radiation or of the absorbing material.

roentgen = amount of radiation which produces, as a consequence of ionization, one esu of charge in 1 cm<sup>3</sup> (0.001293g) of dry air at 0°C/760 mm (Hg). This is equivalent to the production of  $2.1 \times 10^9$  ion pairs and represents an energy deposition of 87.6 ergs/gm of air. This unit can be used for exposure to x- or gamma-radiations of less than 3 Mev. (One rad is approximately equal to 1 roentgen when soft tissue is exposed to medium voltage x-radiation.)

rem (roentgen equivalent man or mammal) = a unit of dose equivalent which is numerically equal to the dose in rads multiplied by appropriate modifying factors such as RBE (or QE) or DF.

RBE (Relative Biological Effectiveness) = factor expressing the relative effectiveness of radiations with differing linear energy transfer (L.E.T.)

QF (Quality Factor) = another name for a linear energy transfer (L.E.T.) dependent factor by which absorbed doses are to be multiplied to account for the varying effectiveness of different radiations.

DF (Dose Distribution Factor) = a factor expressing the modification of biological effect due to nonuniform distribution of internally deposited radionuclides.

| 1                                 | 2                    | 3             | 4     | 5    | 6             | 7     | 8    | 9           | 10                                           | 11          | 12          | 13              | 14                                                                                                                                                                                                                                                                                                     |
|-----------------------------------|----------------------|---------------|-------|------|---------------|-------|------|-------------|----------------------------------------------|-------------|-------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM                       | LEVEL OF INTERACTION | DAMAGE TO EYE |       |      |               |       |      |             | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                                                                                                                                                                                                                                |
|                                   |                      | CORNEA        | PUPIL | LENS | OPTICAL FLUID | CONES | RODS | EYE MUSCLES | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                                                                                                                                                                                                                        |
| ELECTROMAGNETIC (UV, VISIBLE, IR) | SAFE                 | ?             | ?     | ?    | ?             | < 4   | 4    |             |                                              |             |             |                 | Energy Levels of Interaction expressed in watts/cm <sup>2</sup> .<br><br>MICROWAVE: two effects--(1) at ~0.8 W/cm <sup>2</sup> for 5 min = hydrops of the lens, followed by cataract in months; (2) at ~0.3 W/cm <sup>2</sup> for 5 min = slow cataract formation.<br><br>No military value to either. |
|                                   | DEGRADATION          |               |       |      |               | > 4   | > 4  | •           |                                              |             |             |                 | White light (sunlight) in a 1mm spot image; may be less for larger images.                                                                                                                                                                                                                             |
|                                   | INCAPACITATION       |               |       |      |               |       |      |             |                                              |             |             |                 | Not known to contributor                                                                                                                                                                                                                                                                               |
|                                   | LETHALITY            |               |       |      |               |       |      |             |                                              |             |             |                 |                                                                                                                                                                                                                                                                                                        |



| 1                                                    | 2                                                                             | 3             | 4        | 5            | 6       | 7 | 8 | 9 | 10                                                                                                 | 11              | 12 | 13 | 14                                      |
|------------------------------------------------------|-------------------------------------------------------------------------------|---------------|----------|--------------|---------|---|---|---|----------------------------------------------------------------------------------------------------|-----------------|----|----|-----------------------------------------|
| ENERGY FORM<br><br>ELECTROMAGNETIC (UV, VISIBLE, IR) | LEVEL OF INTERACTION                                                          | DAMAGE TO EAR |          |              |         |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION<br><br>ANATOMIC<br><br>PHYSIOLOGIC<br><br>PSYCHOLOGIC | COUNTERMEASURES |    |    | REMARKS<br><br>Not known to contributor |
|                                                      | SAFE<br><br>DEGRA-<br>DATION<br><br>INCAPA-<br>CITATION<br><br>LETHA-<br>LITY | DRUM          | OSCICLES | ROUND WINDOW | COCHLEA |   |   |   |                                                                                                    |                 |    |    |                                         |
|                                                      |                                                                               |               |          |              |         |   |   |   |                                                                                                    |                 |    |    |                                         |
|                                                      |                                                                               |               |          |              |         |   |   |   |                                                                                                    |                 |    |    |                                         |
|                                                      |                                                                               |               |          |              |         |   |   |   |                                                                                                    |                 |    |    |                                         |

| 1                                 | 2                    | 3                    | 4              | 5               | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                                      |
|-----------------------------------|----------------------|----------------------|----------------|-----------------|---|---|---|---|----------------------------------------------|-------------|-------------|-----------------|-----------------------------------------|
| ELECTROMAGNETIC (UV, VISIBLE, IR) | ENERGY FORM          | LEVEL OF INTERACTION | DAMAGE TO NOSE |                 |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS<br><br>Not known to contributor |
|                                   | OLFACTORY EPITHELIUM |                      | OLFACTORY BULB | OLFACTORY TRACT |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                         |
|                                   |                      |                      |                |                 |   |   |   |   |                                              |             |             |                 |                                         |
|                                   |                      |                      |                |                 |   |   |   |   |                                              |             |             |                 |                                         |
|                                   |                      |                      |                |                 |   |   |   |   |                                              |             |             |                 |                                         |
|                                   | SAFE                 |                      |                |                 |   |   |   |   |                                              |             |             |                 |                                         |
|                                   | DEGRADATION          |                      |                |                 |   |   |   |   |                                              |             |             |                 |                                         |
|                                   | INCAPACITATION       |                      |                |                 |   |   |   |   |                                              |             |             |                 |                                         |
|                                   | LETHALITY            |                      |                |                 |   |   |   |   |                                              |             |             |                 |                                         |

| 1           | 2                    | 3                 | 4                    | 5                  | 6                       | 7 | 8 | 9 | 10                                                 | 11 | 12 | 13              | 14                                      |
|-------------|----------------------|-------------------|----------------------|--------------------|-------------------------|---|---|---|----------------------------------------------------|----|----|-----------------|-----------------------------------------|
| ENERGY FORM | LEVEL OF INTERACTION | PRESSURE<br>SENSE | TEMPERATURE<br>SENSE | CHEMICAL<br>(PAIN) | DAMAGE TO SKIN (SENSOR) |   |   |   | SPECIFIC ADVERSE<br>EFFECTS DUE TO<br>TRANSMISSION |    |    | COUNTERMEASURES | REMARKS<br><br>Not known to contributor |
|             |                      |                   |                      |                    |                         |   |   |   |                                                    |    |    |                 |                                         |
|             |                      |                   |                      |                    |                         |   |   |   |                                                    |    |    |                 |                                         |
|             |                      |                   |                      |                    |                         |   |   |   |                                                    |    |    |                 |                                         |
|             |                      |                   |                      |                    |                         |   |   |   |                                                    |    |    |                 |                                         |
|             | SAFE                 |                   |                      |                    |                         |   |   |   |                                                    |    |    |                 |                                         |
|             | DEGRA-<br>DATION     |                   |                      |                    |                         |   |   |   |                                                    |    |    |                 |                                         |
|             | INCAPA-<br>CITATION  |                   |                      |                    |                         |   |   |   |                                                    |    |    |                 |                                         |
|             | LETHA-<br>LITY       |                   |                      |                    |                         |   |   |   |                                                    |    |    |                 |                                         |

|                                   |                      |                                     |                       |                       |   |   |   |   |                                                    |    |    |                 |                                         |
|-----------------------------------|----------------------|-------------------------------------|-----------------------|-----------------------|---|---|---|---|----------------------------------------------------|----|----|-----------------|-----------------------------------------|
| 1                                 | 2                    | 3                                   | 4                     | 5                     | 6 | 7 | 8 | 9 | 10                                                 | 11 | 12 | 13              | 14                                      |
| ENERGY FORM                       | LEVEL OF INTERACTION | POSTURAL SENSIBILITY<br>(LABYRINTH) | GALVA MOTOR<br>SYSTEM | DAMAGE TO KINESTHETIC |   |   |   |   | SPECIFIC ADVERSE<br>EFFECTS DUE TO<br>TRANSMISSION |    |    | COUNTERMEASURES | REMARKS<br><br>Not known to contributor |
|                                   |                      |                                     |                       |                       |   |   |   |   |                                                    |    |    |                 |                                         |
| ELECTROMAGNETIC (UV, VISIBLE, IR) | SAFE                 |                                     |                       |                       |   |   |   |   |                                                    |    |    |                 |                                         |
|                                   | DEGRA-<br>DATION     |                                     |                       |                       |   |   |   |   |                                                    |    |    |                 |                                         |
|                                   | INCAPA-<br>CITATION  |                                     |                       |                       |   |   |   |   |                                                    |    |    |                 |                                         |
|                                   | LETHA-<br>LITY       |                                     |                       |                       |   |   |   |   |                                                    |    |    |                 |                                         |



|                                   |                      |       |       |         |          |                 |        |        |                                              |             |             |                 |         |
|-----------------------------------|----------------------|-------|-------|---------|----------|-----------------|--------|--------|----------------------------------------------|-------------|-------------|-----------------|---------|
| 1                                 | 2                    | 3     | 4     | 5       | 6        | 7               | 8      | 9      | 10                                           | 11          | 12          | 13              | 14      |
| ENERGY FORM                       | LEVEL OF INTERACTION | BLOOD | LYMPH | MUSCLES | SKELETON | CARDIO-VASCULAR | MARROW | SPLEEN | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS |
|                                   |                      |       |       |         |          |                 |        |        | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |         |
| ELECTROMAGNETIC (UV, VISIBLE, IR) | SAFE                 |       |       |         |          |                 |        |        |                                              |             |             |                 |         |
|                                   | DEGRADATION          |       |       |         |          |                 |        |        |                                              |             |             |                 |         |
|                                   | INCAPACITATION       |       |       |         |          |                 |        |        |                                              |             |             |                 |         |
|                                   | LETHALITY            |       |       |         |          |                 |        |        |                                              |             |             |                 |         |

|    |                                              |  |                                   |                          |              |  |                 |  |            |  |  |  |  |
|----|----------------------------------------------|--|-----------------------------------|--------------------------|--------------|--|-----------------|--|------------|--|--|--|--|
| 1  | ENERGY FORM                                  |  | ELECTROMAGNETIC (UV, VISIBLE, IR) |                          |              |  |                 |  |            |  |  |  |  |
| 2  | LEVEL OF INTERACTION                         |  | SAFE                              |                          | DEGRA-DATION |  | INCAPA-CITATION |  | LETHA-LITY |  |  |  |  |
| 3  | DAMAGE TO                                    |  | ADRENALS                          |                          |              |  |                 |  |            |  |  |  |  |
| 4  |                                              |  | PITUITARY                         |                          |              |  |                 |  |            |  |  |  |  |
| 5  |                                              |  | PANCREAS                          |                          |              |  |                 |  |            |  |  |  |  |
| 6  |                                              |  | THYROID                           |                          |              |  |                 |  |            |  |  |  |  |
| 7  |                                              |  | GONADS                            |                          |              |  |                 |  |            |  |  |  |  |
| 8  |                                              |  |                                   |                          |              |  |                 |  |            |  |  |  |  |
| 9  |                                              |  |                                   |                          |              |  |                 |  |            |  |  |  |  |
| 10 | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |  | ANATOMIC                          |                          |              |  |                 |  |            |  |  |  |  |
| 11 |                                              |  | PHYSIOLOGIC                       |                          |              |  |                 |  |            |  |  |  |  |
| 12 |                                              |  | PSYCHOLOGIC                       |                          |              |  |                 |  |            |  |  |  |  |
| 13 |                                              |  | COUNTERMEASURES                   |                          |              |  |                 |  |            |  |  |  |  |
| 14 |                                              |  | REMARKS                           |                          |              |  |                 |  |            |  |  |  |  |
|    |                                              |  |                                   | Not known to contributor |              |  |                 |  |            |  |  |  |  |

|             |                      |                       |         |             |                           |   |   |   |          |             |             |                 |                                         |
|-------------|----------------------|-----------------------|---------|-------------|---------------------------|---|---|---|----------|-------------|-------------|-----------------|-----------------------------------------|
| 1           | 2                    | 3                     | 4       | 5           | 6                         | 7 | 8 | 9 | 10       | 11          | 12          | 13              | 14                                      |
| ENERGY FORM | LEVEL OF INTERACTION | GASTRO-<br>INTESTINAL | URINARY | RESPIRATORY | LIVER AND<br>GALL BLADDER |   |   |   | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES | REMARKS<br><br>Not known to contributor |
|             |                      |                       |         |             |                           |   |   |   |          |             |             |                 |                                         |
|             |                      |                       |         |             |                           |   |   |   |          |             |             |                 |                                         |
|             |                      |                       |         |             |                           |   |   |   |          |             |             |                 |                                         |
|             |                      |                       |         |             |                           |   |   |   |          |             |             |                 |                                         |
|             | SAFE                 |                       |         |             |                           |   |   |   |          |             |             |                 |                                         |
|             | DEGRA-<br>DATION     |                       |         |             |                           |   |   |   |          |             |             |                 |                                         |
|             | INCAPA-<br>CITATION  |                       |         |             |                           |   |   |   |          |             |             |                 |                                         |
|             | LETHA-<br>LITY       |                       |         |             |                           |   |   |   |          |             |             |                 |                                         |



|             |                                              |            |                                   |             |                          |  |                |  |           |  |  |  |  |  |  |  |
|-------------|----------------------------------------------|------------|-----------------------------------|-------------|--------------------------|--|----------------|--|-----------|--|--|--|--|--|--|--|
| 1           | ENERGY FORM                                  |            | ELECTROMAGNETIC (UV, VISIBLE, IR) |             |                          |  |                |  |           |  |  |  |  |  |  |  |
| 2           | LEVEL OF INTERACTION                         |            | SAFE                              |             | DEGRADATION              |  | INCAPACITATION |  | LETHALITY |  |  |  |  |  |  |  |
| 3           | CEREBRAL                                     | CEREBELLUM | BRAIN STEM                        | SPINAL CORD |                          |  |                |  |           |  |  |  |  |  |  |  |
| 4           | DAMAGE TO CENTRAL NERVOUS SYSTEM             |            |                                   |             |                          |  |                |  |           |  |  |  |  |  |  |  |
| 5           |                                              |            |                                   |             |                          |  |                |  |           |  |  |  |  |  |  |  |
| 6           |                                              |            |                                   |             |                          |  |                |  |           |  |  |  |  |  |  |  |
| 7           |                                              |            |                                   |             |                          |  |                |  |           |  |  |  |  |  |  |  |
| 8           |                                              |            |                                   |             |                          |  |                |  |           |  |  |  |  |  |  |  |
| 9           | ALPHA RHYTHM                                 |            |                                   |             |                          |  |                |  |           |  |  |  |  |  |  |  |
| 10          | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |            | ANATOMIC                          |             |                          |  |                |  |           |  |  |  |  |  |  |  |
| PHYSIOLOGIC |                                              |            |                                   |             |                          |  |                |  |           |  |  |  |  |  |  |  |
| PSYCHOLOGIC |                                              |            |                                   |             |                          |  |                |  |           |  |  |  |  |  |  |  |
| 11          |                                              |            |                                   |             |                          |  |                |  |           |  |  |  |  |  |  |  |
| 12          |                                              |            |                                   |             |                          |  |                |  |           |  |  |  |  |  |  |  |
| 13          |                                              |            | COUNTERMEASURES                   |             |                          |  |                |  |           |  |  |  |  |  |  |  |
| 14          |                                              |            | REMARKS                           |             | Not known to contributor |  |                |  |           |  |  |  |  |  |  |  |

| 1                                 | 2                    | 3                     | 4         | 5 | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                                                                                        |
|-----------------------------------|----------------------|-----------------------|-----------|---|---|---|---|---|----------------------------------------------|-------------|-------------|-----------------|-------------------------------------------------------------------------------------------|
| ENERGY FORM                       | LEVEL OF INTERACTION | PSYCHOLOGICAL EFFECTS |           |   |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS<br><br>10Hz flicker white light seems to influence the alpha rhythm of the brain. |
|                                   |                      | ASSOCIATIVE SYMBOLS   | ILLUSIONS |   |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                           |
|                                   | SAFE                 |                       |           |   |   |   |   |   |                                              |             |             |                 |                                                                                           |
|                                   | DEGRADATION          |                       |           |   |   |   |   |   |                                              |             |             |                 |                                                                                           |
|                                   | INCAPACITATION       |                       |           |   |   |   |   |   |                                              |             |             |                 |                                                                                           |
| ELECTROMAGNETIC (UV, VISIBLE, IR) |                      | LETHALITY             |           |   |   |   |   |   |                                              |             |             |                 |                                                                                           |

APPENDIX A - Bibliographic Sources

Add pages if necessary.

APPENDIX B - Amplification of Remarks

Add pages if necessary.

## APPENDIX C - Other Possible Information Sources

Add pages if necessary.

APPENDIX D - Catch-all

Add pages if necessary.

| 1                                   | 2                    | 3                 | 4     | 5    | 6             | 7     | 8     | 9           | 10                                           | 11          | 12          | 13              | 14                                                                                                                                                                                 |
|-------------------------------------|----------------------|-------------------|-------|------|---------------|-------|-------|-------------|----------------------------------------------|-------------|-------------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM                         | LEVEL OF INTERACTION | DAMAGE TO EYE     |       |      |               |       |       |             | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                                                                                                            |
|                                     |                      | CORNEA            | PUPIL | LENS | OPTICAL FLUID | CONES | ROD   | EYE MUSCLES | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                                                                                                    |
| ELECTROMAGNETIC (LASERS AND MASERS) | SAFE                 | ?                 | ?     | ?    | ?             | <0.07 | <0.07 | ?           | +                                            | +           | ?           | filter          | OPTICAL MASER                                                                                                                                                                      |
|                                     |                      | <0.1              | <0.1  | <    | <             | <<    | <<    | ?           | +                                            | +           | +           | filter          | (CO <sub>2</sub> ) INFRARED MASER                                                                                                                                                  |
|                                     | DEGRA-DATION         | >10 <sup>-7</sup> |       |      |               | >0.07 | >0.07 | ?           | +                                            | +           | +           | "               | OPTICAL MASER                                                                                                                                                                      |
|                                     |                      | >0.1              | >     | >    | >             | >>    | >>    | ?           | +                                            | +           | +           | "               | (CO <sub>2</sub> ) INFRARED MASER                                                                                                                                                  |
|                                     | INCAPA-CITATION      |                   |       |      |               |       |       |             |                                              |             |             |                 | OPTICAL MASER: not dependably pre-dictable because of variability of target factors-- position, etc.<br>INFRARED: effects much more depend-ably predictable, but as yet not known. |
|                                     | LETHA-LITY           |                   |       |      |               |       |       |             |                                              |             |             |                 | OPTICAL MASER: no lethal effect likely.<br>INFRARED: lethality from ignition predictable.                                                                                          |

|                                     |                      |      |          |              |         |   |   |   |                                              |          |             |             |                 |                                             |  |  |  |  |  |
|-------------------------------------|----------------------|------|----------|--------------|---------|---|---|---|----------------------------------------------|----------|-------------|-------------|-----------------|---------------------------------------------|--|--|--|--|--|
| 1                                   | 2                    | 3    | 4        | 5            | 6       | 7 | 8 | 9 | 10                                           | 11       | 12          | 13          | 14              |                                             |  |  |  |  |  |
| ENERGY FORM                         | LEVEL OF INTERACTION | DRUM | OSCILLES | ROUND WINDOW | COCHLEA |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES | REMARKS<br>No effects known to contributor. |  |  |  |  |  |
|                                     |                      |      |          |              |         |   |   |   |                                              |          |             |             |                 |                                             |  |  |  |  |  |
|                                     |                      |      |          |              |         |   |   |   |                                              |          |             |             |                 |                                             |  |  |  |  |  |
|                                     |                      |      |          |              |         |   |   |   |                                              |          |             |             |                 |                                             |  |  |  |  |  |
|                                     |                      |      |          |              |         |   |   |   |                                              |          |             |             |                 |                                             |  |  |  |  |  |
| ELECTROMAGNETIC (LASERS AND MASERS) |                      |      |          |              |         |   |   |   |                                              |          |             |             |                 |                                             |  |  |  |  |  |
|                                     | SAFE                 |      |          |              |         |   |   |   |                                              |          |             |             |                 |                                             |  |  |  |  |  |
|                                     | DEGRA-DATION         |      |          |              |         |   |   |   |                                              |          |             |             |                 |                                             |  |  |  |  |  |
|                                     | INCAPA-CITATION      |      |          |              |         |   |   |   |                                              |          |             |             |                 |                                             |  |  |  |  |  |
|                                     | LETHA-LITY           |      |          |              |         |   |   |   |                                              |          |             |             |                 |                                             |  |  |  |  |  |



|                                     |             |                      |                |                                              |                |  |  |  |  |  |  |                 |                                             |
|-------------------------------------|-------------|----------------------|----------------|----------------------------------------------|----------------|--|--|--|--|--|--|-----------------|---------------------------------------------|
| 1                                   | 2           | 3                    |                |                                              |                |  |  |  |  |  |  | 13              | 14                                          |
| ELECTROMAGNETIC (LASERS AND MASERS) | ENERGY FORM | LEVEL OF INTERACTION |                |                                              |                |  |  |  |  |  |  | COUNTERMEASURES | REMARKS<br>No effects known to contributor. |
|                                     | SAFE        | OLFACTORY EPITHELIUM | OLFACTORY BULB | OLFACTORY TRACT                              | DAMAGE TO NOSE |  |  |  |  |  |  |                 |                                             |
|                                     |             | OLFACTORY EPITHELIUM | OLFACTORY BULB | OLFACTORY TRACT                              | DAMAGE TO NOSE |  |  |  |  |  |  |                 |                                             |
|                                     |             | OLFACTORY EPITHELIUM | OLFACTORY BULB | OLFACTORY TRACT                              | DAMAGE TO NOSE |  |  |  |  |  |  |                 |                                             |
|                                     |             | OLFACTORY EPITHELIUM | OLFACTORY BULB | OLFACTORY TRACT                              | DAMAGE TO NOSE |  |  |  |  |  |  |                 |                                             |
| DEGRADATION                         | ANATOMIC    | PHYSIOLOGIC          | PSYCHOLOGIC    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                |  |  |  |  |  |  |                 |                                             |
|                                     | ANATOMIC    | PHYSIOLOGIC          | PSYCHOLOGIC    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                |  |  |  |  |  |  |                 |                                             |
|                                     | ANATOMIC    | PHYSIOLOGIC          | PSYCHOLOGIC    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                |  |  |  |  |  |  |                 |                                             |
|                                     | ANATOMIC    | PHYSIOLOGIC          | PSYCHOLOGIC    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                |  |  |  |  |  |  |                 |                                             |
| INCAPACITATION                      | ANATOMIC    | PHYSIOLOGIC          | PSYCHOLOGIC    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                |  |  |  |  |  |  |                 |                                             |
|                                     | ANATOMIC    | PHYSIOLOGIC          | PSYCHOLOGIC    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                |  |  |  |  |  |  |                 |                                             |
|                                     | ANATOMIC    | PHYSIOLOGIC          | PSYCHOLOGIC    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                |  |  |  |  |  |  |                 |                                             |
|                                     | ANATOMIC    | PHYSIOLOGIC          | PSYCHOLOGIC    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                |  |  |  |  |  |  |                 |                                             |
| LETHALITY                           | ANATOMIC    | PHYSIOLOGIC          | PSYCHOLOGIC    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                |  |  |  |  |  |  |                 |                                             |
|                                     | ANATOMIC    | PHYSIOLOGIC          | PSYCHOLOGIC    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                |  |  |  |  |  |  |                 |                                             |
|                                     | ANATOMIC    | PHYSIOLOGIC          | PSYCHOLOGIC    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                |  |  |  |  |  |  |                 |                                             |
|                                     | ANATOMIC    | PHYSIOLOGIC          | PSYCHOLOGIC    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                |  |  |  |  |  |  |                 |                                             |

| 1                                   | 2                    | 3                       | 4                 | 5               | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                                                                            |
|-------------------------------------|----------------------|-------------------------|-------------------|-----------------|---|---|---|---|----------------------------------------------|-------------|-------------|-----------------|-------------------------------------------------------------------------------|
| ENERGY FORM                         | LEVEL OF INTERACTION | DAMAGE TO SKIN (SENSOR) |                   |                 |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS<br>Energy Levels of Interaction expressed in joules/cm <sup>2</sup> . |
|                                     |                      | PRESSURE SENSE          | TEMPERATURE SENSE | CHEMICAL (PAIN) |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                               |
| ELECTROMAGNETIC (LASERS AND MASERS) | SAFE                 | ?                       | <0.1              | <1.0            |   |   |   |   | ?                                            | +           | +           | fil-ter         | Applies to CO <sub>2</sub> infrared only.                                     |
|                                     | DEGRADATION          |                         | >0.1              | >1.0            |   |   |   |   |                                              |             |             |                 |                                                                               |
|                                     | INCAPACITATION       |                         |                   |                 |   |   |   |   |                                              |             |             |                 | Not known to contributor                                                      |
|                                     | LETHALITY            |                         |                   |                 |   |   |   |   |                                              |             |             |                 | Not known to contributor                                                      |



| 1                                   | 2                    | 3                         | 4      | 5 | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                                                                            |
|-------------------------------------|----------------------|---------------------------|--------|---|---|---|---|---|----------------------------------------------|-------------|-------------|-----------------|-------------------------------------------------------------------------------|
| ENERGY FORM                         | LEVEL OF INTERACTION | DAMAGE TO SKIN (COVERING) |        |   |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS<br>Energy levels of interaction expressed in joules/cm <sup>2</sup> . |
|                                     |                      | EPIDERMIS                 | DERMIS |   |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                               |
| ELECTROMAGNETIC (LASERS AND MASERS) | SAFE                 | <0.1                      |        |   |   |   |   |   | -                                            | +           | +           |                 | Applies only to CO <sub>2</sub>                                               |
|                                     | DEGRADATION          | >1.0                      |        |   |   |   |   |   | +                                            | +           | +           |                 |                                                                               |
|                                     | INCAPACITATION       |                           |        |   |   |   |   |   |                                              |             |             |                 | Not known to contributor                                                      |
|                                     | LETHALITY            |                           |        |   |   |   |   |   |                                              |             |             |                 | Not known to contributor                                                      |

[illegible]



[illegible]

|    |                                                          |             |                                     |                  |                     |                |  |  |  |  |  |  |
|----|----------------------------------------------------------|-------------|-------------------------------------|------------------|---------------------|----------------|--|--|--|--|--|--|
| 1  | ENERGY FORM                                              |             | ELECTROMAGNETIC (LASERS AND MASERS) |                  |                     |                |  |  |  |  |  |  |
| 2  | LEVEL OF INTERACTION                                     |             | SAFE                                | DEGRA-<br>DATION | INCAPA-<br>CITATION | LETHA-<br>LITY |  |  |  |  |  |  |
| 3  | DAMAGE TO CENTRAL NERVOUS SYSTEM                         |             | CEREBRAL<br>HEMISPHERE              |                  |                     |                |  |  |  |  |  |  |
| 4  |                                                          |             | CEREBELLUM                          |                  |                     |                |  |  |  |  |  |  |
| 5  |                                                          |             | BRAIN STEM                          |                  |                     |                |  |  |  |  |  |  |
| 6  |                                                          |             | SPINAL CORD                         |                  |                     |                |  |  |  |  |  |  |
| 7  |                                                          |             |                                     |                  |                     |                |  |  |  |  |  |  |
| 8  |                                                          |             |                                     |                  |                     |                |  |  |  |  |  |  |
| 9  | ALPHA RHYTHM                                             |             |                                     |                  |                     |                |  |  |  |  |  |  |
| 10 | SPECIFIC ADVERSE<br>EFFECTS DUE TO<br>TRANSMISSION       | ANATOMIC    |                                     |                  |                     |                |  |  |  |  |  |  |
| 11 |                                                          | PHYSIOLOGIC |                                     |                  |                     |                |  |  |  |  |  |  |
| 12 |                                                          | PSYCHOLOGIC |                                     |                  |                     |                |  |  |  |  |  |  |
| 13 | COUNTERMEASURES                                          |             |                                     |                  |                     |                |  |  |  |  |  |  |
| 14 | REMARKS<br><br>No credible results known<br>to reporter. |             |                                     |                  |                     |                |  |  |  |  |  |  |



|                                     |                     |                      |                        |           |                       |   |   |   |                                                    |    |    |                 |                                                 |  |  |
|-------------------------------------|---------------------|----------------------|------------------------|-----------|-----------------------|---|---|---|----------------------------------------------------|----|----|-----------------|-------------------------------------------------|--|--|
| 1                                   | 2                   | 3                    | 4                      | 5         | 6                     | 7 | 8 | 9 | 10                                                 | 11 | 12 | 13              | 14                                              |  |  |
| ELECTROMAGNETIC (LASERS AND MASERS) | ENERGY FORM         | LEVEL OF INTERACTION | ASSOCIATIVE<br>SYMBOLS | ILLUSIONS | PSYCHOLOGICAL EFFECTS |   |   |   | SPECIFIC ADVERSE<br>EFFECTS DUE TO<br>TRANSMISSION |    |    | COUNTERMEASURES | REMARKS<br><br>No effects known to<br>reporter. |  |  |
|                                     |                     |                      |                        |           |                       |   |   |   |                                                    |    |    |                 |                                                 |  |  |
|                                     |                     |                      |                        |           |                       |   |   |   |                                                    |    |    |                 |                                                 |  |  |
|                                     |                     |                      |                        |           |                       |   |   |   |                                                    |    |    |                 |                                                 |  |  |
|                                     |                     |                      |                        |           |                       |   |   |   |                                                    |    |    |                 |                                                 |  |  |
|                                     | SAFE                |                      |                        |           |                       |   |   |   |                                                    |    |    |                 |                                                 |  |  |
|                                     | DEGRA-<br>DATION    |                      |                        |           |                       |   |   |   |                                                    |    |    |                 |                                                 |  |  |
|                                     | INCAPA-<br>CITATION |                      |                        |           |                       |   |   |   |                                                    |    |    |                 |                                                 |  |  |
|                                     | LETHA-<br>LITY      |                      |                        |           |                       |   |   |   |                                                    |    |    |                 |                                                 |  |  |

#### APPENDIX A - Bibliographic Sources

1. H. A. Sperling: "Laser Eye Effects," Armed Forces-NRC Committee on Vision, Washington, D. C., AD 667-494, March 1968.
2. TB MED 279: "Control of Hazards to Health from Laser Radiation," Department of the Army, Department of the Navy, Washington, D. C. (Draft, Oct 1968).

Add pages if necessary.

APPENDIX B - Amplification of Remarks

Add pages if necessary.

APPENDIX C - Other Possible Information Sources

Add pages if necessary.

APPENDIX D - Catch-all

Add pages if necessary.

| 1                                                  | 2                    | 3                 | 4              | 5                   | 6                    | 7     | 8    | 9           | 10                                           | 11                   | 12          | 13                | 14 |
|----------------------------------------------------|----------------------|-------------------|----------------|---------------------|----------------------|-------|------|-------------|----------------------------------------------|----------------------|-------------|-------------------|----|
| ENERGY FORM                                        | LEVEL OF INTERACTION | DAMAGE TO EYE     |                |                     |                      |       |      |             | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                      |             | REMARKS           |    |
|                                                    |                      | CORNEA            | PUPIL          | LENS                | OPTICAL FLUID        | CONES | RODS | EYE MUSCLES | ANATOMIC                                     | PHYSIOLOGIC          | PSYCHOLOGIC | COGNITIVE EFFECTS |    |
| ELECTROMAGNETIC (MICROWAVES, UHF, VHF, RF, AF, AC) | SAFE                 | 10.2-15.5         |                |                     |                      |       |      |             |                                              |                      |             |                   |    |
|                                                    | DEGRADATION          | 1-30<br>170<br>A2 | 2.8<br>X<br>A3 | 1.8-10<br>170<br>A4 | 1.8-3<br>X<br>A5     |       |      |             | 10<br>10<br>A6                               | .07-3.0<br>170<br>A7 |             | E                 |    |
|                                                    | INCAPABILITY         |                   |                |                     | 2.5-10<br>>200<br>A4 |       |      |             |                                              |                      |             | E                 |    |
|                                                    | LETALITY             |                   |                |                     |                      |       |      |             |                                              |                      |             | A8                |    |

| 1                                                  | 2                    | 3             | 4              | 5            | 6       | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14 |
|----------------------------------------------------|----------------------|---------------|----------------|--------------|---------|---|---|---|----------------------------------------------|-------------|-------------|-----------------|----|
| ELECTROMAGNETIC (MICROWAVES, UHF, VHF, RF, AF, AC) | ENERGY FORM          | DAMAGE TO EAR |                |              |         |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | REMARKS         |    |
|                                                    | LEVEL OF INTERACTION | DRUM          | OSCILLES       | ROUND WINDOW | COCHLEA |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES |    |
|                                                    | SAFE                 |               | 9.5<br>5       |              |         |   |   |   |                                              |             |             |                 |    |
|                                                    | DEGRADATION          |               | 0.2-6.5<br>0.4 |              |         |   |   |   |                                              | 3-10<br>1   |             | D-1             |    |
|                                                    | INCAPACITATION       |               | A10            |              |         |   |   |   |                                              | A11         |             | A12             |    |
|                                                    | LETALITY             |               |                |              |         |   |   |   |                                              |             |             |                 |    |

| 1           | 2                    | 3                       | 4                 | 5                  | 6              | 7 | 8 | 9 | 10      | 11                                                 | 12          | 13          | 14      |
|-------------|----------------------|-------------------------|-------------------|--------------------|----------------|---|---|---|---------|----------------------------------------------------|-------------|-------------|---------|
| ENERGY FORM | LEVEL OF INTERACTION | OLFACTORY<br>EPITHELIUM | OLFACTORY<br>BULB | OLFACTORY<br>TRACT | DAMAGE TO NOSE |   |   |   |         | SPECIFIC ADVERSE<br>EFFECTS DUE TO<br>TRANSMISSION |             |             | REMARKS |
|             |                      |                         |                   |                    |                |   |   |   |         | ANATOMIC                                           | PHYSIOLOGIC | PSYCHOLOGIC |         |
|             |                      |                         |                   |                    |                |   |   |   |         |                                                    |             |             |         |
|             |                      |                         |                   |                    |                |   |   |   |         |                                                    |             |             |         |
|             |                      |                         |                   |                    |                |   |   |   |         |                                                    |             |             |         |
|             | SAFE                 |                         |                   |                    |                |   |   |   |         |                                                    |             |             |         |
|             | DEGRA-<br>DATION     |                         |                   |                    |                |   |   |   | .003-.3 |                                                    |             | D-I<br>A12  |         |
|             | INCAPA-<br>CITATION  |                         |                   |                    |                |   |   |   | A13     |                                                    |             |             |         |
|             | LETHA-<br>LITY       |                         |                   |                    |                |   |   |   |         |                                                    |             |             |         |



[illegible]

| 1                                                     | 2                    | 3                                   | 4                      | 5                     | 6 | 7 | 8 | 9 | 10                                                 | 11          | 12          | 13              | 14 |
|-------------------------------------------------------|----------------------|-------------------------------------|------------------------|-----------------------|---|---|---|---|----------------------------------------------------|-------------|-------------|-----------------|----|
| ENERGY FORM                                           | LEVEL OF INTERACTION | POSTURAL SENSIBILITY<br>(LABYRINTH) | GALVIA MOTOR<br>SYSTEM | DAMAGE TO KINESTHETIC |   |   |   |   | SPECIFIC ADVERSE<br>EFFECTS DUE TO<br>TRANSMISSION |             |             | REMARKS         |    |
|                                                       |                      |                                     |                        |                       |   |   |   |   | ANATOMIC                                           | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES |    |
|                                                       |                      |                                     |                        |                       |   |   |   |   |                                                    |             |             |                 |    |
|                                                       |                      |                                     |                        |                       |   |   |   |   |                                                    |             |             |                 |    |
|                                                       |                      |                                     |                        |                       |   |   |   |   |                                                    |             |             |                 |    |
| ELECTROMAGNETIC (MICROWAVES, UHF, VHF,<br>RF, AF, AC) | SAFE                 |                                     |                        |                       |   |   |   |   |                                                    |             |             |                 |    |
|                                                       | DEGRA-               | 2.8-10.003-24                       |                        |                       |   |   |   |   | 0.2-2.8                                            |             |             |                 |    |
|                                                       | DATION               | 10-165 10-165                       |                        |                       |   |   |   |   | 165                                                |             |             |                 |    |
|                                                       |                      | A21 A22                             |                        |                       |   |   |   |   | A23                                                |             |             | A8              |    |
| INCAPA-<br>CITATION                                   |                      |                                     |                        |                       |   |   |   |   |                                                    |             |             |                 |    |
|                                                       |                      |                                     |                        |                       |   |   |   |   |                                                    |             |             |                 |    |
| LETHA-<br>LITY                                        |                      |                                     |                        |                       |   |   |   |   |                                                    |             |             |                 |    |
|                                                       |                      |                                     |                        |                       |   |   |   |   |                                                    |             |             |                 |    |

| 1           | 2                    | 3                         | 4      | 5 | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14 |
|-------------|----------------------|---------------------------|--------|---|---|---|---|---|----------------------------------------------|-------------|-------------|-----------------|----|
| ENERGY FORM | LEVEL OF INTERACTION | DAMAGE TO SKIN (COVERING) |        |   |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | REMARKS         |    |
|             |                      | EPIDERMIS                 | DERMIS |   |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES |    |
|             | SAFE                 |                           |        |   |   |   |   |   |                                              |             |             |                 |    |
|             | DEGRADATION          | 2.5-10<br>40<br>A24       |        |   |   |   |   |   | 0.2<br>165<br>A25                            |             |             | D<br>A18        |    |
|             | INCAPACITATION       | 3<br>165<br>A26           |        |   |   |   |   |   |                                              |             |             | D<br>A18        |    |
|             | LETALITY             |                           |        |   |   |   |   |   |                                              |             |             |                 |    |

ELECTROMAGNETIC (MICROWAVES, UHF, VHF, RF, AF, AC)

| 1                                                  | 2                    | 3                            | 4     | 5       | 6                     | 7                       | 8                       | 9                  | 10                                           | 11                      | 12          | 13              | 14      |
|----------------------------------------------------|----------------------|------------------------------|-------|---------|-----------------------|-------------------------|-------------------------|--------------------|----------------------------------------------|-------------------------|-------------|-----------------|---------|
| ENERGY FORM                                        | LEVEL OF INTERACTION | DAMAGE TO                    |       |         |                       |                         |                         |                    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |                         |             |                 | REMARKS |
|                                                    |                      | BLOOD                        | LYMPH | MUSCLES | SKELETON              | CARDIO-VASCULAR         | MARROW                  | SPLEEN             | ANATOMIC                                     | PHYSIOLOGIC             | PSYCHOLOGIC | COUNTERMEASURES |         |
| ELECTROMAGNETIC (MICROWAVES, UHF, VHF, RF, AF, AC) | SAFE                 |                              |       |         | $\frac{0.8-3}{43}$    | $\frac{10}{1}$          | $\frac{0.4-24}{43}$     |                    |                                              | $\frac{3}{1}$           |             |                 |         |
|                                                    | DEGRADATION          | $\frac{1003-24}{10}$ 015 350 | A31   | A32     | $\frac{10-24}{10}$ 20 | $\frac{1003-30}{10}$ 10 | $\frac{1003-30}{10}$ 10 | $\frac{3-24}{8}$ 8 | $\frac{3-24}{8}$ 8                           | $\frac{1003-30}{10}$ 10 |             | D               |         |
|                                                    | INCAPACITATION       |                              |       |         |                       | $\frac{2.5}{70}$        |                         |                    |                                              |                         |             | D               |         |
|                                                    | LETALITY             |                              |       |         |                       | A40                     |                         |                    |                                              |                         |             | A18             |         |

| 1           | 2                    | 3                   | 4                        | 5        | 6                        | 7                        | 8         | 9 | 10                                           | 11       | 12          | 13              | 14      |
|-------------|----------------------|---------------------|--------------------------|----------|--------------------------|--------------------------|-----------|---|----------------------------------------------|----------|-------------|-----------------|---------|
| ENERGY FORM | LEVEL OF INTERACTION | ADRENALS            | PITUITARY                | PANCREAS | THYROID                  | GONADS                   | DAMAGE TO |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |          |             | COUNTERMEASURES | REMARKS |
|             | SAFE                 |                     |                          |          |                          | $\frac{0.4-24}{8}$ A41   |           |   |                                              | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC     |         |
|             | DEGRADATION          | $\frac{2-3}{X}$ A42 | $\frac{0.3-300}{10}$ A43 |          | $\frac{003-300}{10}$ A44 | $\frac{2.5-24}{>10}$ A45 |           |   | $\frac{2-300}{10}$ A46                       |          |             | D<br>A18        |         |
|             | INCAPACITATION       |                     |                          |          |                          |                          |           |   | $\frac{3}{60}$ A47                           |          |             | DI<br>A12       |         |
|             | LETHALITY            |                     |                          |          |                          |                          |           |   |                                              |          |             |                 |         |

ELECTROMAGNETIC (MICROWAVES, UHF, VHF, RF, AF, AC)

| 1                                                  | 2                    | 3                     | 4                   | 5                   | 6                         | 7                                                  | 8 | 9 | 10                         | 11              | 12          | 13                | 14 |
|----------------------------------------------------|----------------------|-----------------------|---------------------|---------------------|---------------------------|----------------------------------------------------|---|---|----------------------------|-----------------|-------------|-------------------|----|
| ELECTROMAGNETIC (MICROWAVES, UHF, VHF, RF, AF, AC) | ENERGY FORM          | DAMAGE TO             |                     |                     |                           | SPECIFIC ADVERSE EFFECTS FROM CO-ORDINATE EXPOSURE |   |   |                            | REMARKS         |             |                   |    |
|                                                    | LEVEL OF INTERACTION | GASTRO-<br>INTESTINAL | URINARY             | RESPIRATORY         | LIVER AND<br>GALL BLADDER |                                                    |   |   | ATMOSPHERIC                | PSYCHOLOGIC     | PSYCHOLOGIC | COGNITIVE EFFECTS |    |
|                                                    | SAFE                 |                       |                     |                     |                           |                                                    |   |   | $\frac{3}{10}$             | A48             |             |                   |    |
|                                                    | DEGRA-<br>DATION     | $\frac{0.2-24}{15}$   | $\frac{24}{50}$     | $\frac{.003}{X}$    | $\frac{24}{50}$           |                                                    |   |   | $\frac{.001-3.003-30}{20}$ | $\frac{10}{10}$ |             | E                 |    |
|                                                    | INCAPA-<br>CITATION  | $\frac{0.3-300}{70}$  | $\frac{2.5-10}{70}$ | $\frac{2.5-24}{70}$ | $\frac{2.5-10}{70}$       |                                                    |   |   | A53                        | A54             | A8          | E                 |    |
|                                                    |                      | A49                   | A50                 | A51                 | A52                       |                                                    |   |   |                            |                 |             | A8                |    |
|                                                    | LITERA-<br>LITY      | A55                   | A56                 | A56                 | A56                       |                                                    |   |   |                            |                 |             |                   |    |



| 1                                                                 | 2                    | 3                   | 4         | 5                     | 6 | 7 | 8 | 9 | 10                                           | 11           | 12             | 13      | 14               |
|-------------------------------------------------------------------|----------------------|---------------------|-----------|-----------------------|---|---|---|---|----------------------------------------------|--------------|----------------|---------|------------------|
| ENERGY FORM<br>ELECTROMAGNETIC (MICROWAVES, UHF, VHF, RF, AF, AC) | LEVEL OF INTERACTION | ASSOCIATIVE SYMBOLS | ILLUSIONS | PSYCHOLOGICAL EFFECTS |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |              |                | REMARKS |                  |
|                                                                   | SAFE                 |                     |           |                       |   |   |   |   | AMATEUR                                      | PSYCHOLOGIC  | PSYCHOLOGIC    |         | NOT REPRODUCIBLE |
|                                                                   | DEGRA-               | .05-25<br>10        |           |                       |   |   |   |   |                                              | 0.2-24<br>30 |                | DI      |                  |
|                                                                   | DATION               |                     |           |                       |   |   |   |   |                                              |              | .003-300<br>30 |         |                  |
|                                                                   | INCAPA-<br>CITATION  | A66                 |           |                       |   |   |   |   |                                              | A67          | A68            | A12     |                  |
| DETER-                                                            |                      |                     |           |                       |   |   |   |   |                                              |              |                |         |                  |
|                                                                   | LITY                 |                     |           |                       |   |   |   |   |                                              |              |                |         |                  |



## Compendium of Pathophysiologic Sensitivities to Microwave Exposure

### Directions for Reading Entries in Matrices

Entries have been made in the box of each matrix where information appropriate to the subject is available. Where a box is left empty, it indicates that no information was available at this time. The three entries in each box include:

Upper figure - frequency (the highest and lowest frequency under which a particular physiologic parameter was studied). The entry for frequency designation is  $1 \times 10^{-3}$  i.e., if the frequency range designation such as in A 2 is 1-30 this is in reality 1000-30000MHz. In some entries for frequency designation the letters P or C may be noted. In these particular instances where differences between pulsed (P) or continuous waves (C) is noted, these are so designated.

Middle figure is the power density or field intensity which is the lowest one reported to produce an effect on the particular system under study, in the degradation, incapacitation, or lethality levels. For entries in the safe level, the highest field density recorded in which no effect was observable, has been used. The power level entry is in mW/cm<sup>2</sup>. In other words under, A 2, 170 indicates 170 mW/cm<sup>2</sup>. In reviewing the field density designations an inconsistency between various levels of safe, degradation or incapacitation may be noted. This is due to the fact that various physiologic parameters were studied at certain frequencies and power levels and not at others. Also, in order to prevent bias of available information a large number of papers from the Soviet Union have been included in these entries. Inasmuch as the Soviet research in microwave effects is based on "conditional response" or "higher nervous activity" approaches, effects at field densities lower than those in the U.S.A. are reported. Where an X is noted for the power density measurement it indicates that such information was not given in the report.

Lower Figure - i.e. A 1; A 2; A 3 are specific notations for Appendix A; this should be referred to for amplification of remarks.

Designations of the countermeasures include:

- E.- for easily accomplished countermeasures
- D - indicates countermeasures are difficult to establish
- I - in the opinion of the reviewer, countermeasures may be impossible in the present state of the art.

## APPENDIX A - Bibliographic Sources

1. Addington, C., F. Fischer, R. Neubauer, C. Osborn, Z. Sarkees, and G. Swartz. 1958. In Proc. second tri-service conf. biol. effects microwave energy. p.189, Univ. Va., Charlottesville.
2. Addington, C., C. Osborn, G. Swartz, F. Fixcher, and Z. Sarkees. 1959. p. 10, In. Proc. third tri-service conf. effects microwave radiating equipments. RADC-TR-59-140. Univ. Calif., Berkeley.
3. Alekseyenko, N. Yu. 1956. In: Materially po evolyutsionnoy fiziologii. Simpozium (Materials on evolutionary physiology, Symposium. Moscow-Leningrad, 1:7.
4. Bach. S. A. 1961. Dig. Intern. Conf. Med. Electron., 4th, 152.
5. Bach, S. A., M. Baldwin, and S. Lewis. 1959. Proc. tri-serv. conf. biol. effects microwave radiation, 3rd, 82.
6. Balutina, A. P. 1965. Biull. Eksp. Biol. Med. 60:41.
7. Baranski, S., Z. Edelwejn. 1967. Acta Physiol. Pol., 18:517.
8. Barron, C. I., and A. A. Baraff. 1958. J. Amer. Med. Ass. 168:1194.
9. Barron, C. I., A. A. Love, and A. A. Baraff. 1955. J. Aviation Med. 26:442.
10. Bartonicek, V. and E. Klimkova. 1964. Casopis Lekarů Ceských. 103:26.
11. Baus, R., and J. D. Fleming. 1959. Proc. tri-serv. conf. biol. effects microwave radiation, 3rd., p. 291.
12. Belova, S. F., and Z. V. Gordon, 1956. Bull. Exper. Biol. Med. (USSR) 41:327, (ATD P 65-17, Libr. Congr. Wash., D. C.).
13. Benitte, A. 1966. C. Concoyrs Med., 88:3667.
14. Bilokrynyts'kyi, V. S. 1966. Fiziol. Zh. Moscow, 12:70.
15. Boyle, A. C., H. F. Cook, and T. J. Buchanan. 1950. Brit. Phys. Med. 13:2.
16. Boysen, J. E. 1953. Amer. Med. Ass. Arch. Ind. Hyg. and Occup. Med. 7:516.
17. Carpenter, R. L. 1958. In proc. second tri-service conf. biol. effects microwave energy, p. 146., ARDC-TR-58-54. Univ. Va., Charlottesville.
18. Carpenter, R. L. 1959. In Proc. third tri-service conf. biol. effects microwave energy. p. 279., Univ. Calif., Berkeley, RADC-TR-59-140.
19. Carpenter, R. L. 1962. RADC-62-131. Griffiss AFB, N. Y. 51 p.

20. Carpenter, R. L., D. K. Biddle, and C. A. Van Ummersen. 1960. Inst. Radio Engrs. Trans. Med. Electron. 7:152.
21. Carpenter, R. L., D. K. Biddle, and C. A. Van Ummersen. 1960. Proc. Intern. Conf. Med. Electron., 3rd, 3:401.
22. Carpenter, R. L., D. K. Biddle, C. A. Van Ummersen, C. P. Mangahas, and H. M. Freeman. 1959. Amer. J. Ophthalmol. 47:94 (Abstr.).
23. Carpenter, R. L., G. H. Hammond, D. K. Biddle, and C. A. Van Ummersen. 1961. In Dig. fourth int. conf. med. electronics, New York, p. 195.
24. Chizhenkova, R. A. 1967. Fiziol Zh Akad Nauk, UKR SSR 53:514.
25. Chukhlovin, B. A., B. N. Grachev, I. V. Likina, 1966. Byull. Eksp. Biol. Med., 61:54.
26. Clark, J. W. 1950. Proc. Inst. Radio Engrs. 38:1028.
27. Clark, L. A. 1959. Proc. tri-service conf. biol. effects microwave radiation, 3rd, p. 239.
28. Cogan, D. G., S. J. Fricker, M. Lubin, D. D. Donaldson, and H. Hardy. 1958. Amer. Med. Ass. Arch. Ind. Hyg. 18:299.
29. Constant, P. C. 1967. Digest Int. Conf. Med. Elect. Med. Biol. Engr. 7:349.
30. Cooper, T. 1965. Experientia 21:28.
31. Daily, L., Jr., K. G. Wakim, J. F. Herrick, E. M. Parkhill, and W. L. Benedict. 1950. Amer. J. Ophthalmol. 33:1241.
32. Daily, L., Jr., E. A. Zeller, K. G. Wakim, J. F. Herrick, and W. L. Benedict. 1951. Amer. J. Ophthalmol. 34:1301.
33. Davis, T. R. A., and J. Mayer. 1954. Amer. J. Physiol. 178:283.
34. Deichman, W. B., E. Bernal, F. Stephens, and K. Landeen. 1963. J. Occup. Med. 5:419.
35. Deichman, W. B., J. Miale, and K. Landeen. 1962. RADC-TDR-62-192, Griffiss AFB, New York. (ASTIA 278 022).
36. Deichmann, W. B., F. H. Stephens, M. Keplinger, and K. F. Lampe. 1959. J. Occup. Med. 1:369.
37. Deichman, W. B. 1960. RADC-TR-61-42, 66 p.
38. Deichman, W. B., J. Miale, and K. Landeen. 1964. Toxicol. Appl. Pharmacol. 6(1):71.
39. Drogichina, E. A. 1960. In: Nauchno-issledovatel'skiy institut gigiyeny truda i profzabolevaniy. Trudy, no. 1, 22.
40. Drogichina, E. A., and M. N. Sadchikova. 1962. Lab. Hyg. Occup. Dis. (Moscow) 9:17. (JPRS 29694).

41. Eakin, S. K. 1965. Psych. Rept. 17:595.
42. Eakin, S. K. and W. D. Thompson. 1962. Psychol. Rept. 11(1):192.
43. Edelwejn, A., and S. Haduch. 1962. Acta. Physiol. Pol. 13:431.
44. Edelwejn, A. 1966. Military Inst. of Aeromedicine, (Warsaw). Lek. Wojsk, No. 9:781.
45. Ely, T. S., and D. E. Goldman. 1957. In proc. tri-service conf. biol. effects microwave radiat. p. 64. George Washington Univ., Washington, D. C.
46. Ely, T. S., D. E. Goldman, J. Z. Hearon, R. B. Williams, and H. M. Carpenter. 1957. Res. Rep. Proj. NM 001 056.13.02 (Naval Med. Res. Inst., Nat. Naval Med. Center, Bethesda, Md.).
47. Ely, T. S., D. E. Goldman, and J. Z. Hearon. 1964. IEEE Trans., Biomed. Eng. BME-11:123.
48. Faytel'berg-Blank, V. R. 1964. Byull. Eksper. biol. i Med. No. 1, 57:45.
49. Fofanov, P. N. 1966. Probl. Endokrinol. Gormonoterap., 12:5, 16 p.
50. Follis, R. H. 1946. Am. J. Physiol. 147:281.
51. Frey, A. H. 1961. Dig. Intern. Conf. Med. Electron., 4th. , 158.
52. Frey, A. H. 1963. Am. J. Med. Electr. 2:28.
53. Fukalova, P. P., Tolgskaya, M. S., Nikogosyan, S. V., Kitsovskaya, I. A., Zenia, I. N. 1966. Gig. Tr. Prof. Zabol., 7:5.
54. Gersten, J. W., 1949. Arch. Phys. Med. 30:7.
55. Gogibedashvili, V. G. 1954. In: Tiflis. Gosudarstvennyy nauchno-issledovatel'skiy institut kurortologii i fizioterapii. Referativnyy sbornik trudov. Tbilisi, 178.
56. Goncharova, N. N., Karamyshev, V. B., Maksimenko, N. V. 1966. Gig. TR. Prof. Zabol., 7:10.
57. Gordon, Z. V., and Ye. A. Lobanova. 1960. In A. A. Letavet and Z. V. Gordon. p. 59. The biological action of ultrahigh frequencies. Acad. Med. Sci., (Moscow). (JPRS 12471).
58. Gordon, Z. V. 1960. Trudy NII Gigiyena. I. Profzaboleaniy. USSR, 1:65.
59. Gordon, Z. V. 1966. Gig. Truda Prof. Zabolev., No. 10:3.
60. Gorodetskaia, S. F. 1960. Fiziol. Zh., Akad. Nauk Ukr RSR 8:390 (ASTIA 292-205).
61. Gorodetskaia, S. F. 1964. Fiziol. Zh. 4:494. (JPRS 26990).

62. Gorodetskaia, S. F. 1964. In A. A. Gorodetskiy. p. 80. Biological action of ultrasound and super-high frequency electromagnetic oscillations. Acad. of Sciences (Kiev). (JPRS 30860).
63. Gunn, S. A., T. C. Gould, W. A. D. Anderson. 1961. Lab. Invest., 10: 301, Univ. of Miami, School of Med., Fla.).
64. Gvozdkova, Z. M., V. M. Anafyev, I. N. Zenia, and V. I. Zak. 1964. Byull. Eksper. Biol. i Med. 58:63.
65. Haduch, S., P. Czerski, and S. Baranski. 1961. Lekarz Wojskowy (Warsaw) 36:792. FTD-TT-61-379 WP-AFB, Ohio. (ASTIA 270 774).
66. Hines, H. M., and J. E. Randall. 1952. Elec. Eng. 71:879.
67. Hirsch, F. G. and J. T. Parker. 1952. Arch. Ind. Hyg. Occupational Med. 6:512.
68. Howland, J. W., and S. Michaelson. 1960. In Proc. third tri-service conf. biol. effects microwave raditing equip. p. 191. Univ. Calif., Berkeley. RADC-TR-59-140.
69. Howland, J. W., R. A. E. Thomson, and S. M. Michaelson. 1961. In Biological effects of microwave radiation. p. 261. Plenum Press, New York.
70. Huzl, F. 1966. Pracovni Lekarstvi 18:100.
71. Imig, C. J. and G. W. Searle. 1958. Proc. 4th tri-service conf. biol. effects microwave rad. 1:261.
72. Imig, C. J., J. D. Thomson, and H. M. Hines. 1948. Proc. Soc. Exp. Biol. Med. 69:382.
73. Jacobson, B. S., and C. Susskind. 1958. In Proc. second tri-service, conf. biol. eff. microwave energy. p. 234. Review of the work conducted at the University of California. Univ. Va., Charlottesville. (ASTIA 131 477).
74. Kapitanenko, A. M. 1964. Voenno-Med. Zh., 10:19.
75. Kekcheyev, K. Kh., A. P. Anisimova, and N. Ye. Didenko. 1941. Fizioterapiya, no. 3-4:44.
76. Kemp, C. R., W. D. Paul, and H. M. Hines. 1948. Arch. Phys. Med. 29:12.
77. Keplinger, M. L. 1958. In Proc. second tri-serv. conf. biol. eff. microwave energy. p. 215. Univ. Va, Charlottesville. (ASTIA 131 477).
78. Kerova, N. I. 1964. In Biol. action of ultrasound and super-high frequency electromagnetic oscillations. p. 108. Kiev. ATD P 65-68. Libr. Cong., Wash., D. C.
79. Kevork'yan, A. A. 1948. Gigiyena i sanitariya, 4:26.

80. Kharchenko, N. S. 1939. Dnepropetrovsk. Universitet. Institut fiziologii. Sbornik rabot, 2:77.
81. Khazan, G. L. 1958. Gigiyena truda i profzabolevaniy, 1:9.
82. Kholodov, Yu. A. 1962. Priroda (USSR) 4:104. ATD P 65-68. Libr. Cong., Wash., D. C. FTD-TT 62-1107. (ASTIA 284 123).
83. Kholodov, Yu. A. 1966. Influence of Electromagnetic Fields on the Central Nervous System. 283 p. Moscow. (NASA Tech. Trans. F-465, 1967).
84. Kholodov, Yu. A., and Z. A. Yanson. 1962. Byulleten' eksperimental'noy biologii i meditsiny, v. 53. no. 11, 8.
85. Kholodov, Yu. A. 1964. Byulleten'eksperimental'noy biologii i meditsiny, 57:98.
86. Kinoshita, J. H. and L. O. Merola, E. Dikmak, and R. L. Carpenter. 1966. Doc. Ophthalmol. 20:91.
87. Kitsovskaya, I. A. 1960. in: Nauchno-issledovatel'skiy institut gigiyeny truda i profzabolevaniy. USSR, Trudy, 1:75.
88. Kitsovskaya, I. A. 1964. Labor Hyg. Occup. Dis. (Moscow) 6:14. (JPRS 31047:TT-65-31545).
89. Klimkova, D. 1963. Int. Arch. Gewerbepath. Gewerbehyg. 20:1.
90. Kolesnik, F. A. and V. M. Malyshev. 1967. Voennno-Med. Zh., No. 4;21.
91. Kolesnik, F. A., V. M. Malyshev, and B. F. Murashov. 1967. Voenno meditsinsky zhurnal, 7:39.
92. Konchalovskaya, N. 1964. Trudy Nii Gigiyena Truda i Profzaboleaniy (USSR) 2:114.
93. Kottke, F. J., 1949. Arch. Phys. Med. 30:431.
94. Krusen, F. H. 1950. Proc. Roy. Soc. Med. 43:641.
95. Krusen, F. H. 1947. Proc. Staff Meetings Mayo Clinic 22:209.
96. Krustanov, L. 1966. Goshev, Hkr. Voennno-Med. Delo, No. 4:41.
97. Kulakova, V. V. 1966. Konferetisiya molodykh nauchnykh rabotnikov, Moscow, 73.
98. Kulakova, V. V. 1964. Trudy Nii Gigiyena Truda i Profzaboleaniy. (USSR) 2:70.
- 98a. Laytes, F. L., and L. A. Shurikhina. 1961. Bull. Exp. Biol. Med. (USSR) 52:47. FTD-TT62-277. (ASTIA 281-169).
99. Levitina, N. A. 1964. Byulleten'eksperimental'noy biologii i med. 7:67.

100. Lidman, B. I., and C. Cohn. 1945. Air Surg. Bull. 2:448.
101. Livshits, N. N. 1957. Biophysics (USSR) 2:198.
102. Lobanova, Ye. A., and Z. V. Gordon. 1960. In: Nauchno-issledovatel'skiy institut gigiyena truda i profzabolevaniy. Trudy, 1:50.
103. Lobanova, Ye. A., and M. S. Tolgskaya. 1960. In: Nauchno-issledovatel'skiy institut gigiyena truda i profzabolevaniy. Trudy, 1:68.
104. Lobanova, Ye. A. 1960. Trudy NII Gigiyena Truda i Profzabolevaniy (USSR) 1:61.
105. Lobanova, Ye. A. 1964. Trudy NII Gigiyena Truda i Profzabolevaniy (USSR) 2:13.
106. Lobanova, Ye. A. 1966. Gig. Truda Prof. Zabolev, (USSR) 10:7.
107. Loshak, A. Ya. 1965. Gigiyena i sanitariya, 6:18.
108. Lubin, M., G. W. Curtis, H. R. Dudley, L. E. Bird, P. F. Daley, D. G. Cogan, and S. J. Fricker. 1960. Amer. Med. Ass. Arch. Indust. Health 21:555.
109. Lysina, G. G. 1965. Gigiyena i sanitariya, no. 6:95.
110. Mackenzie, J. W., J. C. Schuder, H. E. Stephenson, Jr., 1967. J. Surg. Res. 7:133.
111. McAfee, R. D. 1959. Proc. tri-service conf. bio. effects microwave radiation. 3rd. p. 314.
112. McAfee, R. D. 1961. Amer. J. Physiol. 200:192.
113. McNally, J. B. 1962. Federation Proc. 21(2):A255.
114. Mermagen, H. 1961. Proc. Tri-service conf. biol. effects microwave radiation, 4th, 1:143.
115. Merola, L. O., and J. H. Kinoshita. 1961. Proc. tri-service conf. biol. effects of microwave radiation 4th 1:285.
116. Michaelson, S. M., J. W. Howland, and R. A. E. Thomson. 1958. Proc. 2nd tri-service conf. biol. effects microwave radiation. p. 175.
117. Michaelson, S. M., J. W. Howland, R. A. E. Thomson, and H. Mermagen. 1959. In Proc. third tri-service conf. biological effects of microwave radiating equipments. p. 161. RADC-TR-59-140. Cont. AF 30(602) 2248.
118. Michaelson, S. M., R. A. E. Thomson, and J. W. Howland. 1965. Aerospace Med. 36:1059.
119. Michaelson, S. M., R. A. E. Thomson, and W. J. Quinlan. 1967. Aerospace Med. 38:293.

120. Michaelson, S. M., R. A. E. Thomson, M. Y. El Tamami, H. S. Seth, and J. W. Howland. 1964. *Aerospace Med.* 35:824.
121. Michaelson, S. M., R. A. E. Thomson, J. W. Howland. 1967. RADC-TR-67-461. 138 p. AFSC, Griffiss Air Force Base, New York.
122. Minecki, L. 1961. *Medycyna Pracy* (Poland) 12:337. FTD-TT 61-380.
123. Minecki, L. 1964. *Arch za Higijenu Rada i Tuksikologiju.* 1:47.
124. Miro, L. 1962. *Revue de Medecine Aeronautique* (Paris) 1:16.
125. Miro, L., R. Loubiere, and A. Pfister. 1965. *Rev. Med. Aeronaut.* (Paris), 4:37.
126. Mirutenko, V. I. 1964. In A. A. Gorodetskiy, *Biological action of ultrasound and super-high frequency oscillations.* p. 62. Acad. of Sciences (Kiev) (JPRS 30860).
127. Nieset, R. T. 1957. *Ann. Prog. Rept., Tulane University.* Contract NONR 475(03) 22p.
128. Nieset, R. T. et al. 1958. *Proc. tri-service conf. biol. effects microwave radiation.* 2nd., p. 202.
129. Nieset, R. T. 1959. RADC TN 59-311, 110 p.
130. Nikogasyan, S. V. 1959. In L. A. Dolina, *Work hygiene and the biological effect of electromagnetic waves of radio frequency, Theses of reports* (Moscow). p. 81. ATD P 65-68. Libr. Congr., Wash., D. C.
131. Nikogasyan, S. V. 1967. *Byulleten'eksperimental'noy biologii i meditsiny,* 64:56.
132. Nikonova, K. V. 1963. *Authors' abstract of candidates' dissertation* (Moscow). ATD P 65-17. Libr. Congr., Wash., D. C.
133. Oldendorf, W. H. 1949. *Proc. Soc. Exp. Biol. and Med.* 72:432.
134. Orlova, A. A. 1960. In: *Nauchno-issledovatel'skiy institut gigiyena truda i profzabolevaniy. Trudy,* 1:30.
135. Osborne, S., and J. N. Frederick. 1948. *J. Amer. Med. Ass.* 137:1036.
136. Osborne, C., and C. H. Addington. 1950. *Tech. Rept. Investig. Conf. Biol. Eff. Electron. Rad. Equipm* p. 24.
137. Osipov, Yu. A., and T. V. Kalyada. 1964. *Hyg. Sanitation (USSR)* 10:73 (JPRS 23287).
138. Paliev, B., B. Paliyev, K. Goshev. 1966. *Voenno Med. Delo,* 4:34.
139. Panov, A. G., Tyagin, N. V. 1966. *Voenno-Med. Zh.* 9:13.
140. Pelis, L. Jr. 1964. *Med. Surg.* 33:866.



141. Pitenin, I. V., and A. G. Subbota. 1965. Bull. Exper. Biol. Med. (USSR) 60:55. (UDC 616.33-002.44.02:617.551-001.2-092.9).
142. Plurien, G., H. Sentenac-Roumanou, R. Joly, and J. Drouet. 1966. Compt. Rend. Soc. Biol., (Paris). 160:597.
143. Pol, W. 1962. Lekarz Wojskowy (Pol.) 38:318. (ASTIA 433 135).
144. Prausnitz, S., C. Susskind, and P. O. Vogelhut. 1961. Proc. tri-service, conf. bio. effects microwave radiation. 4th 1:135.
145. Prausnitz, S., and C. Susskind. 1962. IRE Trans. Bio-med. Electron. BME-9:104.
146. Pressman, A. S. 1957. Biull. Eksp. Biol. Med. 43:51.
147. Presman, A. S. 1963. Uspekhi sovremennoy biologii (USSR) 5:161. ATD P 65-68. Libr. Congr., Wash., D. C.
148. Presman, A. S., and N. A. Levitina. 1962. Byulleten'eksperimental'noy biologii i meditsiny, 2:39.
149. Revuts'kyy, E. L. 1964. Akademiya nauk UkrSSR. Fiziologichnyy zhurnal. 10:639.
150. Revutskiy, Ye. L. 1965. Fiziologichnyy zhurnal, 11:380.
151. Reynolds, M. R. 1960. p. 71. in Biological Effects of Microwave Radiation. M. F. Peyton ed. Plenum Press, N. Y.
152. Richardson, A. W. 1958. Review of the work done at the St. Louis University School of Medicine. p. 169. In Proc. second tri-serv. conf. bio. effects microwave energy. Univ. Va., Charlottesville. Contr. AF 18(600)1792. (ARDC-TR-58-54; ASTIA 131 477).
153. Richardson, A. W. 1959. Blood 14:1237.
154. Richardson, A. W., T. D. Duane, and H. M. Hines. 1948. Arch. Phys. Med. 29:765.
155. Richardson, A. W. T. D. Duane, and H. M. Hines. 1951. Amer. Med. Ass. Arch. Ophthalmol. 45:382.
156. Rosenthal, D. S., and S. C. Beering. 1968. J. Amer. Med. Ass. 205:245.
157. Sadchikova, M. N. 1960. Nauchno-issledovatel'skiy institut gigiyena truda i profzabolevaniy. Trudy 1: 25. ATD P 65-68. Libr. Congr., Wash., D. C.
158. Sadchikova, M. N. 1964. Trudy NII gigiyena truda i Profzabolevaniy (USSR) 2:110.
159. Schwan, H. P. 1952. Federation Proc. 11:142.
160. Schwan, H. P., E. L. Carstenson, and K. Li. 1954.

161. Searle, G. W., C. J. Imig, and R. W. Dahlen. 1959. In Proc. third ann. tri-service conf. biol. effects microwave radiating equipment. Univ. Calif., Berkeley. RADC-TR-59-140. p. 54.
162. Searle, G. W., C. J. Imig, and R. W. Dahlen, 1961. Proc. 4th tri-service conf. micro. rad. 1:187.
163. Seguin, L, and G. Castelain. 1947. Compt. Rend. Acad. Sci. (Paris) 224:1662.
164. Seth, H. S., and S. M. Michaelson. 1965. J. Occup. Med. 7:439.
165. Sheyvekhman, B. E. 1949. Problemy fiziologicheskoy akustiki, 1:123.
166. Shneyvas, V. B. and Zufarov, K. A. 1968. Meditsinskiy zhurnal Uzbekistana, 6:12.
167. Slepicka, J, A. Slivova, O. Pochmon, and E. Zapletalova. 1967. Prac. Lek. 19:5.
168. Slabospitskiy, A. A. 1965. In A. A. Gorodetskiy, Biological action of ultrasound and super-high frequency electromagnetic oscillations. (JPRS 30860). p. 92.
169. Smirnova, M. I., and M. N. Sadchikova. 1960. In A. A. Letavet and Z. V. Gordon, The biological action of ultrahigh frequencies. Acad. Med. Sci. (Moscow). (JPRS 12471). p. 50.
170. Sokolov, V. V., and M. N. Arievidh. 1960. In A. A. Letavet and Z. V. Gordon, The biological action of ultrahigh frequencies. Acad. Med. Sci. p. 43. (Moscow). (JPRS 12471).
171. Stodolnik-Baranska, W. 1967. Nature 214:102.
172. Stoner, E. K. 1971. Arch. Phys. Med. 32:408.
173. Subbota, A. G. 1957. Cited in A. N. Obrosoy, L. A. Shurikhina, and S. N. Safiulina. 1963. Problems of health resort research, physiotherapy and therapeutic physical culture (Moscow) 28:223. (JPRS 21067).
174. Tallarico, R. 1959. Proc. tri-service conf. biological effects microwave rad. 3:75.
175. Tanner, J. A. 1966. Nature 210:636.
176. Tanner, J. A. 1967. Nature 216:1139.
177. Teixeira-Pinto, A. A., J. L. Cutler, and J. H. Heller. 1959. Tech. Rept. Investrs. Conf. Biol. Effects Electron. Rad. Equip. p. 31.
178. Thomson, R. A. E., S. M. Michaelson, and J. W. Howland. 1966. Blood 28:157.

179. Tolgskaya, M. S. and Z. V. Gordon. 1960. In: Nauchno-issledovatel'skiy institut gigiyeny truda i profzabolevaniy. Trudy, 1:104.
180. Tolgskaya, M. S., Z. V. Gordon, and Ye. A. Lobanova. 1960. In A.A. Letavet and Z. V. Gordon, The biological action of ultrahigh frequencies. p. 90. Acad. Med. Sci. (Moscow) (JPRS 12471).
181. Tolgskaya, M. S., and Z. V. Gordon. 1964. Herald Acad. Med. Sci. (USSR) 19:61. (JPRS 27032).
182. Troyanskiy, M. P., R. I. Kruglikov, R. M. Kornilov, L. B. Petrova-Golubenko, and Z. S. Kalashnikova. 1967. Voenno-meditsinskiy zhurnal, 7:30.
183. Turlygin, S. Ya. 1937. Akademiya nauk SSSR. Doklady, Novaya seriya, 17:19.
184. Tyagin, N. V. 1957. Leningrad. Voenno-meditsinskaya akedemiya. Trudy 73:102.
185. Volkova, A. P., and Ye I Smurova 1967. Gigiyena i sanitariya, 9:107.
186. Wakim, K. G., J. F. Herrick, G. M. Martin, and F. H. Krusen. 1949. J. Amer. Med. Ass. 139:989.
187. Williams, D. B., J. P. Monahan, W. J. Nicholson, and J. J. Aldrich. 1955. Amer. Med. Ass. Arch. Ophthalmol. 54:863.
188. Wise, C. S., B. Castleman, and A. L. Watkins. 1949. J. Bone Joint. Surg. 31A:487.
189. Zaret, M. 1964. Technical Documentary Report No. RADC-TDR-64-273. Griffiss Air Force Base, Rome Air Development Center, New York. (ASTIA 608-746).
190. Zaret, M., S. Cleary, B. Pasternack, and M. Eisenbud. 1961. RADC-TN 61-226. New York Univ., N. Y. 109 p.
191. Zaret, M., S. Cleary, B. Pasternack, M. Eisenbud, and H. Schmidt. 1963. RADC-TDR-63-125. New York Univ., New York. 72 p.
192. Zenina, I. N. 1964. Trudy Nii Gigiyena Truda i Profzabolevaniy (USSR) 2:26.
193. Zhavoronok, S. G. 1968. IVUZ. Khimiya i khimicheskaya tekhnologiya. 11:225.

## APPENDIX B

### Amplification of Remarks

A 1. Most of these exposures were whole-body. It must be realized that in such exposures the eye is not constantly in the microwave field and as the individual or animal moves about there are variable periods during which the eye is not exposed. (1,28,46,68,117,135,136,189).

A 2. These findings include keratoconjunctivitis, iridocyclitis, temporary eye disturbance, photophobia, hyperemia, clouding of the cornea, conjunctivitis. (6,116,121,155,164).

A 3. Miosis (121,164).

A 4. These changes include clouding, opacities, haziness of the lens, broadening and arborization of the lens suture, roughening of the anterior capsule and cataract production after variable periods of exposure ranging from 20 minutes to one hour. (12,17-23,27,31,41,67,71,95,121,122,143,154,155,164,187,189,190,191,).

A 5. Opacities in vitreous fluid. (31,67).

A 6. Temporary eye disturbance, photophobia, hyperemia. (90).

A 7. Biochemical changes consisting of decreased ascorbic acid in the lens within 18 hours post irradiation, decreased glutathione 24 to 48 hours post irradiation, reduced enzyme systems, in experimental animals. Among individuals working in radiofrequency fields of 67 to 230 MHz, a study of speech and visual motor reactions showed that reaction speed was significantly decreased. In other observations increased and subsequent decrease in vision threshold as measured from the edge of the retina were noted when the back or abdomen of experimental subjects completely adapted to darkness were exposed to 3 to 300 MHz. Patients who were dark adapted showed increased sensitivity of marginal vision when

their heads were exposed to 1 to 10 cm waves ( $3 \times 10^3 - 3 \times 10^5$ ). Accidental exposure of the head and upper-trunk of man to 10,000 MHz  $10 \text{ mW/cm}^2$  for 15 minutes produced visual disturbances. (19,20,32,56,75,86,90,115,121,183).

A 8. Countermeasures for this level include the wearing of protective goggles, operation within the  $10 \text{ mW/cm}^2$  maximum permissible exposure. Periodic medical examination such as slit lamp examination of the lens and complete cardiovascular and endocrine examination; visual and aural fatigue can be eliminated by rest. (13,159,164).

A 9. Exposure of man to 9,500 MHz (pulsed)  $5 \text{ mW/cm}^2$  did not result in hearing sensation for audio-modulated waves. (29).

A 10. Humans in a radiofrequency field of 216 to 6,500 MHz with an average intensity as low as  $0.4 \text{ mW/cm}^2$  have hearing sensations produced by audio-modulated waves (29,52).

A 11. Exposure of the auditory region of the cortex to 3 to 300 MHz produces changes in auditory threshold. Exposure of rats to 3,000 to 10,000 MHz  $1 \text{ to } 10 \text{ mW/cm}^2$  produces an initial increase in excitability followed by subthreshold inhibitions manifested as a lowered sensitivity to auditory stimuli. (87,165).

A 12. Countermeasures are difficult because these changes occur within the maximum permissible exposure of  $10 \text{ mW/cm}^2$ . Screening by RF absorbing materials is indicated. (140,151).

A 13. In occupationally exposed individuals in fields between 3 and 300 MHz an increase in olfactory thresholds were found which could be indicative of sympathetic and parasympathetic inhibition. (56,102).

A 14. No physiologic decrements were observed in individuals working in radiofrequency fields of 0.3 to 0.5 MHz (47,57,81,110,118,126, 146,184).

A 15. Individuals working in a 75 MHz field showed considerably higher skin temperature on the forehead and fingers than controls. Localized exposure of the skin of rats to 10,000 MHz, 350 mW/cm<sup>2</sup> showed a linear temperature rise during the initial 3 to 4 minutes at a depth of 1 to 2 mm. During exposures at 350, 220, and 100 mW/cm<sup>2</sup> for 5 to 20 minutes thermal equilibrium was established (81,126,137,146).

A 16. Animals exposed to 3 to 10 MHz, 1 mW/cm<sup>2</sup> showed morphological and histochemical signs of irritation of receptor and interoreceptor apparatus after one hour daily exposures for 5 to 9 months. (168,179).

A 17. Local irradiation with 3,000 MHz, 350 mW/cm<sup>2</sup> to the ventral body area of rabbits reduced cardiac rhythm; radiation of the same body area while the skin was anesthetized did not alter cardiac rhythm. This suggests that reduced cardiac rhythm is a function of skin receptor reaction to microwaves. Rats exposed to 10,000 MHz pulsed, 100 mW/cm<sup>2</sup> for six minutes showed changes in nucleic acid metabolism in the skin. (78,99,179).

A 18. Protective metallic woven suits which, however, are quite cumbersome has been recommended (140,151).

A 19. Animals exposed to 3000 to 10,000 MHz, 100 mW/cm<sup>2</sup>, for several hours developed severe burns in selected body areas, mainly over bony prominences. (121,126).

A 20. Dogs exposed to 3,000 MHz, 165 mW/cm<sup>2</sup> for periods ranging from 2 to 3 hours developed severe skin burns and ulceration; this exposure is in the lethal range for this species. (12 ).

A 21. Accidental exposure of the head and upper trunk of man to 10,000 MHz, 10 mW/cm<sup>2</sup> for 15 minutes resulted in asthenia. Dogs exposed to 2880 MHz, 165 mW/cm<sup>2</sup> developed akinesia. (90,121).

A 22. Rats exposed to 3 to 300 MHz, 10 mW/cm<sup>2</sup> showed decreased

swimming ability. Chickens, pigeons, and sea gulls exposed to 9,300 and 16,000 MHz (pulsed), 10 mW/cm<sup>2</sup> showed sustained extensor activity of wings and legs commencing within a few seconds. These birds showed distress and unsteady gait. Whole-body exposure of chicks to 24,000 MHz produced staggering gait and muscular weakness. (68,104,116,176).

A 23. Dogs exposed to 200 or 2800 MHz (CW or pulsed), 165 mW/cm<sup>2</sup> show disturbed equilibrium and ataxia. (2,121).

A 24. Animals exposed to 2450 to 10,000 MHz, 100 mW/cm<sup>2</sup> developed severe skin burns. (121,179).

A 25. Rats and rabbits exposed to 3000 MHz, 40 mW/cm<sup>2</sup> for 30 minutes show injury to skin receptors, which is greater than to the receptors of internal organs. (179).

A 26. Same as A 23.

A 27. Mice exposed to 3000 MHz or 800 MHz, 43 mW/cm<sup>2</sup> did not show any effect on growth. Exposure of the hind limb of rats to 2720 MHz did not produce any disturbance in bone growth. (11,135).

A 28. In rats exposed to 10,000 MHz, 1 mW/cm<sup>2</sup> there was no appreciable change in blood pressure after several weeks of exposure for 30 minutes daily. (58).

A 29. Mice or rats exposed to 800 MHz or 24,000 MHz at field densities up to 43 mW/cm<sup>2</sup> did not show any evidence of bone marrow alteration. (8,145).

A 30. Rabbits exposed to 3000 MHz, 1 mW/cm<sup>2</sup> showed no changes in cholinesterase activity in the blood after multiple 90 minute exposures. (130).

A 31. In both animals and man exposed to various frequencies ranging from 3 to 24,000 MHz at field densities as low as 10 mW/cm<sup>2</sup> blood changes have been reported including increased temperature of jugular blood,

decrease in lymphocytes, increase in Cx reactive protein, alteration in electrolyte content and blood protein ratios, and increased blood coagulation time. Human lymphocytes cultured under 3000 MHz at  $7 \text{ mW/cm}^2$  showed numerous transformations. (25,97,116,126,131,153,167,171,182).

A 32. At 500 MHz,  $350 \text{ mW/cm}^2$  there was evidence of increased phagocytosis of intravenously injected colloidal carbon. (142,177).

A 33. Exposure of sciatic and radial nerves of cats to 10,000 MHz results in contraction of leg muscles. Sixteen thousand MHz exposure at less than  $10 \text{ mW/cm}^2$  causes neuromuscular responses in birds. Twenty-four thousand MHz produced neuromuscular effects in chicks. (36,111,175).

A 34. Exposure of mice to 10,000 MHz,  $20 \text{ mW/cm}^2$  causes increased growth rate after initial suppression. (128).

A 35. Individuals working in radiofrequency fields of 3 to 30,000 MHz show various cardiovascular effects such as arterial hypotension, bradycardia, sinus arrhythmia, reduction of ECG spikes, ventricular extrasystole, disruption in intrauricular conduction, tachycardia, coronary spasms. Similar results more or less have been reported in animals such as rabbits and dogs exposed to 100 to  $200 \text{ mW/cm}^2$ . When the head of the dog is exposed to 2450 MHz, there was evidence of increased heart rate and diastolic pressure. In rats vascular alteration in the brain and internal organs are seen after 3,000 MHz,  $40 \text{ mW/cm}^2$ . Accidental exposure of man to 10,000 MHz  $15 \text{ mW/cm}^2$  for 45 minutes produced tachycardia (10,16,30,39,54,55,58,60,62,76,89,92,95,107,109,116,127,134,138,139,148,162,172,173,180,184,186).

A 36. Accidental exposure of man to 10,000 MHz,  $15 \text{ mW/cm}^2$  for 45 minutes produced a neutrophil leucocytosis. In man and animals at exposures ranging from 300 to 24,000 MHz at 10 to  $40 \text{ mW/cm}^2$  alteration in various bone marrow functions and blood cell components, such as, granulo-



cytes, leukocytes, red blood cells, reticulocytes, hemoglobin, and red cell life span. (35,38,62,88,96,100,109,118,120,170,178,182).

A 37. Whole-body exposure of rats to 24,000 MHz pulsed at 15 mW/cm<sup>2</sup> resulted in a 5° C temperature rise in 27 minutes. Mice and rats exposed to 3,000 MHz at 8 mW/cm<sup>2</sup> showed slight hyperplasia of the reticuloendothelial system of the spleen. (37,125).

A 38. Exposure of rabbits and rats in the lumbar region to 24,000 MHz resulted in vascular dilation and subcutaneous hemorrhage. Rabbits and rats subjected to 3000 MHz, 10 mW/cm<sup>2</sup> showed changes in the protein fraction of blood serum, residual nitrogen in the blood, amino acid in urine and decrease in RNA content in the liver, brain, and spleen. (77,131).

A 39. Workers exposed to 3,000 to 30,000 MHz under industrial conditions showed increase in blood sugar level and fluctuation in creatinine, lactic acid, and pyruvic acid levels. Workers exposed to 3 to 300 MHz showed increase in blood histamine content. Decreased cholinesterase activity has been noted in the liver, heart, and brain stem in rabbits and rats. At 100 to 2450 MHz, effects on dielectric constant of blood decreased as frequency decreased. Forty-eight MHz, 3.5 watts for 5 minutes evokes changes in the gastrocnemius and sartorius muscles of the frog. In humans exposed to 3 to 30 MHz significant deviation in glucose tolerance occurs and an increase in gamma-globulin was noted. (3,10,39,69,128,130,159,160,167,180,185).

A 40. In rabbits or mice exposed to 2450 MHz, 70 mW/cm<sup>2</sup> right auricular pressure increased for 2 to 10 minutes then decreased precipitously before death; 10,000 MHz, 400 mW/cm<sup>2</sup> produced myocardial necrosis. (152).

A 41. Whole-body exposure of dogs to 24,000 MHz produced no effect on female reproductive organs. Whole-body exposure of guinea pigs to 3000 MHz did not effect reproduction. Exposure to 3000 MHz, 8 mW/cm<sup>2</sup>

did not effect mating of mice or rats. (8,34,45,50,125).

A 42. In animals and man exposed to 2000 to 3000 MHz, adrenal cortical changes, increased blood sugar, and alteration in creatinine, lactic, pyruvic, and blood ascorbic acid levels are noted. (10,98a).

A 43. Exposure of dogs to 3000 MHz, 100 mW/cm<sup>2</sup> results in hypophysial-hypothalamic-adrenal response. In man chronically subjected to 300 to 3000 MHz during routine operational procedures, functional activity of the hypophysial adrenal cortex system is lowered. (91,121,181).

A 44. In individuals occupationally exposed to microwave fields ranging from 3 to 300,000 MHz, thyroid activity is increased. Increased I-131 uptake and alteration in thyroid function is noted in dogs after exposure to 1280 MHz and 2800 MHz, 50 mW/cm<sup>2</sup>. (39,40,49,91,119,121,157,169).

A 45. Exposure of the scrotal area results in varying degrees of testicular damage such as edema, enlargement of the testis, atrophy, fibrosis, and coagulation necrosis of seminiferous tubules in rats, rabbits, or dogs exposed to 2450, 3000, 10,000 or 24,000 MHz at field intensities of 250 mW/cm<sup>2</sup>. Minimal changes have been noted in dogs at field intensities of about 10 to 15 mW/cm<sup>2</sup>; these, however, were simply temperature increases rather than pathological changes. Exposure of 2 to 3 month old mice to 10,000 MHz, 400 mW/cm<sup>2</sup> for 5 minutes causes a decrease in the number of estral cycles with increase in duration of individual cycles. (26,46,61,62,66,71,72).

A 46. Individuals occupationally exposed in 3 to 300,000 MHz fields had lower 17-hydroxycorticosteroid levels in blood, plasma, and urine in comparison with controls indicating depressed functional activity of the hypophysial-adrenal-cortical system. Rats exposed to 2450 or 24,000 MHz, 250 mW/cm<sup>2</sup> showed decreased androgen output. Exposure of pancreatic amylase of swine to frequencies of 10 to 40 MHz resulted in deactivation. (4,10,19,63,91,98a).

A 47. Testicular biopsy in a radar operator revealed tubular atrophy with focal necrosis and interstitial edema; hypospermia continued for a

period of at least a year after the patients last exposure. Exposure of rats to 2816 MHz, 60 mW/cm<sup>2</sup>, 2 minutes daily over a period of time resulted in severe damage to the testes. (123,156).

A 48. The epigastric region of humans was exposed to 13.56, 40 and 2375 MHz without evident disturbance in the periodic motor activity of the stomach. In rats exposed to 3,000 MHz, 10 mW/cm<sup>2</sup>, no appreciable morphologic changes in internal organs were noted after 30 minutes of exposure. (149,180).

A 49. Accidental exposure of man to 10,000 MHz for 45 to 47 minutes, 15 mW/cm<sup>2</sup> resulted in nausea. Whole-body exposure of rats to 24,000 MHz (pulsed), 15 mW/cm<sup>2</sup> for 27 minutes resulted in a 5° C temperature rise in the stomach and rectum. (2,37,90,150).

A 50. Whole-body exposure of rats to 24,000 MHz pulsed, 50 mW/cm<sup>2</sup> for 27 minutes resulted in a 5° C temperature rise in the kidneys. (37).

A 51. Whole-body exposure of mice to 27.2 MHz produced an increase in respiratory rate. (33).

A 52. Whole-body exposure of rats to 24,000 MHz (pulsed), 50 mW/cm<sup>2</sup>, 27 minutes resulted in a 5° C temperature rise in the liver. (37).

A 53. Rats exposed to 3000 MHz, 20 mW/cm<sup>2</sup> for 30 minutes showed negligible overheating symptoms without reversible morphologic changes in internal organs. Mice were exposed to 39 and 1.6 MHz; a number of changes in subcellular structures were found after exposure; these included many binuclear cells in the liver, irregular thickening, and breaks in the nuclear membrane. (166,180).

A 54. Radiation with 2450 MHz over the kidney in man resulted in decreased glomerular and renal plasma flow. Exposure of rats to 3000 MHz, 10 mW/cm<sup>2</sup> produced changes in appetite patterns. Whole-body exposure of mice to 27.2. MHz resulted in decreased oxygen consumption.

Whole-body exposure of rats to 2450 MHz resulted in increased rate of glucose absorption and transfer of glucose in the small intestine. Local irradiation of a portion of the stomach in dogs with 3 to 300 MHz results in stimulation of gastric juice secretion. (2,33,48,55,93,98,113,130).

A 55. Gastric ulcers have been produced in rabbits following exposure of the epigastric region to 300 to 300,000 MHz at 70 to 160 mW/cm<sup>2</sup>. (141).

A 56. Exposure of mice, rabbits, or rats either whole-body or head alone to fields between 2450 and 24,000 MHz, 70 mW/cm<sup>2</sup> may produce variable damage to organs, such as, liver and kidney abscesses, hemorrhage and progressive fibrosis, of the brain, lungs, liver, and kidneys, lung congestion, and thrombic emboli. (60,77,141,144).

A 57. Rabbits exposed to 3000 MHz (CW) or 10,000 MHz (pulsed) at 5 mW/cm<sup>2</sup> showed no changes in EEG tracings. (7).

A 58. Rabbits exposed to 10,000 MHz (pulsed) 5 mW/cm<sup>2</sup> showed no evidence of morphologic damage to the brain. Exposure of the head of the dog to 2450 MHz (CW) produced no effect on brain or cerebrospinal fluid. (7,161).

A 59. A nociceptive reflex in cats occurs after 10,000 MHz, 200 mW/cm<sup>2</sup> focal irradiation. Whole-body exposure of rabbits and rats to 24,000 MHz results in muscle spasms, tremors, convulsions, stimulation and depression of activity. (77,112).

A 60. EEG tracings in rabbits exposed to 3000 MHz (pulsed) 5 mW/cm<sup>2</sup> showed slight desynchronization from the motor region; at 20 mW/cm<sup>2</sup> variations in the amplitude were observed. Rabbits irradiated with 300 to 3000 MHz showed changes in the EEG; 300 MHz had the greatest biologic effect while 3000 MHz had proportionately less pronounced effects. Pulsed microwaves produced a greater effect than CW microwaves. Rabbits exposed to

40 MHz,  $0.1 \text{ mW/cm}^2$ , show EEG changes in the cortical and subcortical brain structures produced by a 3 minute exposure. Exposure of rabbits to 300, 577, or 2400 MHz (CW) for 5 minutes at power levels as low as  $0.02 \text{ mW/cm}^2$  resulted in EEG changes in more than 50% of the animals studied. In individuals occupationally exposed in microwave fields of 3 to 300 MHz, lowering of the alpha index and slower waves are noted. An individual exposed to 10,000 MHz, 15 to  $20 \text{ mW/cm}^2$  for 10 to 15 minutes showed lowered voltage, a rapid beta rhythm and a slow theta rhythm. (7, 24, 43, 44, 64, 83, 85, 91, 167, 182, 192).

A 61. Rabbits exposed to 3000 MHz (pulsed or CW), 5 to  $20 \text{ mW/cm}^2$  showed evidence of brain injury; cells of the cortex, cerebellum and subcortical structures had deficient tigroid content, vacuolization was observed in some cells, proliferation of glial cells, congestion of the meninges and superficial cerebral cortex vessels was frequently observed at  $30 \text{ mW/cm}^2$ ; some red cell effusion and enlarged perivascular spaces, was noted. There were more pronounced morphologic changes in the nervous system of rats following 3000 MHz than 10,000 MHz at 1 to  $10 \text{ mW/cm}^2$ . Pulsed waves are more effective than CW. Exposure of cats for 1 hour to 10,000 MHz  $400 \text{ mW/cm}^2$  resulted in injury to cerebral and spinal cord nerve cells. Changes occurred in the tigroid substance and in other components of nerve cells in the cerebrum and spinal cord of cats subjected to 300 to 300,000 MHz,  $400 \text{ mW/cm}^2$ . In animals exposed to 14 to 88 MHz damage to neural structures consisting of thickening of neural fibers, swelling and vacuolization of cell protoplasm in the hypothalamic area and the medulla oblongata and local karyocytolysis of individual neurons are noted. (7, 14, 53, 180).

A 62. Rabbits whose heads were exposed for 30 minutes to 3 to 300 MHz show increased excitation of cortical and other visual analyzers.

Exposure of the head of monkeys to 390 MHz results in alternation of arousal and drowsy periods. Alteration in cellular protein metabolism of the nervous system is seen in experimental animals following 3000 to 30,000 MHz at  $10 \text{ mW/cm}^2$ . Increase in brain cholinesterase is noted after 3000 to 30,000 MHz. In individuals occupationally exposed to frequencies ranging from 3 to 10,000 MHz at levels as low as  $1 \text{ mW/cm}^2$  nervous system effect is noted i.e. decrease in speech and visual motor reaction, increase in olfactory thresholds, general weakness, lower working capacity, increased irritability, headaches, dizziness, lowered emotional status, apathy, hypokinesia, loss of memory, and or insomnia. (5,36,44,56,74,84,109,130,132,139,157,158,181,182).

A 63. In individuals occupationally exposed to frequencies ranging from 3 to 300,000 MHz symptoms of a neurosis like complex, or a quasi neurotic reaction has been noted. (42,43,44).

A 64. Degeneration of neurons in the cerebral cortex and retrograde changes in the kidney and myocardium of rabbits have been produced by exposure to 200 MHz. Head exposure of rabbits to 2450 MHz results in focal lesions in the cerebral cortex. Whole-body exposures of rats to 1430 MHz produced lesions of the brain (133,163,180).

A 65. Death has occurred in various species after exposure to CW or pulsed 200 to 24,000 MHz at power levels ranging from 50 to  $800 \text{ mW/cm}^2$  for periods of time varying from several minutes to several hours. (2,15,16,36,108,121,126,157).

A 66. In conditional response studies in dogs irradiated with 50 MHz to specific zones of the cerebral cortex exposure at 20 to 25 watts caused defensive reactions and deterioration of discrimination. At fields of 3 to 300 MHz, rats exposed at  $10 \text{ mW/cm}^2$  showed changes in conditional response activity after several one hour daily exposures.

Exposure of a pigeons head to a frequency field produced by a 35 watt generator for a period of 3 to 5 minutes caused latent periods of conditioned food reflexes to extend to more than twice normal time. Rats exposed at  $10 \text{ mW/cm}^2$  showed changes in some conditional activity after several one hour daily exposures. Exposure of rats to 2860 MHz,  $30 \text{ mW/cm}^2$ , for more than two minutes produced changes in conditional responses. At 3000 MHz  $10 \text{ mW/cm}^2$  30 minutes daily changes in conditional responses which are more pronounced in pulsed than continuous microwaves such as, changes characterized by increased excitability and decrease in inhibitory processes are noted. Rats given head irradiation at 24,500 MHz try to avoid the microwave field suggesting awareness of a stimulus. In mice exposed to 10,000 MHz,  $450 \text{ mW/cm}^2$  for 5 minutes a partial decrease in conditional response is noted up to three days after exposure. Brief exposure of rabbits to 3 MHz at  $10 \text{ mW/cm}^2$  intensifies conditional responses to different stimuli whereas prolonged exposure produced an inhibitory effect. In rats exposed to 300,000 MHz,  $40 \text{ mW/cm}^2$  for 15 minutes for a total of 99 times shifts in reflex activity were found with pulsed and continuous microwaves characterized by disinhibition and a depression of reflex activity. However, the effects of the pulsed microwaves were more pronounced and occurred earlier during the first to 19th exposure. Reflex shifts in animals exposed to continuous wave microwaves occurred considerably later in the 81st to 99th exposure. (9,40,62,65,77,80,82,101,102,103,105,106,107,109,123,124,147,157).

A 67. Whole-body exposure of man to 200 to 300 MHz produces a buzzing or knocking sound which was heard no matter where radiation was aimed; source was identified as a short distance behind the head. Whole-body exposure of animals to 3000 MHz results in movement to positions where irradiation makes them less uncomfortable, dogs show agitation and apprehension. Occupationally employed individuals who have been exposed

to 6000 to 10,000 MHz exhibit functional disorders of the nervous system characterized by dystonia, insomnia, and amnesia. Chickens exposed to 10,000 MHz,  $30 \text{ mW/cm}^2$  for 15 minutes show a tendency to move away from the radar beam. Twenty-four thousand MHz (pulsed)  $109 \text{ mW/cm}^2$  produces changes in behavioral patterns in rats. (51,68,73,79,116,129,174).

A 68. Individuals occupationally exposed to fields ranging from 3 to 300,000 MHz show a variety of subjective symptoms which include neural disturbances and neurasthenia. Rats exposed to 300 to 900 MHz, CW show behavioral changes. (41,44,70).



## APPENDIX C

### Critique

Quantitation of the biological response to microwaves is a complex problem because of the wide frequency spectrum, the large number of physical and biological variables and the interrelationships of these variables.

The factors which have to be considered include: frequency, intensity, waveform (continuous wave, pulsed, and modulation), animal orientation with respect to source, size of animal with respect to wavelength, portion of the body irradiated, exposure time-intensity factors, environmental conditions (temperature, humidity), and shielding. The condition of the subject such as state of health, restraint, medication, etc. has to be considered. These variables, individually and in combination, affect the biological response to microwaves. An effect observed at a particular frequency should not be attributed to the frequency alone without consideration of the many variables noted above and their interrelationships.

Since radiation in the millimeter range tends to penetrate only a few millimeters into the body, while radiation of longer wavelengths penetrates progressively deeper, the internal structures of smaller animals, being closer to the body surface, may be more strongly affected by certain wavelengths of electromagnetic radiation than those of larger animals, thus producing discrepancies in any comparative evaluation. The inherent thermal regulation ability of the animal is also a factor in such biological responses. The intensity of radiation required to produce a given biological effect can vary considerably with frequency. When a particular biological effect is reported at a specific frequency it does

not mean that the effect occurs only at that frequency; the effect may be produced at other frequencies, but the particular parameter may not have been studied.

Interpretation of the relationship of frequency to a particular biological response should be approached with caution since not all investigators look for all responses at all frequencies. Acquisition of data are determined by the particular type of generating equipment available and the interests of the investigator.

## APPENDIX D

### ABSTRACTS FROM ARTICLES ON BIOLOGICAL EFFECTS OF MICROWAVE RADIATION

Schwan, H. P., and Li, K., "Hazards Due to Total Body Irradiation by Radar", Proc. IRE, Vol 44, p 1572.

At 10-cm wavelength irreversible damage to the eye occurs if the energy flux is in excess of about  $0.2 \text{ watt/cm}^2$ . Intolerable temperature rise, due to total body irradiation may be anticipated for flux values in excess of  $0.02 \text{ watt/cm}^2$ . Hence a discussion of hazards due to total body irradiation is of primary interest. This paper presents data which analyze the mode of propagation of electromagnetic radiation into the human body and resultant heat development.

- (1) The amount of absorbed energy is near 40 percent at frequencies much smaller than 1000 and higher than 3000 Mc. In the range from about 1000 to 3000 Mc the coefficient of absorption may vary from 20 to 100 percent.
- (2) Radiation of a frequency below 1000 Mc will cause deep heating, not well indicated by the sensory elements in the skin and, therefore, considered especially dangerous. Radiation of a frequency between 1000 and 3000 Mc will be absorbed in both body surface and in the deeper tissues, the ratio being dependent on parameters involved.
- (3) Arguments are advanced in support of tolerance values for total body irradiation near  $0.01 \text{ watt/cm}^2$ .

Conclusions of practical value are: (1) Since sensory elements are located primarily in the skin, low-frequency radiation ( $f < 1000 \text{ Mc}$ ) is much more dangerous than high-frequency radiation. (2) Radiation of very high frequency ( $f > 3000 \text{ Mc}$ ) causes only superficial heating with much the same effects as infrared and sunlight. The sensory reaction of the skin should provide adequate warning.

Kulberg, M. E., "Kadar Can be Tamed", Natl. Safety News, Vol 81, pp 22-23, 56, 70 (May 1960).

Major hazards associated with radar include: (1) material handling hazards, particularly with portable equipment and during its installation or removal; (2) falls from towers or in or around the radar unit; (3) electrical hazards connected with use and servicing of high-voltage electrical equipment, (4) flammable oil fire hazard in certain transformers and condensers of high-voltage electrical equipment (in addition, a fire hazard may exist when flammable gases, fumes, vapors, or explosives or other highly combustible materials are present in the radar beam; (5) toxicity of gas fills in certain wave guides; (6) hazardous x-radiation from high-voltage tubes; (7) hazardous radioactivity from radioactive activators in certain radar switching tubes; (8) harmful effect of electromagnetic radiation on the body or its parts. The hazard of greatest interest seems to be that of electromagnetic radiations. When placed in a radar beam, the body will be warmed, as will any other conductive object. If the temperature rise exceeds the capacity of the body to dissipate the energy applied, the condition aggravates itself, and it is possible that damage could occur. In the event of low-power radar sets, such as used in radar speed-measuring devices or weather-mapping radar on aircraft, the amount of power available is too low to cause difficulty. A possible exception is made in the case of the eyes, if a direct observation is made of the output of the unit. The eyes and other parts of the body not provided with many blood vessels tend to rise in temperature more rapidly than the rest of the body. Studies indicate that harmful body heating cannot possibly result if the incident energy level does not exceed  $1 \text{ mw/cm}^2$  at the eyes, kidney, and liver.

Morgan, W. E., "Microwave Radiation Hazards, A.M.A. Arch. Ind. Health, Vol 21, pp 570-573 (June 1960).

The author offers the following suggestions for the control of possible radiation hazards: (1) avoid any exposure to radio-frequency energy having a power density of  $0.01 \text{ w/cm}^2$  or greater. Areas accessible to transit personnel and having a power density equal to or greater than  $0.01 \text{ w/cm}^2$  should be posted with a caution sign and flashing light, and should not be occupied for any length of time; (2) do not make detailed visual examination of any microwave radiator, reflector, wave guide horn, or magnetron during periods of transmission; (3) limit the number

of personnel having access to areas immediately adjacent to test stands or benches containing equipment radiation energy of hazardous power. (only those required to perform specific tests should be present); (4) use dummy loads, water loads, or other absorbent materials whenever possible to absorb the energy output of the transmitter while it is being operated or tested; (5) when Item No. 4 cannot be complied with; provide absorbent screening to isolate test stands from each other or from adjacent administrative areas which may be affected by the microwave radiation. It is believed that repeated exposure to radar waves while observing proper precaution does not lead to any cumulative or chronic effects on the body. This seems to be proven by the lack of evidence showing that anyone has been seriously injured from working with radar equipment. There have been some reports in the past concerning alleged injuries, but it is the opinion of most medical scientists that the reported disorders were not caused by radar.

Lubin, M., et al., "Effects of Ultra-High-Frequency Radiation on Animals", A.M.A. Arch. Ind. Health, Vol 21, pp 555-558 (June 1960).

Twenty-nine rabbits and 44 rats were subjected to repeated whole-body exposure with ultrahigh-frequency radiation at about 400 Mc. About an equal number of animals served as controls. No pathological damage was found which could be attributed to the effects of radiation.

Goldman, D. E., "Short Wave Electromagnetic Radiation as a Hazard to Personnel", NP-9992, Lecture and Review Series No. 60-6. (Naval Research Institute, Bethesda, Md.) 8 pp (Sept. 17, 1960). Obtainable from: Office of Technical Services, U. S. Department of Commerce, Washington 25, D. C.

The radiation hazards of short-wave electromagnetic radiation are discussed. It is pointed out that electromagnetic radiation produces electrical and magnetic forces and generates heat upon contact with biological systems. Reactions are induced which are potentially dangerous to animals. Reported cases of eye damage and other serious injuries to personnel working with high-powered radar generators are discussed. Results are reported from studies with monkeys in which a number of neurological disturbances were induced by exposure to radio frequencies in the 300 to 400-Mc range. Results of other animal studies are discussed briefly, and reaction mechanisms involved in the biological effects of primary radiations in the range 100 to 30,000 Mc are summarized. Data are presented

from measurements of the conductivity and dielectric constant of skin; the dielectric constant of selected tissues; the percent energy absorption by whole rats, rabbits, and dogs; and the cooling time constant for mice, rats, rabbits, dogs, and humans exposed to radiation in this energy range. Data are also included on the heat input and output of the body at various temperatures under steady-state conditions.

Weiss, M. M., and Mumford, W. W., "Microwave Radiation Hazards", Health Physics (London), Vol 5, pp 160-168 (June 1961).

A review of the published literature on the exposure of animals to microwave radiation indicates that the principal hazard results from the heating effect as the energy in the microwave radiation is absorbed in the body. The interpretation of extensive experimental data on small fur-bearing animals has led to the establishment of recommended exposure limits. These limits are discussed from the standpoint of the probable safety factor involved for total immersion of the human being in the microwave radiation field and for localized exposure confined to particular portions of the anatomy. Precautionary measures are discussed and a method of estimating the distance from a radiating antenna is presented. Some presently available microwave radiation-intensity measuring devices are described.

Minecki, L., "Critical Evaluation of Maximum Permissible Levels of Microwave Radiation", Arhiv hig. Rada, Vol 15, pp 47-55 (1964).

The biological effect of microwaves and electromagnetic radiation of lower frequency is reviewed, with particular reference to the problem of the so-called extrathermal effect, which -- in the author's opinion -- should be given due consideration. The assumption that the biological effect of microwaves is only based on thermal effect, unduly simplifies the whole problem, especially in connection with the determination of maximum permissible doses. Results are presented of the clinical observations of a larger group of persons occupationally exposed to microwaves ranging from 750 to 200 MHz. These results indicate that in the group with prolonged exposure the occurrence of some symptoms was considerably higher than in the control group. The results of some experimental work on the effect of microwaves, with special reference to the so-called thermal effect, are also

Pelis, L., Jr., "The Hazards of Low Voltage Radiation", Ind. Med. & Surg., Vol. 33, pp 866-868 (Dec. 1964).

In the absence of a foolproof standard and to minimize the hazards of radio-frequency radiation the following recommendations should be considered: unauthorized persons should be prohibited from entering microwave areas. Those areas which may exceed the maximum permissible level should be posted with caution signs and other warning devices including visible or audible signals. Equipment power should be shut off whenever wave guides are open for the purpose of making changes during the experimental work. Exposure of whole body to microwave radiation should be avoided. Dummy loads such as water loads or other absorbent material should be used to absorb the energy output of the transmitter while it is being operated or tested. Absorbent screening should be installed to isolate test stands from one another and from adjacent workers. Calculations should be made to determine areas of probable unsafe exposure. Where it is known or suspected that workers will be exposed to microwave radiation in excess of  $10 \text{ mw/cm}^2$ , a preplacement medical examination should be given the worker.

| 1                                       | 2                    | 3      | 4     | 5    | 6             | 7     | 8    | 9           | 10                                           | 11          | 12          | 13                  | 14      |
|-----------------------------------------|----------------------|--------|-------|------|---------------|-------|------|-------------|----------------------------------------------|-------------|-------------|---------------------|---------|
| ENERGY FORM                             | LEVEL OF INTERACTION | CORNEA | PUPIL | LENS | OPTICAL FLUID | CONES | RODS | EYE MUSCLES | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COGNITIVE ABILITIES | REMARKS |
|                                         |                      |        |       |      |               |       |      |             | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                     |         |
|                                         |                      |        |       |      |               |       |      |             |                                              |             |             |                     |         |
|                                         |                      |        |       |      |               |       |      |             |                                              |             |             |                     |         |
|                                         |                      |        |       |      |               |       |      |             |                                              |             |             |                     |         |
|                                         | SAFE                 |        |       |      |               |       |      |             |                                              |             |             |                     |         |
|                                         | DEGRADATION          |        |       |      |               |       |      |             |                                              |             |             |                     |         |
|                                         | INCAPACITATION       |        |       |      |               |       |      |             |                                              |             |             |                     |         |
|                                         | LETHALITY            |        |       |      |               |       |      |             |                                              |             |             |                     |         |
| MAGNETO STATIC AND ELECTROSTATIC FIELDS |                      |        |       |      |               |       |      |             |                                              |             |             |                     |         |

Visual sensations produced by pulses of 100K gauss fields were observed in close vicinity of high field-strength magnets (1m to 5m from poleshoes). See Appendix A 1 and 2.

No symptoms were reported when subjects were exposed to high field-strength electric fields (10,000V/m)



|                                         |                 |                      |      |            |              |         |               |                                              |          |             |             |                 |         |
|-----------------------------------------|-----------------|----------------------|------|------------|--------------|---------|---------------|----------------------------------------------|----------|-------------|-------------|-----------------|---------|
| 1                                       | 2               | 3                    | 4    | 5          | 6            | 7       | 8             | 9                                            | 10       | 11          | 12          | 13              | 14      |
| MAGNETO STATIC AND ELECTROSTATIC FIELDS | ENERGY FORM     | LEVEL OF INTERACTION | DRUM | OSCILLATES | ROUND WINDOW | COCHLEA | DAMAGE TO EAR | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC | COURTESY/STRESS | REMARKS |
|                                         | SAFE            |                      |      |            |              |         |               |                                              |          |             |             |                 |         |
|                                         | DEGRA-DATION    |                      |      |            |              |         |               |                                              |          |             |             |                 |         |
|                                         | INCAPA-CITATION |                      |      |            |              |         |               |                                              |          |             |             |                 |         |
|                                         | LETHA-LITY      |                      |      |            |              |         |               |                                              |          |             |             |                 |         |

[illegible]

| 1           | 2                    | 3                       | 4                 | 5               | 6                                            | 7 | 8 | 9               | 10       | 11          | 12          | 13 | 14                                                                                                               |
|-------------|----------------------|-------------------------|-------------------|-----------------|----------------------------------------------|---|---|-----------------|----------|-------------|-------------|----|------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM | LEVEL OF INTERACTION | DAMAGE TO SKIN (SENSOR) |                   |                 | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |   |   | COUNTERMEASURES |          |             | REMARKS     |    |                                                                                                                  |
|             |                      | PRESSURE SENSE          | TEMPERATURE SENSE | CHEMICAL (PAIN) |                                              |   |   |                 | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC |    | Electric fields (10,000V/m) produce sensations of standing-up of hair, and corona discharges have been observed. |
|             | SAFE                 |                         |                   |                 |                                              |   |   |                 |          |             |             |    |                                                                                                                  |
|             | DEGRA-DATION         |                         |                   |                 |                                              |   |   |                 |          |             |             |    |                                                                                                                  |
|             | INCAPA-CITATION      |                         |                   |                 |                                              |   |   |                 |          |             |             |    |                                                                                                                  |
|             | LETH-LIT             |                         |                   |                 |                                              |   |   |                 |          |             |             |    |                                                                                                                  |

NOT REPRODUCIBLE

[illegible]

| 1               | 2                                            | 3                | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |  |
|-----------------|----------------------------------------------|------------------|---|---|---|---|---|---|----|----|----|----|----|--|
| ENERGY FORM     | MAGNETO STATIC AND ELECTROSTATIC FIELDS      |                  |   |   |   |   |   |   |    |    |    |    |    |  |
|                 | LEVEL OF INTERACTION                         | NOT REPRODUCIBLE |   |   |   |   |   |   |    |    |    |    |    |  |
|                 |                                              | SAFE             |   |   |   |   |   |   |    |    |    |    |    |  |
|                 |                                              | DEGRA-DATION     |   |   |   |   |   |   |    |    |    |    |    |  |
|                 |                                              | INCAPA-CITATION  |   |   |   |   |   |   |    |    |    |    |    |  |
|                 | DAMAGE TO SKIN (COVERING)                    | LETHA-LITY       |   |   |   |   |   |   |    |    |    |    |    |  |
|                 |                                              | EPIDERMIS        |   |   |   |   |   |   |    |    |    |    |    |  |
|                 |                                              | DERMIS           |   |   |   |   |   |   |    |    |    |    |    |  |
|                 |                                              | ANATOMIC         |   |   |   |   |   |   |    |    |    |    |    |  |
|                 | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION | PHYSIOLOGIC      |   |   |   |   |   |   |    |    |    |    |    |  |
| PSYCHOLOGIC     |                                              |                  |   |   |   |   |   |   |    |    |    |    |    |  |
| COUNTERMEASURES |                                              |                  |   |   |   |   |   |   |    |    |    |    |    |  |
| REMARKS         |                                              |                  |   |   |   |   |   |   |    |    |    |    |    |  |

|                                         |                      |       |       |         |          |                 |        |       |          |             |             |                 |         |
|-----------------------------------------|----------------------|-------|-------|---------|----------|-----------------|--------|-------|----------|-------------|-------------|-----------------|---------|
| 1                                       | 2                    | 3     | 4     | 5       | 6        | 7               | 8      | 9     | 10       | 11          | 12          | 13              | 14      |
| ENERGY FORM                             | LEVEL OF INTERACTION | BLOOD | LYMPH | MUSCLES | SKELETON | CARDIO-VASCULAR | NARROW | SPERM | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES | REMARKS |
|                                         |                      |       |       |         |          |                 |        |       |          |             |             |                 |         |
| MAGNETO STATIC AND ELECTROSTATIC FIELDS |                      |       |       |         |          |                 |        |       |          |             |             |                 |         |
|                                         | SAFE                 |       |       |         |          |                 |        |       |          |             |             |                 |         |
|                                         | DEGRA-               |       |       |         |          |                 |        |       |          |             |             |                 |         |
|                                         | DATION               |       |       |         |          |                 |        |       |          |             |             |                 |         |
|                                         | INCAPA-              |       |       |         |          |                 |        |       |          |             |             |                 |         |
|                                         | CITATION             |       |       |         |          |                 |        |       |          |             |             |                 |         |
|                                         | LETINA-              |       |       |         |          |                 |        |       |          |             |             |                 |         |
|                                         | LITY                 |       |       |         |          |                 |        |       |          |             |             |                 |         |

NOT REPRODUCIBLE

| 1                                       | 2                    | 3        | 4         | 5        | 6       | 7      | 8         | 9 | 10 | 11                                           | 12 | 13 | 14      |  |  |
|-----------------------------------------|----------------------|----------|-----------|----------|---------|--------|-----------|---|----|----------------------------------------------|----|----|---------|--|--|
| ENERGY FORM                             | LEVEL OF INTERACTION | ADRENALS | PITUITARY | PANCREAS | THYROID | GONADS | DAMAGE TO |   |    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |    |    | REMAINS |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
| MAGNETO STATIC AND ELECTROSTATIC FIELDS |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         | SAFE                 |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         | DEGRA-DATION         |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         | INCAPA-CITATION      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         | LETHA-LITY           |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          |         |        |           |   |    |                                              |    |    |         |  |  |
|                                         |                      |          |           |          | </      |        |           |   |    |                                              |    |    |         |  |  |

NOT REPRODUCIBLE

[illegible]



|                                         |                      |                         |            |            |             |   |   |              |          |             |             |          |         |                     |  |  |  |  |  |  |  |  |  |  |  |  |
|-----------------------------------------|----------------------|-------------------------|------------|------------|-------------|---|---|--------------|----------|-------------|-------------|----------|---------|---------------------|--|--|--|--|--|--|--|--|--|--|--|--|
| 1                                       | 2                    | 3                       | 4          | 5          | 6           | 7 | 8 | 9            | 10       | 11          | 12          | 13       | 14      |                     |  |  |  |  |  |  |  |  |  |  |  |  |
| ENERGY FORM                             | LEVEL OF INTERACTION | CEREBRAL<br>Hemispheres | CEREBELLUM | BRAIN STEM | SPINAL CORD |   |   | ALPHA RHYTHM | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC | COMMENTS | REMARKS |                     |  |  |  |  |  |  |  |  |  |  |  |  |
| MAGNETO STATIC AND ELECTROSTATIC FIELDS |                      |                         |            |            |             |   |   |              |          |             |             |          |         |                     |  |  |  |  |  |  |  |  |  |  |  |  |
|                                         |                      |                         |            |            |             |   |   |              |          |             |             |          |         | SAFE                |  |  |  |  |  |  |  |  |  |  |  |  |
|                                         |                      |                         |            |            |             |   |   |              |          |             |             |          |         | DEGRA-<br>DATION    |  |  |  |  |  |  |  |  |  |  |  |  |
|                                         |                      |                         |            |            |             |   |   |              |          |             |             |          |         | INCAPA-<br>CITATION |  |  |  |  |  |  |  |  |  |  |  |  |
|                                         |                      |                         |            |            |             |   |   |              |          |             |             |          |         | LETHAL-<br>LITY     |  |  |  |  |  |  |  |  |  |  |  |  |

NOT REPRODUCIBLE

| 1                                         | 2                    | 3                      | 4         | 5                     | 6 | 7 | 8 | 9 | 10                                                 | 11          | 12          | 13      | 14 |
|-------------------------------------------|----------------------|------------------------|-----------|-----------------------|---|---|---|---|----------------------------------------------------|-------------|-------------|---------|----|
| ENERGY FORM                               | LEVEL OF INTERACTION | ASSOCIATIVE<br>SYMBOLS | ILLUSIONS | PSYCHOLOGICAL EFFECTS |   |   |   |   | SPECIFIC ADVERSE<br>EFFECTS DUE TO<br>TRANSMISSION |             |             | REMARKS |    |
|                                           |                      |                        |           |                       |   |   |   |   | ANALYTIC                                           | PHYSIOLOGIC | PSYCHOLOGIC |         |    |
| SECRETARY STATIC AND ELECTROSTATIC FIELDS |                      |                        |           |                       |   |   |   |   |                                                    |             |             |         |    |
|                                           | SAFE                 |                        |           |                       |   |   |   |   |                                                    |             |             |         |    |
|                                           | DEGRA-<br>DATION     |                        |           |                       |   |   |   |   |                                                    |             |             |         |    |
|                                           | INCAPA-<br>CITATION  |                        |           |                       |   |   |   |   |                                                    |             |             |         |    |
|                                           | LETHA-<br>LITY       |                        |           |                       |   |   |   |   |                                                    |             |             |         |    |

#### APPENDIX A - Bibliographic Sources

1. A. Kolin: "Magnetic Fields in Biology," Physics Today, Vol. 21, page 42 ff (1968).
2. M. F. Barnothy, Editor: Biological Effects of Magnetic Fields, Plenum Press, New York, N. Y. (1964)

Add pages if necessary.

APPENDIX B - Amplification of Remarks

Add pages if necessary.

## APPENDIX C - Other Possible Information Sources

Add pages if necessary.

APPENDIX D - Catch-all

Add pages if necessary.

| 1           | 2                    | 3                                                              | 4     | 5                  | 6             | 7                  | 8    | 9                  | 10                                           | 11          | 12          | 13              | 14                                                                                                                                                            |
|-------------|----------------------|----------------------------------------------------------------|-------|--------------------|---------------|--------------------|------|--------------------|----------------------------------------------|-------------|-------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM | LEVEL OF INTERACTION | DAMAGE TO EYE                                                  |       |                    |               |                    |      |                    | SPECIFIC ADVERSE EFFECTS NOT TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                                                                                       |
|             |                      | CORNEA                                                         | PUPIL | LENS               | OPTICAL FLUID | CONES              | RODS | EYE MUSCLES        | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                                                                               |
| ULTRASONIC  | SAFE                 | 0.5W-<br>cm <sup>-2</sup><br>*1 W<br>cm <sup>-2</sup><br>3 min |       |                    |               |                    |      |                    | U N K N O W N                                |             |             | none            | See Appendices A(1,2), B, C.<br><br>* Reported by J. W. Condex, rabbit in waterbath (See Appendix A-2)                                                        |
|             | DEGRA-<br>DATION     | 1.0W-<br>cm <sup>-2</sup><br>* 3W<br>cm <sup>-2</sup><br>3 min |       | none               |               | none               |      | none               | U N K N O W N                                |             |             |                 |                                                                                                                                                               |
|             | INCAPA-<br>CITATION  | 1-2W-<br>cm <sup>-2</sup><br>*3W-<br>cm <sup>-2</sup><br>5 min |       | See<br>note<br>(1) |               | See<br>note<br>(2) |      | See<br>note<br>(2) | U N K N O W N                                |             |             |                 |                                                                                                                                                               |
|             | LETHA-<br>LITY       | 3.0W-<br>cm <sup>-2</sup>                                      |       | See<br>note<br>(1) |               | See<br>note<br>(2) |      | See<br>note<br>(2) | U N K N O W N                                |             |             |                 |                                                                                                                                                               |
|             |                      |                                                                |       |                    |               |                    |      |                    |                                              |             |             |                 | Note (1): Reversible lens changes depending upon duration of exposure and omdiced temperature rise.<br><br>Note (2): Dependent upon temperature rise induced. |

|            |                      |               |          |              |         |   |   |   |                                              |             |             |                 |         |
|------------|----------------------|---------------|----------|--------------|---------|---|---|---|----------------------------------------------|-------------|-------------|-----------------|---------|
| 1          | 2                    | 3             | 4        | 5            | 6       | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14      |
| ULTRASONIC | ENERGY FORM          | DAMAGE TO EAR |          |              |         |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS |
|            | LEVEL OF INTERACTION | DRUM          | OSCICLES | ROUND WINDOW | COCHLEA |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |         |
|            | SAFE                 |               |          |              |         |   |   |   |                                              |             |             |                 |         |
|            | DEGRA-DATION         |               |          |              |         |   |   |   |                                              |             |             |                 |         |
|            | INCAPA-CITATION      |               |          |              |         |   |   |   |                                              |             |             |                 |         |
|            | LETHA-LITY           |               |          |              |         |   |   |   |                                              |             |             |                 |         |



|            |                      |                      |                |                 |   |   |   |   |                                              |             |             |                 |         |
|------------|----------------------|----------------------|----------------|-----------------|---|---|---|---|----------------------------------------------|-------------|-------------|-----------------|---------|
| 1          | 2                    | 3                    | 4              | 5               | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14      |
| ULTRASONIC | ENERGY FORM          | DAMAGE TO NOSE       |                |                 |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS |
|            | LEVEL OF INTERACTION | OLFACTORY EPITHELIUM | OLFACTORY BULB | OLFACTORY TRACT |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |         |
|            | SAFE                 |                      |                |                 |   |   |   |   |                                              |             |             |                 |         |
|            | DEGRADATION          |                      |                |                 |   |   |   |   |                                              |             |             |                 |         |
|            | INCAPACITATION       |                      |                |                 |   |   |   |   |                                              |             |             |                 |         |
|            | LETHALITY            |                      |                |                 |   |   |   |   |                                              |             |             |                 |         |

|             |                      |                   |                      |                    |   |   |   |   |          |             |             |                 |         |                         |      |                  |                     |                |            |
|-------------|----------------------|-------------------|----------------------|--------------------|---|---|---|---|----------|-------------|-------------|-----------------|---------|-------------------------|------|------------------|---------------------|----------------|------------|
| 1           | 2                    | 3                 | 4                    | 5                  | 6 | 7 | 8 | 9 | 10       | 11          | 12          | 13              | 14      |                         |      |                  |                     |                |            |
| ENERGY FORM | LEVEL OF INTERACTION | PRESSURE<br>SENSE | TEMPERATURE<br>SENSE | CHEMICAL<br>(PAIN) |   |   |   |   | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES | REMARKS |                         |      |                  |                     |                |            |
|             |                      |                   |                      |                    |   |   |   |   |          |             |             |                 |         | DAMAGE TO SKIN (SENSOR) |      |                  |                     |                |            |
|             |                      |                   |                      |                    |   |   |   |   |          |             |             |                 |         |                         | SAFE | DEGRA-<br>DATION | INCAPA-<br>CITATION | LETHA-<br>LITY |            |
|             |                      |                   |                      |                    |   |   |   |   |          |             |             |                 |         |                         |      |                  |                     |                | ULTRASONIC |
|             |                      |                   |                      |                    |   |   |   |   |          |             |             |                 |         |                         |      |                  |                     |                |            |

|            |             |                      |                                  |                    |   |   |   |   |    |                                              |             |             |                 |         |
|------------|-------------|----------------------|----------------------------------|--------------------|---|---|---|---|----|----------------------------------------------|-------------|-------------|-----------------|---------|
| 1          | 2           | 3                    | 4                                | 5                  | 6 | 7 | 8 | 9 | 10 | 11                                           | 12          | 13          | 14              |         |
| ULTRASONIC | ENERGY FORM | LEVEL OF INTERACTION | DAMAGE TO KINESTHETIC            |                    |   |   |   |   |    | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS |
|            |             | SAFE                 | POSTURAL SENSIBILITY (LABYRINTH) | GAMMA MOTOR SYSTEM |   |   |   |   |    | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |         |
|            |             | DEGRADATION          |                                  |                    |   |   |   |   |    |                                              |             |             |                 |         |
|            |             | INCAPACITATION       |                                  |                    |   |   |   |   |    |                                              |             |             |                 |         |
|            |             | LETHALITY            |                                  |                    |   |   |   |   |    |                                              |             |             |                 |         |

| 1           | 2                    | 3                                               | 4                                              | 5 | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                                   |
|-------------|----------------------|-------------------------------------------------|------------------------------------------------|---|---|---|---|---|----------------------------------------------|-------------|-------------|-----------------|--------------------------------------|
| ENERGY FORM | LEVEL OF INTERACTION | DAMAGE TO SKIN (COVERING)                       |                                                |   |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                              |
|             |                      | EPIDERMIS                                       | DERMIS                                         |   |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                      |
| ULTRASONIC  | SAFE                 | 1W-2<br>cm-2<br>1 min                           | 1W-2<br>cm-2<br>1 min                          |   |   |   |   |   |                                              |             |             |                 | None                                 |
|             | DEGRA-<br>DATION     | 1W-2<br>cm-2<br>5 min                           | 1W-2<br>cm-2<br>5 min                          |   |   |   |   |   |                                              |             |             |                 | Erythema and light burn              |
|             | INCAPA-<br>CITATION  | 2W-2<br>cm-2<br>5 min                           | 2W-2<br>cm-2<br>5 min                          |   |   |   |   |   |                                              |             |             |                 | Burn with charring of tissue         |
|             | LETHA-<br>LITY       | 2W-2<br>cm-2<br>10 min<br>3W-2<br>cm-2<br>3 min | 2W-2<br>cm-2<br>3 min<br>3W-2<br>cm-2<br>3 min |   |   |   |   |   |                                              |             |             |                 | Complete necrosis<br>2nd degree burn |

| 1           | 2                    | 3         | 4     | 5                                | 6                         | 7               | 8      | 9      | 10                                           | 11          | 12          | 13              | 14                                                                                                  |
|-------------|----------------------|-----------|-------|----------------------------------|---------------------------|-----------------|--------|--------|----------------------------------------------|-------------|-------------|-----------------|-----------------------------------------------------------------------------------------------------|
| ENERGY FORM | LEVEL OF INTERACTION | DAMAGE TO |       |                                  |                           |                 |        |        | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                             |
|             |                      | BLOOD     | LYMPH | MUSCLES*                         | SKELETON*                 | CARDIO-VASCULAR | MARROW | SPLEEN | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                     |
| ULTRASONIC  | SAFE                 |           |       | ?                                | ?                         |                 |        |        |                                              |             |             |                 |                                                                                                     |
|             | DEGRADATION          |           |       |                                  |                           |                 |        |        |                                              |             |             |                 |                                                                                                     |
|             | INCAPACITATION       |           |       | 3 W<br>cm <sup>-2</sup><br>5 min | cm <sup>-2</sup><br>5 min |                 |        |        | **                                           | **          |             |                 | *** Paralysis of hind quarters<br>Necrosis of skin and muscle                                       |
|             | LETHALITY            |           |       | 3 W<br>cm <sup>-2</sup><br>5 min | cm <sup>-2</sup><br>5 min |                 |        |        | ***                                          | ***         |             |                 | *** Necrosis of bone and muscle,<br>with tail falling off,<br>hind quarters paralysis<br>and death. |

See Appendix A-2

\*Underwater bath; Wistar rats were used as experimental animals.

| 1           | 2                    | 3         | 4         | 5        | 6       | 7                                 | 8                                 | 9               | 10                                           | 11          | 12          | 13              | 14                                                                                                    |
|-------------|----------------------|-----------|-----------|----------|---------|-----------------------------------|-----------------------------------|-----------------|----------------------------------------------|-------------|-------------|-----------------|-------------------------------------------------------------------------------------------------------|
| ENERGY FORM | LEVEL OF INTERACTION | DAMAGE TO |           |          |         |                                   |                                   |                 | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                               |
|             |                      | ADRENALS  | PITUITARY | PANCREAS | THYROID | GONADS *                          | GONADS **                         | GONADS ***      | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                       |
| ULTRASONIC  |                      |           |           |          |         | 1 W<br>cm <sup>-2</sup><br>1 min  | 3 W<br>cm <sup>-2</sup><br>1 min  | not safe        |                                              |             |             |                 | * Rat testes, direct application<br>** Rat testes, water bath<br>*** Rat testes, focussed beam, 37.5W |
|             | SAFE                 |           |           |          |         | 1 W<br>cm <sup>-2</sup><br>10 min | 3 W<br>cm <sup>-2</sup><br>5 min  | 37.5W<br>5 min  |                                              |             |             |                 |                                                                                                       |
|             | DEGRA-<br>DATION     |           |           |          |         | 2 W<br>cm <sup>-2</sup><br>5 min  | 37.5W<br>5 min                    | 37.5W<br>5 min  |                                              |             |             |                 |                                                                                                       |
|             | INCAPA-<br>CITATION  |           |           |          |         | 2 W<br>cm <sup>-2</sup><br>5 min  | 37.5W<br>5 min                    | 37.5W<br>5 min  |                                              |             |             |                 |                                                                                                       |
|             | LETHA-<br>LITY       |           |           |          |         | 2 W<br>cm <sup>-2</sup><br>5 min  | 3 W<br>cm <sup>-2</sup><br>10 min | 37.5W<br>10 min |                                              |             |             |                 |                                                                                                       |

| 1           | 2                    | 3                                  | 4                                  | 5           | 6                                 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                                                                                                                                                      |
|-------------|----------------------|------------------------------------|------------------------------------|-------------|-----------------------------------|---|---|---|----------------------------------------------|-------------|-------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM | LEVEL OF INTERACTION | DAMAGE TO                          |                                    |             |                                   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                                                                                 |
|             |                      | GASTRO-<br>INTESTINAL              | URINARY                            | RESPIRATORY | LIVER AND<br>GALL BLADDER         |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                                                                         |
| ULTRASOUND  | SAFE                 | 1-2 W<br>cm <sup>-2</sup><br>1 min | 1-2 W<br>cm <sup>-2</sup><br>1 min |             | 1 W<br>cm <sup>-2</sup><br>1 min  |   |   |   | **                                           |             |             |                 | Pathology: (below)<br><br>** None                                                                                                                       |
|             | DEGRA-<br>DATION     | 1 W<br>cm <sup>-2</sup><br>5 min   | 1 W<br>cm <sup>-2</sup><br>5 min   |             | 1 W<br>cm <sup>-2</sup><br>5 min  |   |   |   | ***                                          |             |             |                 | *** Intestine: congestion,<br>hemorrhage, and necrosis;<br>Kidney: congestion                                                                           |
|             | INCAPA-<br>CITATION  | 1 W<br>cm <sup>-2</sup><br>10 min  | 1 W<br>cm <sup>-2</sup><br>10 min  |             | 1 W<br>cm <sup>-2</sup><br>10 min |   |   |   | ****                                         | ****        |             |                 | **** Liver: congestion;<br>Intestine: congestion,<br>hemorrhage, and necrosis<br>**** Kidney: hyaline droplet de-<br>generation of distended<br>bladder |
|             | LETFA-<br>LITY       | 2 W<br>cm <sup>-2</sup><br>5 min   | 1 W<br>cm <sup>-2</sup><br>5 min   |             | 2 W<br>cm <sup>-2</sup><br>5 min  |   |   |   | ***<br>***                                   |             |             |                 | *** Liver: necrosis;<br>*** Intestine: necrosis;<br>*** Kidney: hyaline droplet<br>degeneration.                                                        |

| 1           | 2                    | 3                                | 4          | 5          | 6                      | 7 | 8 | 9            | 10                                           | 11          | 12          | 13              | 14                                                                                                                                                                                            |
|-------------|----------------------|----------------------------------|------------|------------|------------------------|---|---|--------------|----------------------------------------------|-------------|-------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM | LEVEL OF INTERACTION | DAMAGE TO CENTRAL NERVOUS SYSTEM |            |            |                        |   |   | ALPHA RHYTHM | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                                                                                                                       |
|             |                      | CEREBRAL HEMISPHERE              | CEREBELLUM | BRAIN STEM | * SPINAL CORD          |   |   |              | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                                                                                                               |
| ULTRASONIC  | SAFE                 |                                  |            |            | ?                      |   |   |              |                                              |             |             |                 | * Underwater application, rats were used as experimental animals<br><br>** Paralysis of lower extremities<br><br>1/2 of the animals died; rest were paralyzed<br><br>3/4 of the animals died. |
|             | DEGRADATION          |                                  |            |            | 3 W<br>-2 cm<br>5 min  |   |   |              |                                              | **          |             |                 |                                                                                                                                                                                               |
|             | INCAPACITATION       |                                  |            |            | 3 W<br>-2 cm<br>10 min |   |   |              |                                              |             |             |                 |                                                                                                                                                                                               |
|             | LETHALITY            |                                  |            |            | 3 W<br>-2 cm<br>10 min |   |   |              |                                              |             |             |                 |                                                                                                                                                                                               |



|            |                     |                      |                       |          |             |             |                                                 |   |                                              |    |    |                 |         |
|------------|---------------------|----------------------|-----------------------|----------|-------------|-------------|-------------------------------------------------|---|----------------------------------------------|----|----|-----------------|---------|
| 1          | 2                   | 3                    | 4                     | 5        | 6           | 7           | 8                                               | 9 | 10                                           | 11 | 12 | 13              | 14      |
| ULTRASOUND | ENERGY FORM         | LEVEL OF INTERACTION | PSYCHOLOGICAL EFFECTS |          |             |             |                                                 |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |    |    | COUNTERMEASURES | REMARKS |
|            | ASSOCIATIVE SYMBOLS |                      | ILLUSIONS             | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC | No psychological effects known except for pain. |   |                                              |    |    |                 |         |
|            |                     |                      |                       |          |             |             |                                                 |   |                                              |    |    |                 |         |
|            |                     |                      |                       |          |             |             |                                                 |   |                                              |    |    |                 |         |
|            |                     |                      |                       |          |             |             |                                                 |   |                                              |    |    |                 |         |
|            | SAFE                |                      |                       |          |             |             |                                                 |   |                                              |    |    |                 |         |
|            | DEGRADATION         |                      |                       |          |             |             |                                                 |   |                                              |    |    |                 |         |
|            | INCAPACITATION      |                      |                       |          |             |             |                                                 |   |                                              |    |    |                 |         |
|            | LETHALITY           |                      |                       |          |             |             |                                                 |   |                                              |    |    |                 |         |

#### APPENDIX A - Bibliographic Sources

1. Gilbert Baum: "The Effect of Ultrasonic Radiation Upon the Eye and Ocular Adnexa," Am. J. Ophthalmology, Vol. 2, Nov 1956.
2. J. W. Cowden and M. R. Abell: "Some Effects of Ultrasonic Radiation on Normal Tissues," Experimental and Molecular Pathology, Vol. 2, August 1963, pp 367-383

Add pages if necessary.

## APPENDIX B - Amplification of Remarks

The experiments cited in the Matrix were performed with the transducer in direct contact with the eye. The effects observed appear to be due to a temperature rise rather than a mechanical effect. When a fluid coupling medium (water) was interposed between the transducer and the tissues, these effects disappeared. This may in part be explained by a dissipation of energy by the use of a coupling medium whose acoustic impedance lies between tissue and the transducer.

I have never observed any anatomical or physiological damage resulting from the use of pulsed ultrasound (0.1µs pulses, 2000 pulses/s repetition rate, 2000V applied to  $\frac{1}{2}$ " diameter heavily damped quartz transducer--regardless of the duration of the exposure) at the levels used for diagnostic purposes, nor have I ever heard of any such damage spoken of by any investigators in this field. A number of unpublished studies indicate that dosage levels ten to a hundred fold greater than those normally employed for diagnostic studies do not produce any detrimental damage.

Data entered in the matrix are for continuous waves.

Add pages if necessary.

## APPENDIX C - Other Possible Information Sources

Professor Ian Donald, University of Glasgow, Glasgow, Scotland;  
Dr. George Kossoff, at the Interscience Research Institute; and the  
Smith, Kline Instrument Co., Philadelphia, Penna.

Add pages if necessary.

APPENDIX D - Catch-all

Add pages if necessary.

|       |                      |               |       |      |               |       |      |             |                                              |             |             |         |    |
|-------|----------------------|---------------|-------|------|---------------|-------|------|-------------|----------------------------------------------|-------------|-------------|---------|----|
| 1     | 2                    | 3             | 4     | 5    | 6             | 7     | 8    | 9           | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | 13      | 14 |
| SONIC | ENERGY FORM          | DAMAGE TO EYE |       |      |               |       |      |             | COUNTERMEASURES                              |             |             | REMARKS |    |
|       | LEVEL OF INTERACTION | CORNEA        | PUPIL | LENS | OPTICAL FLUID | CONES | RODS | EYE MUSCLES | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |         |    |
|       | SAFE                 |               |       |      |               |       |      |             |                                              |             |             |         |    |
|       | DEGRA-DATION         |               |       |      |               |       |      |             |                                              |             |             |         |    |
|       | INCAPA-CITATION      |               |       |      |               |       |      |             |                                              |             |             |         |    |
|       | LETHA-LITY           |               |       |      |               |       |      |             |                                              |             |             |         |    |

| 1           | 2                    | 3                      | 4                       | 5            | 6         | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                                                                                                                            |
|-------------|----------------------|------------------------|-------------------------|--------------|-----------|---|---|---|----------------------------------------------|-------------|-------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------|
| ENERGY FORM | LEVEL OF INTERACTION | DAMAGE TO EAR          |                         |              |           |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                                                       |
|             |                      | DRUM                   | OSCICLES                | ROUND WINDOW | COCHLEA   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                                               |
| SONIC       | SAFE                 |                        |                         |              |           |   |   |   |                                              |             |             | ear<br>plugs    | See Appendix 1<br>0 db = 0.0002 $\mu$ bar<br><br>120 db: discomfort in ear<br>130 db: mild ear pain<br>140 db: sharp ear pain |
|             | DEGRA-<br>DATION     | 140<br>db              | 140<br>db               | 140<br>db    | 140<br>db |   |   |   |                                              |             |             | ear<br>plugs    | 150 db: limit of subjective<br>tolerance at 3 mi<br>maximum exposure                                                          |
|             | INCAPA-<br>CITATION  | 160 <sup>x</sup><br>db | 160 <sup>xx</sup><br>db | 150<br>db    | 150<br>db |   |   |   |                                              |             |             | ear<br>plugs    | x rupture<br>xx oscicular chain disruption.                                                                                   |
|             | LETHA-<br>LITY       |                        |                         |              |           |   |   |   |                                              |             |             |                 |                                                                                                                               |





|   |                      |                |                         |                   |                 |   |   |   |   |                                              |             |             |                 |         |
|---|----------------------|----------------|-------------------------|-------------------|-----------------|---|---|---|---|----------------------------------------------|-------------|-------------|-----------------|---------|
| 1 | ENERGY FORM          |                |                         |                   |                 |   |   |   |   |                                              |             |             |                 | 14      |
| 2 | LEVEL OF INTERACTION |                | DAMAGE TO SKIN (SENSOR) |                   |                 |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | 13              | REMARKS |
|   |                      |                | 3                       | 4                 | 5               | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          |                 |         |
|   |                      |                | PRESSURE SENSE          | TEMPERATURE SENSE | CHEMICAL (PAIN) |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES |         |
|   |                      |                |                         |                   |                 |   |   |   |   |                                              |             |             |                 |         |
|   |                      |                |                         |                   |                 |   |   |   |   |                                              |             |             |                 |         |
|   |                      | SAFE           |                         |                   |                 |   |   |   |   |                                              |             |             |                 |         |
|   |                      | DEGRADATION    |                         |                   |                 |   |   |   |   |                                              |             |             |                 |         |
|   |                      | INCAPACITATION |                         |                   |                 |   |   |   |   |                                              |             |             |                 |         |
|   |                      | LETHALITY      |                         |                   |                 |   |   |   |   |                                              |             |             |                 |         |

|             |                      |                                     |                       |                       |   |   |   |   |                                                    |             |             |                 |         |
|-------------|----------------------|-------------------------------------|-----------------------|-----------------------|---|---|---|---|----------------------------------------------------|-------------|-------------|-----------------|---------|
| 1           | 2                    | 3                                   | 4                     | 5                     | 6 | 7 | 8 | 9 | 10                                                 | 11          | 12          | 13              | 14      |
| ENERGY FORM | LEVEL OF INTERACTION | POSTURAL SENSIBILITY<br>(LABYRINTH) | GAMMA MOTOR<br>SYSTEM | DAMAGE TO KINESTHETIC |   |   |   |   | SPECIFIC ADVERSE<br>EFFECTS DUE TO<br>TRANSMISSION |             |             | COUNTERMEASURES | REMARKS |
|             |                      |                                     |                       |                       |   |   |   |   | ANATOMIC                                           | PHYSIOLOGIC | PSYCHOLOGIC |                 |         |
| SONIC       | SAFE                 |                                     |                       |                       |   |   |   |   |                                                    |             |             |                 |         |
|             | DEGRA-<br>DATION     |                                     |                       |                       |   |   |   |   |                                                    |             |             |                 |         |
|             | INCAPA-<br>CITATION  |                                     |                       |                       |   |   |   |   |                                                    |             |             |                 |         |
|             | LETHA-<br>LITY       |                                     |                       |                       |   |   |   |   |                                                    |             |             |                 |         |

|             |                      |           |        |   |   |   |   |   |          |             |             |                 |         |  |  |  |  |  |  |  |  |  |  |  |  |
|-------------|----------------------|-----------|--------|---|---|---|---|---|----------|-------------|-------------|-----------------|---------|--|--|--|--|--|--|--|--|--|--|--|--|
| 1           | 2                    | 3         | 4      | 5 | 6 | 7 | 8 | 9 | 10       | 11          | 12          | 13              | 14      |  |  |  |  |  |  |  |  |  |  |  |  |
| ENERGY FORM | LEVEL OF INTERACTION | EPIDERMIS | DERMIS |   |   |   |   |   | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES | REMARKS |  |  |  |  |  |  |  |  |  |  |  |  |
|             |                      |           |        |   |   |   |   |   |          |             |             |                 |         |  |  |  |  |  |  |  |  |  |  |  |  |
|             |                      |           |        |   |   |   |   |   |          |             |             |                 |         |  |  |  |  |  |  |  |  |  |  |  |  |
|             |                      |           |        |   |   |   |   |   |          |             |             |                 |         |  |  |  |  |  |  |  |  |  |  |  |  |
|             |                      |           |        |   |   |   |   |   |          |             |             |                 |         |  |  |  |  |  |  |  |  |  |  |  |  |
|             | SAFE                 |           |        |   |   |   |   |   |          |             |             |                 |         |  |  |  |  |  |  |  |  |  |  |  |  |
|             | DEGRA-<br>DATION     |           |        |   |   |   |   |   |          |             |             |                 |         |  |  |  |  |  |  |  |  |  |  |  |  |
|             | INCAPA-<br>CITATION  |           |        |   |   |   |   |   |          |             |             |                 |         |  |  |  |  |  |  |  |  |  |  |  |  |
|             | LETHA-<br>LITY       |           |        |   |   |   |   |   |          |             |             |                 |         |  |  |  |  |  |  |  |  |  |  |  |  |
| SONIC       |                      |           |        |   |   |   |   |   |          |             |             |                 |         |  |  |  |  |  |  |  |  |  |  |  |  |

|             |                      |       |       |         |          |                 |        |        |          |             |             |                 |         |
|-------------|----------------------|-------|-------|---------|----------|-----------------|--------|--------|----------|-------------|-------------|-----------------|---------|
| 1           | 2                    | 3     | 4     | 5       | 6        | 7               | 8      | 9      | 10       | 11          | 12          | 13              | 14      |
| ENERGY FORM | LEVEL OF INTERACTION | BLOOD | LYMPH | MUSCLES | SKELETON | CARDIO-VASCULAR | MARROW | SPLEEN | ANATOMIC | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES | REMARKS |
|             |                      |       |       |         |          |                 |        |        |          |             |             |                 |         |
| SONIC       | SAFE                 |       |       |         |          |                 |        |        |          |             |             |                 |         |
|             | DEGRA-DATION         |       |       |         |          |                 |        |        |          |             |             |                 |         |
|             | INCAPA-CITATION      |       |       |         |          |                 |        |        |          |             |             |                 |         |
|             | LETHA-LITY           |       |       |         |          |                 |        |        |          |             |             |                 |         |



[illegible]

|    |                      |  |       |                |
|----|----------------------|--|-------|----------------|
| 1  | ENERGY FORM          |  | SONIC |                |
| 2  | LEVEL OF INTERACTION |  | SAFE  | DEGRADATION    |
| 3  | CEREBRAL HEMISPHERE  |  |       | INCAPACITATION |
| 4  | CEREBELLUM           |  |       | LETHALITY      |
| 5  | BRAIN STEM           |  |       |                |
| 6  | SPINAL CORD          |  |       |                |
| 7  |                      |  |       |                |
| 8  |                      |  |       |                |
| 9  | ALPHA RHYTHM         |  |       |                |
| 10 | ANATOMIC             |  |       |                |
| 11 | PHYSIOLOGIC          |  |       |                |
| 12 | PSYCHOLOGIC          |  |       |                |
| 13 | COUNTERMEASURES      |  |       |                |
| 14 | REMARKS              |  |       |                |





APPENDIX A - Bibliographic Sources

- D. F. Goldman: Mechanical Vibrations and Its Effects on Man.  
Naval Research Institute (1952). AD 6117.
- D. F. Goldman: Biological Effects of Vibration.  
NRC Committee on Hearing and Bioacoustics (Apr 1961).  
AD 256 926.
- Nixon, Hille, Kettler: Attenuation Characteristics of Earmuffs at Low  
Audio and Infrasonic Frequencies. Aerospace  
Medicine, AMRL-TR 67-27 (1967) AD 655939..
- T. F. Hueter, R. H. Bolt: Sonics, John Wiley & Sons, Inc., New York (1953)

Add pages if necessary.

APPENDIX B - Amplification of Remarks

Add pages if necessary.

## APPENDIX C - Other Possible Information Sources

Add pages if necessary.

APPENDIX D - Catch-all

Add pages if necessary.

|                           |                      |        |       |      |               |       |      |             |                                              |    |    |                 |                                            |  |  |  |  |
|---------------------------|----------------------|--------|-------|------|---------------|-------|------|-------------|----------------------------------------------|----|----|-----------------|--------------------------------------------|--|--|--|--|
| 1                         | 2                    | 3      | 4     | 5    | 6             | 7     | 8    | 9           | 10                                           | 11 | 12 | 13              | 14                                         |  |  |  |  |
| ENERGY FORM               | LEVEL OF INTERACTION | CORNEA | PUPIL | LENS | OPTICAL FLUID | CONES | RODS | EYE MUSCLES | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |    |    | COUNTERMEASURES | REMARKS                                    |  |  |  |  |
|                           |                      |        |       |      |               |       |      |             |                                              |    |    |                 |                                            |  |  |  |  |
|                           |                      |        |       |      |               |       |      |             |                                              |    |    |                 |                                            |  |  |  |  |
|                           |                      |        |       |      |               |       |      |             |                                              |    |    |                 |                                            |  |  |  |  |
|                           |                      |        |       |      |               |       |      |             |                                              |    |    |                 |                                            |  |  |  |  |
|                           | SAFE                 |        |       |      |               |       |      |             |                                              |    |    |                 | Perceptible visual field vibration: 130 db |  |  |  |  |
|                           | DEGRADATION          |        |       |      |               |       |      |             |                                              |    |    |                 |                                            |  |  |  |  |
|                           | INCAPACITATION       |        |       |      |               |       |      |             |                                              |    |    |                 |                                            |  |  |  |  |
|                           | LETHALITY            |        |       |      |               |       |      |             |                                              |    |    |                 |                                            |  |  |  |  |
| INFRASONIC AND BAROMETRIC |                      |        |       |      |               |       |      |             |                                              |    |    |                 |                                            |  |  |  |  |

Infrasound: 1-20 Hz  
Visual blurring at 140 db  
(= approx.  $0.08W_{cm^{-2}}$ )

|                           |                      |         |          |              |         |   |   |   |    |    |    |                 |                                                                              |
|---------------------------|----------------------|---------|----------|--------------|---------|---|---|---|----|----|----|-----------------|------------------------------------------------------------------------------|
| 1                         | 2                    | 3       | 4        | 5            | 6       | 7 | 8 | 9 | 10 | 11 | 12 | 13              | 14                                                                           |
| ENERGY FORM               | LEVEL OF INTERACTION | DRUM    | OSCILLES | ROUND WINDOW | COCHLEA |   |   |   |    |    |    | COUNTERMEASURES | REMARKS                                                                      |
|                           |                      |         |          |              |         |   |   |   |    |    |    |                 |                                                                              |
| INFRASONIC AND BAROMETRIC | SAFE                 |         |          |              |         |   |   |   |    |    |    |                 | 120 db: discomfort in ear<br>130 db: mild ear pain<br>140 db: sharp ear pain |
|                           | DEGRA-DATION         | 140 db  | 140 db   | 140 db       | 140 db  |   |   |   |    |    |    |                 | 150 db limit of subjective tolerance at 3-min maximum exposure.              |
|                           | INCAPA-CITATION      | 160* db | 160** db | 150 db       | 150 db  |   |   |   |    |    |    |                 | *rupture (A-1)<br>**oscicular chain disruption                               |
|                           | LETHA-LITY           |         |          |              |         |   |   |   |    |    |    |                 |                                                                              |

SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION

DAMAGE TO EAR

ANATOMIC  
PHYSIOLOGIC  
PSYCHOLOGIC

|                           |                      |                      |                |                 |   |   |   |   |                                              |             |             |                 |                                 |
|---------------------------|----------------------|----------------------|----------------|-----------------|---|---|---|---|----------------------------------------------|-------------|-------------|-----------------|---------------------------------|
| 1                         | 2                    | 3                    | 4              | 5               | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                              |
| ENERGY FORM               | LEVEL OF INTERACTION | DAMAGE TO NOSE       |                |                 |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                         |
|                           |                      | OLFACTORY EPITHELIUM | OLFACTORY BULB | OLFACTORY TRACT |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                 |
| INFRASONIC AND BAROMETRIC | SAFE                 |                      |                |                 |   |   |   |   |                                              |             |             |                 |                                 |
|                           | DEGRADATION          |                      |                |                 |   |   |   |   |                                              |             |             |                 |                                 |
|                           | INCAPACITATION       |                      |                |                 |   |   |   |   |                                              |             |             |                 |                                 |
|                           | LETHALITY            |                      |                |                 |   |   |   |   |                                              |             |             |                 |                                 |
|                           |                      |                      |                |                 |   |   |   |   |                                              |             |             |                 | 120 db: nasal cavity vibrations |

| 1                         | 2                    | 3                       | 4                 | 5               | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13      | 14                |
|---------------------------|----------------------|-------------------------|-------------------|-----------------|---|---|---|---|----------------------------------------------|-------------|-------------|---------|-------------------|
| ENERGY FORM               | LEVEL OF INTERACTION | DAMAGE TO SKIN (SENSOR) |                   |                 |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | REMARKS |                   |
|                           |                      | PRESSURE SENSE          | TEMPERATURE SENSE | CHEMICAL (PAIN) |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |         |                   |
| INFRASONIC AND BAROMETRIC | SAFE                 | 110<br>qp               |                   |                 |   |   |   |   |                                              |             |             |         |                   |
|                           | DEGRA-<br>DATION     |                         |                   |                 |   |   |   |   |                                              |             |             |         |                   |
|                           | INCAPA-<br>CITATION  |                         |                   |                 |   |   |   |   |                                              |             |             |         |                   |
|                           | LETHA-<br>LITY       |                         |                   |                 |   |   |   |   |                                              |             |             |         |                   |
|                           |                      |                         |                   |                 |   |   |   |   |                                              |             |             |         | senses sound wave |



[illegible]

|                            |                      |                           |        |   |   |   |   |   |                                              |             |             |                 |         |
|----------------------------|----------------------|---------------------------|--------|---|---|---|---|---|----------------------------------------------|-------------|-------------|-----------------|---------|
| 1                          | 2                    | 3                         | 4      | 5 | 6 | 7 | 8 | 9 | 10                                           | 11          | 12          | 13              | 14      |
| ENERGY FORM                | LEVEL OF INTERACTION | DAMAGE TO SKIN (COVERING) |        |   |   |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS |
|                            |                      | EPIDERMIS                 | DERMIS |   |   |   |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |         |
|                            |                      |                           |        |   |   |   |   |   |                                              |             |             |                 |         |
|                            |                      |                           |        |   |   |   |   |   |                                              |             |             |                 |         |
|                            |                      |                           |        |   |   |   |   |   |                                              |             |             |                 |         |
| INFRA-SONIC AND BAROMETRIC |                      |                           |        |   |   |   |   |   |                                              |             |             |                 |         |
|                            | SAFE                 |                           |        |   |   |   |   |   |                                              |             |             |                 |         |
|                            | DEGRADATION          |                           |        |   |   |   |   |   |                                              |             |             |                 |         |
|                            | INCAPACITATION       |                           |        |   |   |   |   |   |                                              |             |             |                 |         |
|                            | LETHALITY            |                           |        |   |   |   |   |   |                                              |             |             |                 |         |

| 1           | 2                    | DAMAGE TO |       |         |          |                 |        |        | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | 13              | 14      |                                                                  |
|-------------|----------------------|-----------|-------|---------|----------|-----------------|--------|--------|----------------------------------------------|-------------|-------------|-----------------|---------|------------------------------------------------------------------|
| ENERGY FORM | LEVEL OF INTERACTION | BLOOD     | LYMPH | MUSCLES | SKELETON | CARDIO-VASCULAR | MARROW | SPLEEN | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES | REMARKS |                                                                  |
|             | SAFE                 |           |       |         |          | 120*<br>db      | *      |        |                                              |             |             |                 |         | * Chest cavity vibrates                                          |
|             | DEGRA-DATION         |           |       |         |          | 130**<br>db     |        |        |                                              |             |             |                 |         | ** Moderate chest cavity vibrations, pulse rate increases 10-40% |
|             | INCAPA-CITATION      |           |       |         |          |                 |        |        |                                              |             |             |                 |         | 170 db: probable organ damage                                    |
|             | LETHA-LITY           |           |       |         |          |                 |        |        |                                              |             |             |                 |         | 180+ db: Death?                                                  |

| 1                         | 2                    | 3         | 4         | 5        | 6       | 7      | 8 | 9 | 10                                           | 11          | 12          | 13              | 14                                                                                                |
|---------------------------|----------------------|-----------|-----------|----------|---------|--------|---|---|----------------------------------------------|-------------|-------------|-----------------|---------------------------------------------------------------------------------------------------|
| ENERGY FORM               | LEVEL OF INTERACTION | DAMAGE TO |           |          |         |        |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS                                                                                           |
|                           |                      | ADRENALS  | PITUITARY | PANCREAS | THYROID | GONADS |   |   | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                   |
| INFRASONIC AND BAROMETRIC | SAFE                 |           |           |          |         |        |   |   |                                              |             |             |                 | See Appendix A-4<br>150 db: chronic stimulation causes failure of functional capacity of enzymes. |
|                           | DEGRA-DATION         |           |           |          |         | 150 db |   |   |                                              |             |             |                 | testicular aching                                                                                 |
|                           | INCAPA-CITATION      |           |           |          |         |        |   |   |                                              |             |             |                 | 170 db: Probable organ damage                                                                     |
|                           | LETHA-LITY           |           |           |          |         |        |   |   |                                              |             |             |                 | 180+ db: death?                                                                                   |

| 1           | 2                    | DAMAGE TO             |         |             |                           |   |   |   | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | 13              | 14      |                                                                             |  |
|-------------|----------------------|-----------------------|---------|-------------|---------------------------|---|---|---|----------------------------------------------|-------------|-------------|-----------------|---------|-----------------------------------------------------------------------------|--|
| ENERGY FORM | LEVEL OF INTERACTION | 3                     | 4       | 5           | 6                         | 7 | 8 | 9 | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC | COUNTERMEASURES | REMARKS |                                                                             |  |
|             |                      | GASTRO-<br>INTESTINAL | URINARY | RESPIRATORY | LIVER AND<br>GALL BLADDER |   |   |   |                                              |             |             |                 |         |                                                                             |  |
|             |                      | 130<br>db             |         |             |                           |   |   |   |                                              |             |             |                 |         | Abdominal discomfort                                                        |  |
|             |                      | 140*<br>db            |         | 140**<br>db |                           |   |   |   |                                              |             |             |                 |         | *Nausea, vomiting;<br>**Respiratory rhythm disrupted,<br>gagging sensation. |  |
|             |                      | 150<br>db             |         |             |                           |   |   |   |                                              |             |             |                 |         | Limit of tolerance<br>170 db: Probable organ damage.                        |  |
|             | LETHA-<br>LITY       |                       |         |             |                           |   |   |   |                                              |             |             | 180+ db: death? |         |                                                                             |  |

See Appendix A-2, 3.  
150 db: death, 1 min for mice;  
8 min for rats, guinea  
pigs.

Abdominal discomfort

\*Nausea, vomiting;  
\*\*Respiratory rhythm disrupted,  
gagging sensation.

Limit of tolerance  
170 db: Probable organ damage.

180+ db: death?

| 1                         | 2                    | 3                                | 4          | 5          | 6           | 7 | 8 | 9            | 10                                           | 11          | 12          | 13              | 14                                                                                                   |
|---------------------------|----------------------|----------------------------------|------------|------------|-------------|---|---|--------------|----------------------------------------------|-------------|-------------|-----------------|------------------------------------------------------------------------------------------------------|
| ENERGY FORM               | LEVEL OF INTERACTION | DAMAGE TO CENTRAL NERVOUS SYSTEM |            |            |             |   |   | ALPHA RHYTHM | SPECIFIC ADVERSE EFFECTS DUE TO TRANSMISSION |             |             | COUNTERMEASURES | REMARKS<br><br>See Appendix A-4<br><br>150 db: breakdown nervous cells, disrupts molecular structure |
|                           |                      | CEREBRAL HEMISPHERE              | CEREBELLUM | BRAIN STEM | SPINAL CORD |   |   |              | ANATOMIC                                     | PHYSIOLOGIC | PSYCHOLOGIC |                 |                                                                                                      |
|                           |                      |                                  |            |            |             |   |   |              |                                              |             |             |                 |                                                                                                      |
|                           |                      |                                  |            |            |             |   |   |              |                                              |             |             |                 |                                                                                                      |
|                           |                      |                                  |            |            |             |   |   |              |                                              |             |             |                 |                                                                                                      |
|                           |                      | SAFE                             |            |            |             |   |   |              |                                              |             |             |                 |                                                                                                      |
|                           |                      | DEGRADATION                      | 150 db     |            |             |   |   |              |                                              |             |             |                 | Transient headaches                                                                                  |
|                           |                      | INCAPACITATION                   |            |            |             |   |   |              |                                              |             |             |                 | 170 db: probable organ damage                                                                        |
|                           |                      | LETHALITY                        |            |            |             |   |   |              |                                              |             |             |                 | 180+ db: Death?<br>See Appendix A-5,6,7,8,9,10,11                                                    |
| INFRASONIC AND BAROMETRIC |                      |                                  |            |            |             |   |   |              |                                              |             |             |                 |                                                                                                      |

|                           |                     |                      |                        |           |                       |   |   |   |                                                    |                 |    |    |                                                    |  |  |
|---------------------------|---------------------|----------------------|------------------------|-----------|-----------------------|---|---|---|----------------------------------------------------|-----------------|----|----|----------------------------------------------------|--|--|
| 1                         | 2                   | 3                    | 4                      | 5         | 6                     | 7 | 8 | 9 | 10                                                 | 11              | 12 | 13 | 14                                                 |  |  |
| INFRASONIC AND BAROMETRIC | ENERGY FORM         | LEVEL OF INTERACTION | ASSOCIATIVE<br>SYMBOLS | ILLUSIONS | PSYCHOLOGICAL EFFECTS |   |   |   | SPECIFIC ADVERSE<br>EFFECTS DUE TO<br>TRANSMISSION | COUNTERMEASURES |    |    | REMARKS                                            |  |  |
|                           |                     |                      |                        |           |                       |   |   |   |                                                    |                 |    |    |                                                    |  |  |
|                           |                     |                      |                        |           |                       |   |   |   |                                                    |                 |    |    |                                                    |  |  |
|                           |                     |                      |                        |           |                       |   |   |   |                                                    |                 |    |    |                                                    |  |  |
|                           |                     |                      |                        |           |                       |   |   |   |                                                    |                 |    |    |                                                    |  |  |
|                           | SAFE                |                      |                        |           |                       |   |   |   |                                                    |                 |    |    | 110 db: Apprehension<br>140 db: Anxiety, confusion |  |  |
|                           | DEGRA-<br>DATION    |                      |                        |           |                       |   |   |   |                                                    |                 |    |    | 150 db: limit of subjective<br>tolerance.          |  |  |
|                           | INCAPA-<br>CITATION |                      |                        |           |                       |   |   |   |                                                    |                 |    |    |                                                    |  |  |
|                           | LETHA-<br>LITY      |                      |                        |           |                       |   |   |   |                                                    |                 |    |    |                                                    |  |  |

#### APPENDIX A - Bibliographic Sources

1. D. E. Bushy, M. D., "Effects of Low Frequency Noise on Man," Life Sciences Dept., Garrett Corporation, Airesearch Manufacturing Division.
2. Physiological Effects of Intense Sound, Aero Medical Laboratory, ATI-28968, May 1948.
3. H. Frings, C. H. Allen, and I. Rudnick, "The Physical Effects of High Intensity Air-Borne Waves on Animals," J. Cellular and Comparative Physiology, Vol. 31, 1948, pp. 339-358.
4. Z. Angeluscheff, "Decibel vs Hearing Cell," J. Acoust. Soc. Am., Vol. 35, No. 5, May 1963.
5. E. Damon, N. Gaylord, J. Yelverton, D. Richmond, and C. White, The Effects of Ambient Pressure on Tolerance of Mammals to Air Blast, AD 652 892, August 1966.
6. D. Richmond, E. Damon, R. Fletcher, G. Bowen, and C. White, The Relationship Between Selected Blast-Wave Parameters and Response of Mammals Exposed to Air Blast, AD 653131, March 1966.
7. E. Guild, LTC, USAF, The Infrasonic Noise Environment in Aerospace Operations. Collected papers presented at the 22nd meeting of the Agard Medical Panel, AD 660197, September 1965.
8. H. E. Von Gierke, Arch. Environ. Health, Vol. 11, 1963, p. 327.
9. E. G. Wever and C. W. Bray, "The Perception of Low Tones and the Resonance Volley Theory," J. Psych., Vol. 3, 1936, p. 101.
10. O. R. Plutchick, "The Effects of Intensity Intermittent Sound on Performance, Feeling, and Physiology," Psychological Bulletin, Vol 56, No. 2, 1960.
11. Kryter, Ward, and Miller, "Hazardous Exposure to Intermittent and Steady-State Noise," J. Acoust. Soc. Am., Vol. 39, 1966, p. 451.
12. K. J. Oscar: "An Infrasonic System," MERDC Report 1940, March 1969 (C).

Add pages if necessary.



## APPENDIX B - Amplification of Remarks

Data entered in this matrix relate to infrasound only (1 - 20 Hz), sinusoidal, pulsed, or modulated on a higher frequency carrier (100-3000 Hz)

No data were available on barometric-type pressure changes (from 1 Hz - 0.001 Hz).

Add pages if necessary.

UNCLASSIFIED

Security Classification

## DOCUMENT CONTROL DATA - R &amp; D

(Security classification of title, body of abstract and indexing annotation must be entered when the overall report is classified)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |                                                                             |                 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------|-----------------|
| 1. ORIGINATING ACTIVITY (Corporate author)<br>USA Advanced Materiel Concepts Agency<br>Washington, D. C. 20315                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  | 2a. REPORT SECURITY CLASSIFICATION<br>UNCLASSIFIED                          |                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  | 2b. GROUP                                                                   |                 |
| 3. REPORT TITLE<br><br>BIOLOGICAL SENSITIVITIES TO VARIOUS ENERGY FORMS (MATRIX)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |  |                                                                             |                 |
| 4. DESCRIPTIVE NOTES (Type of report and inclusive dates)<br>Annex A to AHWG #3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |                                                                             |                 |
| 5. AUTHOR(S) (First name, middle initial, last name)<br>USA Advanced Materiel Concepts Agency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  |                                                                             |                 |
| 6. REPORT DATE<br>July 1970                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |  | 7a. TOTAL NO. OF PAGES<br>261                                               | 7b. NO. OF REFS |
| 8a. CONTRACT OR GRANT NO.<br>DAAB-09-70-C-0033                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  | 8b. ORIGINATOR'S REPORT NUMBER(S)<br>AMCA-71-004                            |                 |
| a. PROJECT NO.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |                                                                             |                 |
| c.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |  | 9a. OTHER REPORT NO(S) (Any other numbers that may be assigned this report) |                 |
| d.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |  |                                                                             |                 |
| 10. DISTRIBUTION STATEMENT<br>Each transmittal of this document outside of the agencies of the US Government must have prior approval of the Director, AMCA.                                                                                                                                                                                                                                                                                                                                                                                                                            |  |                                                                             |                 |
| 11. SUPPLEMENTARY NOTES<br>Annex A to AHWG #3, Directed Energies for Military Applications (U), May 1969, AD 503559L.                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |  | 12. SPONSORING MILITARY ACTIVITY                                            |                 |
| 13. ABSTRACT<br>This report contains biological vulnerabilities to various energy forms such as electromagnetic radiations, ionizing particles, static electric and magnetic fields and acoustical energy forms. The vulnerabilities are given in Watt per $\text{cm}^2$ or Watt-Seconds per $\text{cm}^2$ for various body organs and body biological systems (blood circulation, lymphatic system, etc.).<br><br>This volume should be of interest to anyone who is concerned about health safety of individuals who would be potentially exposed to the abovementioned energy forms. |  |                                                                             |                 |

DD FORM 1473  
1 NOV 66REPLACES DD FORM 1473, 1 JAN 64, WHICH IS  
OBSOLETE FOR ARMY USE.

UNCLASSIFIED

Security Classification